[
  {
    "id": "40580757",
    "title_en": "The effect of graphene oxide-polyethylene glycol on lung cell and treatment of sulforaphane.",
    "pub_date": "2026 Jan",
    "journal": "Talanta",
    "abstract_en": "This study explores the cytotoxic and biochemical effects of PEGylated graphene oxide (GO-PEG) nanoparticles, sulforaphane, and Raphanus sativus L. (black radish) juice on BEAS-2B human bronchial epithelial cells. Sulforaphane was extracted from radish juice through pH-adjusted aqueous treatment followed by organic solvent extraction, and quantified via high-performance liquid chromatography (HPLC) at 202Â nm, with a retention time of 11.0Â min. GO-PEG nanoparticles produced from graphites (50Â nm and 400Â nm) were tested at concentrations ranging from 50-225 Î¼gÂ mL<sup>-1</sup> and 100-1000 Î¼gÂ mL<sup>-1</sup> to have IC<sub>50</sub> values, respectively. Sulforaphane and black radish juice were also administered. The MTT assay revealed IC<sub>50</sub> values of 8.7Â Î¼gÂ mL<sup>-1</sup> for sulforaphane, 197.0 mgÂ mL<sup>-1</sup> for black radish juice, 175.8Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (50Â nm), and 650.6Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (400Â nm). Biochemical analyses showed that sulforaphane and radish juice decreased IL-6 levels and increased antioxidant enzyme activities (GSH-Px and CAT). These results highlight the therapeutic potential of GO-PEG, sulforaphane, and black radish juice for anti-inflammatory and antioxidant applications.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“å¥åº·æœ‰æ­£é¢å½±éŸ¿ï¼Œé€™å°æ–¼é é˜²èˆ‡å‘¼å¸ç³»çµ±ç›¸é—œçš„ç–¾ç—…ä¾†èªªï¼Œæˆ–è¨±æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚é€éé€™äº›æˆåˆ†çš„ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥äº†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç‰©è³ªä¾†ä¿ƒé€²å¥åº·ï¼Œä¸¦å¯èƒ½æ¸›å°‘æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³é¡†ç²’ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰çš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›ç‰©è³ªå°ç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ½›åŠ›æ–¹é¢ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼æ¢ç´¢æ–°å‹çš„æ²»ç™‚æ–¹æ³•ï¼Œé‚„èƒ½ç‚ºæœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æä¾›ç§‘å­¸ä¾æ“šã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…æå–äº†é»‘è˜¿è””æ±ä¸­çš„è˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•ï¼ˆHPLCï¼‰é€²è¡Œå®šé‡åˆ†æã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸åŒå¤§å°çš„GO-PEGå¥ˆç±³é¡†ç²’ï¼Œä¸¦æ¸¬è©¦äº†å®ƒå€‘åœ¨ä¸åŒæ¿ƒåº¦ä¸‹å°BEAS-2Bç´°èƒçš„å½±éŸ¿ã€‚é€éMTTæ¸¬è©¦ï¼Œç ”ç©¶è€…è©•ä¼°äº†é€™äº›ç‰©è³ªçš„IC50å€¼ï¼Œé€™æ˜¯ä¸€å€‹è¡¡é‡ç´°èƒå­˜æ´»ç‡çš„é‡è¦æŒ‡æ¨™ï¼Œå¹«åŠ©äº†è§£å®ƒå€‘çš„ç´°èƒæ¯’æ€§ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœæš—ç¤ºäº†GO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ‡‰ç”¨ä¸Šçš„æ½›åŠ›ï¼Œé›–ç„¶é€™äº›çµæœéœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆï¼Œä½†å·²ç¶“ç‚ºæœªä¾†çš„ç ”ç©¶æ–¹å‘æä¾›äº†æœ‰åƒ¹å€¼çš„è³‡è¨Šã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“å¥åº·æœ‰æ­£é¢å½±éŸ¿ï¼Œé€™å°æ–¼é é˜²èˆ‡å‘¼å¸ç³»çµ±ç›¸é—œçš„ç–¾ç—…ä¾†èªªï¼Œæˆ–è¨±æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚é€éé€™äº›æˆåˆ†çš„ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥äº†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç‰©è³ªä¾†ä¿ƒé€²å¥åº·ï¼Œä¸¦å¯èƒ½æ¸›å°‘æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³é¡†ç²’ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰çš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›ç‰©è³ªå°ç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ½›åŠ›æ–¹é¢ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼æ¢ç´¢æ–°å‹çš„æ²»ç™‚æ–¹æ³•ï¼Œé‚„èƒ½ç‚ºæœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æä¾›ç§‘å­¸ä¾æ“šã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…æå–äº†é»‘è˜¿è””æ±ä¸­çš„è˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•ï¼ˆHPLCï¼‰é€²è¡Œå®šé‡åˆ†æã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸åŒå¤§å°çš„GO-PEGå¥ˆç±³é¡†ç²’ï¼Œä¸¦æ¸¬è©¦äº†å®ƒå€‘åœ¨ä¸åŒæ¿ƒåº¦ä¸‹å°BEAS-2Bç´°èƒçš„å½±éŸ¿ã€‚é€éMTTæ¸¬è©¦ï¼Œç ”ç©¶è€…è©•ä¼°äº†é€™äº›ç‰©è³ªçš„IC50å€¼ï¼Œé€™æ˜¯ä¸€å€‹è¡¡é‡ç´°èƒå­˜æ´»ç‡çš„é‡è¦æŒ‡æ¨™ï¼Œå¹«åŠ©äº†è§£å®ƒå€‘çš„ç´°èƒæ¯’æ€§ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœæš—ç¤ºäº†GO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ‡‰ç”¨ä¸Šçš„æ½›åŠ›ï¼Œé›–ç„¶é€™äº›çµæœéœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆï¼Œä½†å·²ç¶“ç‚ºæœªä¾†çš„ç ”ç©¶æ–¹å‘æä¾›äº†æœ‰åƒ¹å€¼çš„è³‡è¨Šã€‚",
    "fb_post": "æ ¹æ“šã€ŠTalantaã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± è½èªªè˜¿è””ä¹Ÿèƒ½å¹«åŠ©æˆ‘å€‘çš„å‘¼å¸é“å¥åº·ï¼Ÿé€™ä¸æ˜¯é–‹ç©ç¬‘ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶è®“æˆ‘å€‘å°è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±çš„å¥½è™•æœ‰äº†æ–°çš„èªè­˜ã€‚ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼é€™äº›å¤©ç„¶æˆåˆ†å°æˆ‘å€‘å‘¼å¸ç³»çµ±çš„å½±éŸ¿ï¼Œä¸¦æ¢è¨å®ƒå€‘å¦‚ä½•å¹«åŠ©æ¸›å°‘ç™¼ç‚å’Œæ°§åŒ–å£“åŠ›ã€‚\n\nä»–å€‘æå–äº†é»‘è˜¿è””æ±ä¸­çš„è˜¿è””ç¡«ç´ ï¼Œä¸¦ç”¨ä¸€ç¨®å«é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•çš„æŠ€è¡“é€²è¡Œåˆ†æã€‚æ¥è‘—ï¼Œç ”ç©¶è€…å€‘æ¸¬è©¦äº†ä¸åŒå¤§å°çš„å¥ˆç±³é¡†ç²’å°äººé¡æ”¯æ°£ç®¡ç´°èƒçš„å½±éŸ¿ï¼Œä¸¦è©•ä¼°äº†é€™äº›æˆåˆ†çš„ç´°èƒæ¯’æ€§ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±ä¸åƒ…èƒ½é™ä½ä¸€ç¨®å«IL-6çš„ç™¼ç‚æŒ‡æ¨™ï¼Œé‚„èƒ½æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œé€™å°æ–¼æˆ‘å€‘çš„å¥åº·éå¸¸é‡è¦ï¼é›–ç„¶é€™äº›çµæœéœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªï¼Œä½†é€™å·²ç¶“ç‚ºæœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æä¾›äº†æœ‰åƒ¹å€¼çš„è³‡è¨Šã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½æœ‰åŠ©æ–¼å‘¼å¸é“å¥åº·ã€‚\n2. é€™äº›æˆåˆ†èƒ½é™ä½ç™¼ç‚æŒ‡æ¨™ï¼Œæå‡æŠ—æ°§åŒ–èƒ½åŠ›ã€‚\n3. ç ”ç©¶çµæœç‚ºæœªä¾†çš„å¥åº·ç”¢å“æä¾›äº†ç§‘å­¸ä¾æ“šã€‚",
    "image_prompt": "Create a simple and informative illustration explaining the experiment and main results of the study on daikon sulforaphane and black radish juice. Use a flat design style with a light background and soft colors. Include symbols representing daikon or sulforaphane, simplified illustrations of human or cell subjects, arrows or flow lines to indicate the experimental steps, and a section clearly labeling the 'Main Results' such as protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‘¼å¸é“ç–¾ç—… Respiratory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40580757/"
  },
  {
    "id": "40961586",
    "title_en": "Design, synthesis and biological evaluation of magnolol-sulforaphane hybrid analogues as potential therapeutics of triple-negative breast cancer.",
    "pub_date": "2025 Dec",
    "journal": "European journal of medicinal chemistry",
    "abstract_en": "Triple-negative breast cancer (TNBC) is an aggressive subtype that primarily relies on chemotherapy. Natural products like magnolol and sulforaphane, especially their synthetic hybrid, have shown promising antitumor activity. To develop more potent agents, we designed and synthesized 15 novel magnolol-sulforaphane hybrid analogues and evaluated their anticancer efficacy. Among them, compound 17a demonstrated the highest potency, exhibiting an average 7.4-fold increase in antiproliferative activity with IC<sub>50</sub> values ranging from 0.85Â Â±Â 0.04Â Î¼M to 1.34Â Â±Â 0.02Â Î¼M in TNBC cell lines compared to the parent hybrid CT1-3. In vitro, 17a significantly suppressed TNBC cell proliferation, colony formation, migration, and invasion while inducing apoptosis. In vivo, administration of 17a effectively inhibited tumor growth without apparent toxicity in an MDA-MB-231 xenograft model, as evidenced by normal organ morphology. Mechanistically, RNA sequencing revealed that 17a downregulated the nucleotide excision repair (NER) and NF-ÎºB pathways, suppressing expression of NER-related genes (ERCC2, POLE2, LIG1, GTF2H3, and DDB2) at mRNA and protein levels and inhibiting phosphorylation of IKKÎ± and p65. These findings position 17a as a potent therapeutic candidate for TNBC treatment, warranting further clinical investigation.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ç”±æ–¼ä¸‰é™°æ€§ä¹³ç™Œä¸»è¦ä¾è³´åŒ–ç™‚ï¼Œé€™ä½¿å¾—æ¢ç´¢å¤©ç„¶ç”¢å“çš„æ½›åŠ›è®Šå¾—å°¤ç‚ºé—œéµã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶åŒ–åˆç‰©å¦‚è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é†‡çš„åˆæˆæ··åˆç‰©ï¼Œå¯èƒ½å°æŠ—è…«ç˜¤æœ‰è‰¯å¥½çš„æ•ˆæœï¼Œé€™ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚ã€‚ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼åˆæˆ15ç¨®æ–°çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦è©•ä¼°å®ƒå€‘çš„æŠ—ç™Œæ•ˆæœã€‚é€™äº›æ–°åŒ–åˆç‰©çš„è¨­è¨ˆæ—¨åœ¨æé«˜æŠ—è…«ç˜¤æ´»æ€§ï¼Œå¾è€Œç‚ºä¸‰é™°æ€§ä¹³ç™Œæ‚£è€…æä¾›æ›´æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘é¦–å…ˆåˆæˆäº†15ç¨®æ–°çš„æ··åˆç‰©ï¼Œç„¶å¾Œåœ¨å¯¦é©—å®¤ç’°å¢ƒä¸­æ¸¬è©¦é€™äº›åŒ–åˆç‰©å°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å½±éŸ¿ã€‚ä»–å€‘è©•ä¼°äº†é€™äº›åŒ–åˆç‰©çš„ç´°èƒå¢æ®–æŠ‘åˆ¶æ´»æ€§ï¼Œä¸¦è§€å¯Ÿäº†å®ƒå€‘å°ç´°èƒç”Ÿé•·ã€é·ç§»å’Œä¾µè¥²èƒ½åŠ›çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨å‹•ç‰©æ¨¡å‹ä¸­æ¸¬è©¦äº†æœ€æœ‰æ•ˆçš„åŒ–åˆç‰©ï¼Œä»¥è©•ä¼°å…¶å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœåŠå…¶å®‰å…¨æ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aé¡¯ç¤ºå‡ºæœ€é«˜çš„æŠ—å¢æ®–æ´»æ€§ï¼Œå…¶IC50å€¼åœ¨0.85åˆ°1.34å¾®æ‘©çˆ¾ä¹‹é–“ï¼Œé¡¯è‘—æŠ‘åˆ¶äº†ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²ï¼ŒåŒæ™‚èª˜å°ç´°èƒå‡‹äº¡ã€‚åœ¨å‹•ç‰©å¯¦é©—ä¸­ï¼Œ17aæœ‰æ•ˆæŠ‘åˆ¶äº†è…«ç˜¤çš„ç”Ÿé•·ï¼Œä¸”æœªè¦‹æ˜é¡¯çš„æ¯’æ€§ã€‚æ©Ÿåˆ¶ç ”ç©¶é¡¯ç¤ºï¼Œ17aèƒ½ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€šè·¯ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™äº›çµæœè¡¨æ˜17aæœ‰æ½›åŠ›æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ç”±æ–¼ä¸‰é™°æ€§ä¹³ç™Œä¸»è¦ä¾è³´åŒ–ç™‚ï¼Œé€™ä½¿å¾—æ¢ç´¢å¤©ç„¶ç”¢å“çš„æ½›åŠ›è®Šå¾—å°¤ç‚ºé—œéµã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶åŒ–åˆç‰©å¦‚è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é†‡çš„åˆæˆæ··åˆç‰©ï¼Œå¯èƒ½å°æŠ—è…«ç˜¤æœ‰è‰¯å¥½çš„æ•ˆæœï¼Œé€™ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚ã€‚ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼åˆæˆ15ç¨®æ–°çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦è©•ä¼°å®ƒå€‘çš„æŠ—ç™Œæ•ˆæœã€‚é€™äº›æ–°åŒ–åˆç‰©çš„è¨­è¨ˆæ—¨åœ¨æé«˜æŠ—è…«ç˜¤æ´»æ€§ï¼Œå¾è€Œç‚ºä¸‰é™°æ€§ä¹³ç™Œæ‚£è€…æä¾›æ›´æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘é¦–å…ˆåˆæˆäº†15ç¨®æ–°çš„æ··åˆç‰©ï¼Œç„¶å¾Œåœ¨å¯¦é©—å®¤ç’°å¢ƒä¸­æ¸¬è©¦é€™äº›åŒ–åˆç‰©å°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å½±éŸ¿ã€‚ä»–å€‘è©•ä¼°äº†é€™äº›åŒ–åˆç‰©çš„ç´°èƒå¢æ®–æŠ‘åˆ¶æ´»æ€§ï¼Œä¸¦è§€å¯Ÿäº†å®ƒå€‘å°ç´°èƒç”Ÿé•·ã€é·ç§»å’Œä¾µè¥²èƒ½åŠ›çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨å‹•ç‰©æ¨¡å‹ä¸­æ¸¬è©¦äº†æœ€æœ‰æ•ˆçš„åŒ–åˆç‰©ï¼Œä»¥è©•ä¼°å…¶å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœåŠå…¶å®‰å…¨æ€§ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aé¡¯ç¤ºå‡ºæœ€é«˜çš„æŠ—å¢æ®–æ´»æ€§ï¼Œå…¶IC50å€¼åœ¨0.85åˆ°1.34å¾®æ‘©çˆ¾ä¹‹é–“ï¼Œé¡¯è‘—æŠ‘åˆ¶äº†ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²ï¼ŒåŒæ™‚èª˜å°ç´°èƒå‡‹äº¡ã€‚åœ¨å‹•ç‰©å¯¦é©—ä¸­ï¼Œ17aæœ‰æ•ˆæŠ‘åˆ¶äº†è…«ç˜¤çš„ç”Ÿé•·ï¼Œä¸”æœªè¦‹æ˜é¡¯çš„æ¯’æ€§ã€‚æ©Ÿåˆ¶ç ”ç©¶é¡¯ç¤ºï¼Œ17aèƒ½ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€šè·¯ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™äº›çµæœè¡¨æ˜17aæœ‰æ½›åŠ›æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠEuropean journal of medicinal chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæœ‰ä¸€ç¨®ç™Œç—‡å«åšä¸‰é™°æ€§ä¹³ç™Œï¼Œé€™ç¨®ç™Œç—‡ç‰¹åˆ¥é›£å°ä»˜ï¼Œç§‘å­¸å®¶å€‘æ­£åœ¨åŠªåŠ›æ‰¾å‡ºæ›´å¥½çš„æ²»ç™‚æ–¹æ³•ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†å°æŠ—é€™ç¨®ç™Œç—‡ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é†‡çš„çµåˆã€‚é€™äº›å¤©ç„¶ç”¢å“çš„æ½›åŠ›è®“äººæœŸå¾…ï¼\n\nç ”ç©¶åœ˜éšŠåˆæˆäº†15ç¨®æ–°çš„åŒ–åˆç‰©ï¼Œä¸¦åœ¨å¯¦é©—å®¤è£¡æ¸¬è©¦å®ƒå€‘å°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å½±éŸ¿ã€‚ä»–å€‘ç™¼ç¾é€™äº›åŒ–åˆç‰©èƒ½æœ‰æ•ˆæŠ‘åˆ¶ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œç”šè‡³åœ¨å‹•ç‰©å¯¦é©—ä¸­ä¹Ÿé¡¯ç¤ºå‡ºè‰¯å¥½çš„è…«ç˜¤æŠ‘åˆ¶æ•ˆæœã€‚\n\næœ€ä»¤äººæŒ¯å¥®çš„æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨å¯¦é©—ä¸­è¡¨ç¾æœ€ä½³ï¼Œèƒ½å¤ é¡¯è‘—æ¸›å°‘ç™Œç´°èƒçš„å¢é•·ï¼Œä¸¦ä¸”æ²’æœ‰æ˜é¡¯çš„æ¯’æ€§ã€‚é€™äº›çµæœè®“ç§‘å­¸å®¶å€‘å°æœªä¾†çš„ç™Œç—‡æ²»ç™‚å……æ»¿å¸Œæœ›ï¼\n\nç¸½çµä¸€ä¸‹ï¼š  \n1. ä¸‰é™°æ€§ä¹³ç™Œæ˜¯ä¸€ç¨®é›£æ²»çš„ç™Œç—‡ï¼Œå°‹æ‰¾æ–°ç™‚æ³•éå¸¸é‡è¦ã€‚  \n2. ç ”ç©¶è€…åˆæˆäº†15ç¨®æ–°åŒ–åˆç‰©ä¾†å°æŠ—ç™Œç—‡ã€‚  \n3. åŒ–åˆç‰©17aé¡¯ç¤ºå‡ºè‰¯å¥½çš„æŠ—ç™Œæ•ˆæœï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ï¼",
    "image_prompt": "Create a flat design infographic on the study of a new anti-cancer compound. The image should have a light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified icons of experimental subjects like cells or animals, and use arrows or flow lines to illustrate the experimental process. There should be a designated area highlighting the main results, such as protective effects or changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ä¸‰é™°æ€§ä¹³ç™Œ Triple-negative Breast Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40961586/"
  },
  {
    "id": "41108925",
    "title_en": "Enhancing myocardial injury recovery: Nrf2 activation by sulforaphane regulates ferroptosis and oxidative stress in takotsubo-like models.",
    "pub_date": "2025 Dec",
    "journal": "International immunopharmacology",
    "abstract_en": "Takotsubo syndrome (TTS), once considered benign, can cause life-threatening myocardial injury. Although oxidative stress and ferroptosis are implicated in its pathogenesis, targeted therapies are not available for TTS. We demonstrate that sulforaphane (SFN), a natural Nrf2 activator, mitigates TTS-related injury in isoproterenol-induced rat models and AC16 cardiomyocytes. Isoproterenol induced ferroptosis and oxidative stress by impairing Nrf2 signaling. SFN treatment restored myocardial structure and function while enhancing antioxidant capacity, reducing mitochondrial damage, and suppressing ferroptosis markers. Additionally, similar to Fer-1 (a ferroptosis inhibitor), SFN reduced intracellular ferrous levels but uniquely activated Nrf2-driven endogenous defenses. Notably, Nrf2 inhibition abrogated the benefits of SFN in both in vitro and in vivo experiments. These findings highlight SFN as a dual-action therapeutic for TTS, simultaneously targeting oxidative stress and ferroptosis via Nrf2 activation. The therapeutic efficacy of SFN, combined with endogenous pathway modulation, underscores its translational potential for improving TTS outcomes.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé›–ç„¶å¡”å…‹èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå®ƒå¯èƒ½å°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‚Œæå‚·ã€‚å› æ­¤ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•è®Šå¾—éå¸¸é‡è¦ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¤©ç„¶çš„Nrf2æ¿€æ´»åŠ‘ï¼Œå¯èƒ½å°æ”¹å–„TTSç›¸é—œçš„å¿ƒè‚Œæå‚·æœ‰å¹«åŠ©ï¼Œé€™ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›äº†æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨é‡å°æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡çš„æ²»ç™‚ä¸Šï¼Œå¯èƒ½æœƒæœ‰æ›´å¥½çš„æ•ˆæœã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¡”å…‹èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼ŒTTSå¦‚ä½•å°è‡´å¿ƒè‚Œæå‚·ï¼Œä»¥åŠç›®å‰ç¼ºä¹é‡å°é€™ç¨®ç—…ç—‡çš„æœ‰æ•ˆæ²»ç™‚æ–¹æ³•ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡çš„æ©Ÿåˆ¶ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æ‰¾åˆ°æ”¹å–„TTSç—…æ‚£å¿ƒè‡ŸåŠŸèƒ½çš„å¯èƒ½é€”å¾‘ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç•°ä¸™è…ä¸Šè…ºç´ èª˜å°çš„è€é¼ æ¨¡å‹å’ŒAC16å¿ƒè‚Œç´°èƒä¾†æ¨¡æ“¬TTSçš„æƒ…æ³ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è§€å¯Ÿç•°ä¸™è…ä¸Šè…ºç´ å¦‚ä½•å¼•èµ·æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡ï¼Œä¸¦è©•ä¼°è˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…èƒ½å¤ åˆ†æè˜¿è””ç¡«ç´ å°å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½çš„å½±éŸ¿ï¼Œä»¥åŠå®ƒå¦‚ä½•å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›å’Œæ¸›å°‘ç·šç²’é«”æå‚·ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒæ™‚æ¸›å°‘ç´°èƒæ­»äº¡çš„æ¨™è¨˜ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç´°èƒå…§çš„äºéµæ°´å¹³ï¼Œä¸¦æ¿€æ´»Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œç•¶æŠ‘åˆ¶Nrf2æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„ç™‚æ•ˆæœƒæ¶ˆå¤±ï¼Œé€™è¡¨æ˜Nrf2åœ¨å…¶æ²»ç™‚ä½œç”¨ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ã€‚é€™äº›çµæœçªé¡¯äº†è˜¿è””ç¡«ç´ ä½œç‚ºTTSé›™é‡ä½œç”¨ç™‚æ³•çš„æ½›åŠ›ï¼Œå¯èƒ½åŒæ™‚é‡å°æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé›–ç„¶å¡”å…‹èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå®ƒå¯èƒ½å°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‚Œæå‚·ã€‚å› æ­¤ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•è®Šå¾—éå¸¸é‡è¦ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¤©ç„¶çš„Nrf2æ¿€æ´»åŠ‘ï¼Œå¯èƒ½å°æ”¹å–„TTSç›¸é—œçš„å¿ƒè‚Œæå‚·æœ‰å¹«åŠ©ï¼Œé€™ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›äº†æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨é‡å°æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡çš„æ²»ç™‚ä¸Šï¼Œå¯èƒ½æœƒæœ‰æ›´å¥½çš„æ•ˆæœã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¡”å…‹èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼ŒTTSå¦‚ä½•å°è‡´å¿ƒè‚Œæå‚·ï¼Œä»¥åŠç›®å‰ç¼ºä¹é‡å°é€™ç¨®ç—…ç—‡çš„æœ‰æ•ˆæ²»ç™‚æ–¹æ³•ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡çš„æ©Ÿåˆ¶ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æ‰¾åˆ°æ”¹å–„TTSç—…æ‚£å¿ƒè‡ŸåŠŸèƒ½çš„å¯èƒ½é€”å¾‘ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç•°ä¸™è…ä¸Šè…ºç´ èª˜å°çš„è€é¼ æ¨¡å‹å’ŒAC16å¿ƒè‚Œç´°èƒä¾†æ¨¡æ“¬TTSçš„æƒ…æ³ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è§€å¯Ÿç•°ä¸™è…ä¸Šè…ºç´ å¦‚ä½•å¼•èµ·æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡ï¼Œä¸¦è©•ä¼°è˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…èƒ½å¤ åˆ†æè˜¿è””ç¡«ç´ å°å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½çš„å½±éŸ¿ï¼Œä»¥åŠå®ƒå¦‚ä½•å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›å’Œæ¸›å°‘ç·šç²’é«”æå‚·ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒæ™‚æ¸›å°‘ç´°èƒæ­»äº¡çš„æ¨™è¨˜ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç´°èƒå…§çš„äºéµæ°´å¹³ï¼Œä¸¦æ¿€æ´»Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œç•¶æŠ‘åˆ¶Nrf2æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„ç™‚æ•ˆæœƒæ¶ˆå¤±ï¼Œé€™è¡¨æ˜Nrf2åœ¨å…¶æ²»ç™‚ä½œç”¨ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ã€‚é€™äº›çµæœçªé¡¯äº†è˜¿è””ç¡«ç´ ä½œç‚ºTTSé›™é‡ä½œç”¨ç™‚æ³•çš„æ½›åŠ›ï¼Œå¯èƒ½åŒæ™‚é‡å°æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡ã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational immunopharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæœ‰ä¸€ç¨®å«åšå¡”å…‹èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰çš„ç—…ç—‡ï¼Œéå»è¢«èªç‚ºæ˜¯ç„¡å®³çš„ï¼Œä½†å…¶å¯¦å¯èƒ½æœƒå°å¿ƒè‡Ÿé€ æˆåš´é‡æå‚·ï¼é€™è®“äººæ“”å¿ƒï¼Œå› ç‚ºç›®å‰å°æ–¼é€™ç¨®ç—…ç—‡çš„æœ‰æ•ˆæ²»ç™‚æ–¹æ³•é‚„ä¸å¤šã€‚æœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æ˜¯ä¸€å€‹æœ‰å¸Œæœ›çš„è§£æ±ºæ–¹æ¡ˆï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿TTSé€ æˆçš„å¿ƒè‚Œæå‚·ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†è€é¼ æ¨¡å‹å’Œå¿ƒè‚Œç´°èƒï¼Œæ¨¡æ“¬TTSçš„æƒ…æ³ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ åœ¨é€™éç¨‹ä¸­çš„æ•ˆæœã€‚é€éé€™äº›å¯¦é©—ï¼Œä»–å€‘ç™¼ç¾è˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œé‚„èƒ½å¢å¼·å¿ƒè‡Ÿçš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç´°èƒæ­»äº¡ã€‚\n\nä»¥ä¸‹æ˜¯é€™é …ç ”ç©¶çš„å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ èƒ½æ”¹å–„å¿ƒè‡Ÿçš„å¥åº·ç‹€æ³ã€‚\n2. å®ƒæœ‰åŠ©æ–¼é™ä½å¿ƒè‡Ÿç´°èƒå…§çš„æå‚·ã€‚\n3. Nrf2é€™å€‹è›‹ç™½è³ªåœ¨è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ã€‚\n\né›–ç„¶é€™äº›ç™¼ç¾å¾ˆæœ‰å¸Œæœ›ï¼Œä½†æˆ‘å€‘ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ï¼Œæ‰èƒ½ç¢ºå®šè˜¿è””ç¡«ç´ çš„çœŸæ­£ç™‚æ•ˆï¼",
    "image_prompt": "Create a flat design infographic with a light background that explains the experiment and main results of a study on the potential effects of sulforaphane in Takotsubo syndrome (TTS). Include simplified illustrations of broccoli or sulforaphane as a symbol, experimental subjects like mice or heart cells, and arrows or flow lines to show the experimental steps. Add a section that highlights the main results, such as protective effects and changes observed in heart function.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "å¡”å…‹èŒ²åšç—‡å€™ç¾¤ Takotsubo Syndrome",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41108925/"
  },
  {
    "id": "41340527",
    "title_en": "Metabolomics and Transcriptomics Analyses Reveal the Mechanisms of Sulforaphane Conversion and Adaptive Strategies in the Absence of Glucose by <i>Lactiplantibacillus plantarum</i>.",
    "pub_date": "2025 Dec",
    "journal": "Journal of agricultural and food chemistry",
    "abstract_en": "Sulforaphane is a beneficial but unstable bioactive compound that can be converted from glucoraphanin by <i>Lactiplantibacillus plantarum</i>. However, the sulforaphane conversion rate is low, and the conversion mechanism of <i>L. plantarum</i> remains unclear. This research utilized the adaptive laboratory evolution technology to enhance the sulforaphane conversion rate of <i>L. plantarum</i>. The results showed that an increase in the glucose replacement ratio significantly downregulated carbohydrate metabolism and upregulated amino acid metabolism. Transcriptomic analysis showed that the ALE-adapted strain significantly upregulated carbohydrate metabolism and amino acid metabolism. In the conversion pathway, glucoraphanin is imported into <i>L. plantarum</i> cells, and its glucose moiety is phosphorylated by bglF (the phosphate group may be derived from phosphoenolpyruvate via the phosphotransferase system). Subsequently, the S-glycosidic bond of phosphorylated glucoraphanin is hydrolyzed by bglA (6-phospho-Î²-glucosidase), followed by nonenzymatic rearrangement and sulfate elimination, ultimately yielding sulforaphane. This research can contribute to revealing the interaction mechanism between microorganisms and natural active substances.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„æ–°è¦‹è§£ï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ çš„è½‰æ›éç¨‹ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å°å¥åº·æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œå¯èƒ½åœ¨æŠ—ç™Œå’ŒæŠ—æ°§åŒ–æ–¹é¢ç™¼æ®ä½œç”¨ã€‚äº†è§£å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰æ›ç‡ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ›´æœ‰æ•ˆçš„è†³é£Ÿè£œå……å“ï¼Œé€²è€Œä¿ƒé€²å¥åº·å’Œé é˜²ç–¾ç—…ã€‚é€™å°æ–¼å¸Œæœ›é€éé£²é£Ÿæ”¹å–„å¥åº·çš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°‡é’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®å‰é«”åŒ–åˆç‰©â€”â€”è‘¡è„ç³–è‹·ï¼ˆglucoraphaninï¼‰è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚ç ”ç©¶è€…é—œæ³¨çš„å•é¡Œæ˜¯ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ å…·æœ‰å¤šç¨®å¥åº·ç›Šè™•ï¼Œä½†å…¶è½‰æ›ç‡å»ç›¸å°è¼ƒä½ï¼Œä¸”è½‰æ›çš„æ©Ÿåˆ¶å°šä¸æ¸…æ¥šã€‚å› æ­¤ï¼Œç ”ç©¶çš„é‡é»åœ¨æ–¼æ­ç¤ºé€™ä¸€éç¨‹çš„ç´°ç¯€ï¼Œä¸¦å°‹æ‰¾æé«˜è½‰æ›ç‡çš„æ–¹æ³•ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ï¼Œå°ä¹³é…¸èŒé€²è¡Œæ”¹é€ ï¼Œä»¥æé«˜å…¶è½‰æ›è˜¿è””ç¡«ç´ çš„èƒ½åŠ›ã€‚ç ”ç©¶åœ˜éšŠè§€å¯Ÿäº†ä¸åŒçš„è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å°ç´°èƒä»£è¬çš„å½±éŸ¿ï¼Œä¸¦é€²è¡Œäº†è½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£æ”¹é€ å¾Œçš„èŒæ ªåœ¨ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬æ–¹é¢çš„è®ŠåŒ–ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ·±å…¥äº†è§£ä¹³é…¸èŒå¦‚ä½•è™•ç†é’èŠ±æ¤°èœä¸­çš„è‘¡è„ç³–è‹·ï¼Œä¸¦æœ€çµ‚ç”¢ç”Ÿè˜¿è””ç¡«ç´ ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å¢åŠ æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ã€‚é€™è¡¨æ˜ï¼Œé€šéèª¿æ•´åŸ¹é¤Šæ¢ä»¶ï¼Œå¯ä»¥ä¿ƒé€²è˜¿è””ç¡«ç´ çš„ç”Ÿæˆã€‚ç ”ç©¶é‚„æ­ç¤ºäº†è‘¡è„ç³–è‹·åœ¨ä¹³é…¸èŒç´°èƒå…§çš„è½‰æ›è·¯å¾‘ï¼ŒåŒ…æ‹¬å…¶å¦‚ä½•è¢«é€²å£ã€ç£·é…¸åŒ–åŠæœ€çµ‚æ°´è§£ç”Ÿæˆè˜¿è””ç¡«ç´ ã€‚é€™äº›çµæœç‚ºæœªä¾†çš„å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªçš„ç›¸äº’ä½œç”¨æ©Ÿåˆ¶ç ”ç©¶æä¾›äº†é‡è¦çš„åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„æ–°è¦‹è§£ï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ çš„è½‰æ›éç¨‹ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å°å¥åº·æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œå¯èƒ½åœ¨æŠ—ç™Œå’ŒæŠ—æ°§åŒ–æ–¹é¢ç™¼æ®ä½œç”¨ã€‚äº†è§£å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰æ›ç‡ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ›´æœ‰æ•ˆçš„è†³é£Ÿè£œå……å“ï¼Œé€²è€Œä¿ƒé€²å¥åº·å’Œé é˜²ç–¾ç—…ã€‚é€™å°æ–¼å¸Œæœ›é€éé£²é£Ÿæ”¹å–„å¥åº·çš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°‡é’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®å‰é«”åŒ–åˆç‰©â€”â€”è‘¡è„ç³–è‹·ï¼ˆglucoraphaninï¼‰è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚ç ”ç©¶è€…é—œæ³¨çš„å•é¡Œæ˜¯ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ å…·æœ‰å¤šç¨®å¥åº·ç›Šè™•ï¼Œä½†å…¶è½‰æ›ç‡å»ç›¸å°è¼ƒä½ï¼Œä¸”è½‰æ›çš„æ©Ÿåˆ¶å°šä¸æ¸…æ¥šã€‚å› æ­¤ï¼Œç ”ç©¶çš„é‡é»åœ¨æ–¼æ­ç¤ºé€™ä¸€éç¨‹çš„ç´°ç¯€ï¼Œä¸¦å°‹æ‰¾æé«˜è½‰æ›ç‡çš„æ–¹æ³•ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ï¼Œå°ä¹³é…¸èŒé€²è¡Œæ”¹é€ ï¼Œä»¥æé«˜å…¶è½‰æ›è˜¿è””ç¡«ç´ çš„èƒ½åŠ›ã€‚ç ”ç©¶åœ˜éšŠè§€å¯Ÿäº†ä¸åŒçš„è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å°ç´°èƒä»£è¬çš„å½±éŸ¿ï¼Œä¸¦é€²è¡Œäº†è½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£æ”¹é€ å¾Œçš„èŒæ ªåœ¨ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬æ–¹é¢çš„è®ŠåŒ–ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ·±å…¥äº†è§£ä¹³é…¸èŒå¦‚ä½•è™•ç†é’èŠ±æ¤°èœä¸­çš„è‘¡è„ç³–è‹·ï¼Œä¸¦æœ€çµ‚ç”¢ç”Ÿè˜¿è””ç¡«ç´ ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å¢åŠ æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ã€‚é€™è¡¨æ˜ï¼Œé€šéèª¿æ•´åŸ¹é¤Šæ¢ä»¶ï¼Œå¯ä»¥ä¿ƒé€²è˜¿è””ç¡«ç´ çš„ç”Ÿæˆã€‚ç ”ç©¶é‚„æ­ç¤ºäº†è‘¡è„ç³–è‹·åœ¨ä¹³é…¸èŒç´°èƒå…§çš„è½‰æ›è·¯å¾‘ï¼ŒåŒ…æ‹¬å…¶å¦‚ä½•è¢«é€²å£ã€ç£·é…¸åŒ–åŠæœ€çµ‚æ°´è§£ç”Ÿæˆè˜¿è””ç¡«ç´ ã€‚é€™äº›çµæœç‚ºæœªä¾†çš„å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªçš„ç›¸äº’ä½œç”¨æ©Ÿåˆ¶ç ”ç©¶æä¾›äº†é‡è¦çš„åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of agricultural and food chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ å—ï¼Ÿé€™å¯æ˜¯å€‹å¥åº·çš„å°ç§˜å¯†å“¦ï¼æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œå°ˆé–€æ¢è¨å¦‚ä½•è®“é€™ç¨®å°èº«é«”æœ‰ç›Šçš„åŒ–åˆç‰©æ›´å®¹æ˜“è¢«æˆ‘å€‘å¸æ”¶ã€‚ç ”ç©¶è€…ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æŠ—ç™Œå’ŒæŠ—æ°§åŒ–ï¼Œä½†å®ƒçš„è½‰æ›ç‡ä¸€ç›´ä¸é«˜ï¼Œé€™è®“ç§‘å­¸å®¶å€‘éå¸¸å¥½å¥‡ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ˜¯é—œå¿ƒæ€éº¼æé«˜ä¸€ç¨®å«åšä¹³é…¸èŒçš„å¾®ç”Ÿç‰©ï¼ŒæŠŠé’èŠ±æ¤°èœè£¡çš„è‘¡è„ç³–è‹·è½‰æ›æˆè˜¿è””ç¡«ç´ ã€‚ä»–å€‘ä½¿ç”¨äº†ä¸€ç¨®å«é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“çš„æ–¹æ³•ï¼Œå°é€™äº›ä¹³é…¸èŒé€²è¡Œæ”¹é€ ï¼Œç„¶å¾Œè§€å¯Ÿå®ƒå€‘çš„ä»£è¬è®ŠåŒ–ã€‚\n\nçµæœé¡¯ç¤ºï¼Œç•¶ç ”ç©¶è€…èª¿æ•´äº†åŸ¹é¤Šæ¢ä»¶ï¼Œè®“è‘¡è„ç³–çš„æ¯”ä¾‹å¢åŠ æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å»ä¸Šå‡ï¼Œé€™è¡¨ç¤ºè˜¿è””ç¡«ç´ çš„ç”Ÿæˆæœ‰äº†æ”¹å–„ï¼é€™äº›ç™¼ç¾ä¸åƒ…æ­ç¤ºäº†è˜¿è””ç¡«ç´ çš„ç”Ÿæˆéç¨‹ï¼Œé‚„ç‚ºæœªä¾†çš„å¥åº·ç ”ç©¶æ‰“ä¸‹äº†åŸºç¤ã€‚\n\nâœ¨ ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æŠ—ç™Œå’ŒæŠ—æ°§åŒ–ã€‚\n2. ä¹³é…¸èŒèƒ½æé«˜è˜¿è””ç¡«ç´ çš„è½‰æ›ç‡ã€‚\n3. èª¿æ•´åŸ¹é¤Šæ¢ä»¶èƒ½ä¿ƒé€²è˜¿è””ç¡«ç´ çš„ç”Ÿæˆï¼",
    "image_prompt": "Create an informative and simplified illustration explaining the experimental process and main results of a study on sulforaphane production from glucoraphanin in broccoli by Lactiplantibacillus plantarum. Use a flat design style with a light background and soft colors. Include symbols for broccoli and sulforaphane, simplified representations of the experimental subjects (like human, animal, or cells), arrows or flow lines indicating the experimental steps, and a section highlighting the main results, such as changes in metabolic pathways.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41340527/"
  },
  {
    "id": "41341174",
    "title_en": "Sulforaphane attenuates oxidative stress, senescence, and ferroptosis induced by cigarette smoke extract <i>in vitro</i> and <i>in vivo via</i> upregulating the expression of SIRT1.",
    "pub_date": "2025 Dec",
    "journal": "Research in pharmaceutical sciences",
    "abstract_en": "Cigarette smoking induces lung toxicity by triggering oxidative stress, leading to apoptosis, ferroptosis, and senescence. Sulforaphane (SFN), a potent antioxidant, activates the SIRT1 pathway, enhancing cellular stress resistance and survival. This study aimed to evaluate the protective effects of SFN against cigarette smoke extract (CSE)-induced damage in human airway epithelial cells (BEAS-2B) and in mouse lungs, focusing on its role in upregulating SIRT1 expression. BEAS-2B cells were treated with CSE and SFN, and cell viability was assessed using the MTT assay. Cellular senescence was assessed using the SA-Î²-gal assay and the expression of genes associated with senescence (p16 and p21). The expression levels of SIRT1, senescence-associated secretory phenotype (SASP) cytokines (IL-1Î², IL-6, IL-8, TNF-Î±), GPX4, and SLC7A11 were quantified using qRT-PCR. Additionally, ROS production, GSH and MDA levels, and iron content were measured. An emphysema mouse model was induced by intraperitoneal administration of CSE (7.2 mg/kg) alone or in combination with SFN (10.2 mg/kg) over 28 days, and subsequent histopathological changes were evaluated. Our findings revealed that SFN co-treatment effectively mitigated CSE-induced cytotoxicity, senescence, and SASP cytokine secretion, as well as the pronounced emphysematous changes in lung tissues. Furthermore, SFN reversed CSE-induced downregulation of SIRT1 and upregulation of NF-ÎºB. Notably, SFN also inhibited CSE-induced ferroptosis by increasing GPX4 and SLC7A11 expression while reducing iron and MDA levels. The findings of the present study demonstrated that sulforaphane offers protective effects against CSE-induced toxicity by mitigating oxidative stress, ferroptosis, and cellular senescence.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€å¼•èµ·çš„è‚ºéƒ¨æ¯’æ€§å•é¡Œã€‚å¸ç…™æœƒå°è‡´æ°§åŒ–å£“åŠ›ï¼Œé€²è€Œå¼•ç™¼ç´°èƒæ­»äº¡å’Œè€åŒ–ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·ç´°èƒå°é€™äº›å£“åŠ›çš„æŠµæŠ—åŠ›ï¼Œå¾è€Œä¿è­·è‚ºéƒ¨å¥åº·ã€‚é€™å°æ–¼å¸ç…™è€…æˆ–é•·æœŸæš´éœ²æ–¼ç…™éœ§ä¸­çš„äººä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„å¥åº·æç¤ºï¼Œè®“ä»–å€‘äº†è§£å¦‚ä½•é€éé£²é£Ÿè£œå……ä¾†æ¸›å°‘å¸ç…™å¸¶ä¾†çš„å‚·å®³ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯å¸ç…™æå–ç‰©å°äººé¡æ°£é“ä¸Šçš®ç´°èƒå’Œå°é¼ è‚ºéƒ¨çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒçš„ç”Ÿå­˜å’ŒæŠµæŠ—åŠ›ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ ä¸Šèª¿SIRT1çš„è¡¨é”ï¼Œé€™æ˜¯ä¸€å€‹èˆ‡ç´°èƒå£“åŠ›æŠµæŠ—æœ‰é—œçš„é‡è¦é€šè·¯ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bç´°èƒï¼Œé€™æ˜¯ä¸€ç¨®äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ çš„æ··åˆç‰©ä¸­ã€‚é€éMTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ï¼Œä¸¦ä½¿ç”¨SA-Î²-galæ¸¬è©¦ä¾†æª¢æŸ¥ç´°èƒçš„è€åŒ–æƒ…æ³ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é‡æ¸¬äº†èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œä»¥åŠæ°§åŒ–å£“åŠ›æŒ‡æ¨™çš„è®ŠåŒ–ã€‚åœ¨å°é¼ æ¨¡å‹ä¸­ï¼Œç ”ç©¶è€…å‰‡é€éè…¹è…”æ³¨å°„å¸ç…™æå–ç‰©ä¾†èª˜å°è‚ºæ°£è…«ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†èƒ½æœ‰æ•ˆæ¸›å°‘å¸ç…™æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–å’Œç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„å°é¼ è‚ºéƒ¨çš„ç—…ç†è®ŠåŒ–ã€‚è˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™æå–ç‰©å°SIRT1çš„ä¸‹èª¿å’ŒNF-ÎºBçš„ä¸Šèª¿ï¼Œä¸¦æŠ‘åˆ¶å¸ç…™æå–ç‰©å¼•èµ·çš„éµæ­»äº¡ï¼Œé€™æ˜¯é€éå¢åŠ GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†å¯¦ç¾çš„ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–å…·æœ‰ä¸€å®šçš„ä¿è­·ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€å¼•èµ·çš„è‚ºéƒ¨æ¯’æ€§å•é¡Œã€‚å¸ç…™æœƒå°è‡´æ°§åŒ–å£“åŠ›ï¼Œé€²è€Œå¼•ç™¼ç´°èƒæ­»äº¡å’Œè€åŒ–ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·ç´°èƒå°é€™äº›å£“åŠ›çš„æŠµæŠ—åŠ›ï¼Œå¾è€Œä¿è­·è‚ºéƒ¨å¥åº·ã€‚é€™å°æ–¼å¸ç…™è€…æˆ–é•·æœŸæš´éœ²æ–¼ç…™éœ§ä¸­çš„äººä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„å¥åº·æç¤ºï¼Œè®“ä»–å€‘äº†è§£å¦‚ä½•é€éé£²é£Ÿè£œå……ä¾†æ¸›å°‘å¸ç…™å¸¶ä¾†çš„å‚·å®³ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯å¸ç…™æå–ç‰©å°äººé¡æ°£é“ä¸Šçš®ç´°èƒå’Œå°é¼ è‚ºéƒ¨çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒçš„ç”Ÿå­˜å’ŒæŠµæŠ—åŠ›ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ ä¸Šèª¿SIRT1çš„è¡¨é”ï¼Œé€™æ˜¯ä¸€å€‹èˆ‡ç´°èƒå£“åŠ›æŠµæŠ—æœ‰é—œçš„é‡è¦é€šè·¯ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bç´°èƒï¼Œé€™æ˜¯ä¸€ç¨®äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ çš„æ··åˆç‰©ä¸­ã€‚é€éMTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ï¼Œä¸¦ä½¿ç”¨SA-Î²-galæ¸¬è©¦ä¾†æª¢æŸ¥ç´°èƒçš„è€åŒ–æƒ…æ³ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é‡æ¸¬äº†èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œä»¥åŠæ°§åŒ–å£“åŠ›æŒ‡æ¨™çš„è®ŠåŒ–ã€‚åœ¨å°é¼ æ¨¡å‹ä¸­ï¼Œç ”ç©¶è€…å‰‡é€éè…¹è…”æ³¨å°„å¸ç…™æå–ç‰©ä¾†èª˜å°è‚ºæ°£è…«ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†èƒ½æœ‰æ•ˆæ¸›å°‘å¸ç…™æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–å’Œç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„å°é¼ è‚ºéƒ¨çš„ç—…ç†è®ŠåŒ–ã€‚è˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™æå–ç‰©å°SIRT1çš„ä¸‹èª¿å’ŒNF-ÎºBçš„ä¸Šèª¿ï¼Œä¸¦æŠ‘åˆ¶å¸ç…™æå–ç‰©å¼•èµ·çš„éµæ­»äº¡ï¼Œé€™æ˜¯é€éå¢åŠ GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†å¯¦ç¾çš„ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–å…·æœ‰ä¸€å®šçš„ä¿è­·ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠResearch in pharmaceutical sciencesã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± è½èªªåƒè˜¿è””èƒ½å¹«åŠ©è‚ºéƒ¨å¥åº·ï¼Ÿé€™å¯ä¸æ˜¯éš¨ä¾¿èªªèªªçš„ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆé–€æ¢è¨äº†è˜¿è””ç¡«ç´ ï¼ˆé€™æ˜¯ä¸€ç¨®è˜¿è””è£¡çš„å¥½æˆåˆ†ï¼‰å°å¸ç…™é€ æˆçš„è‚ºéƒ¨æå‚·çš„å½±éŸ¿ã€‚\n\nç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œå¸ç…™æœƒè®“æˆ‘å€‘çš„è‚ºéƒ¨æ‰¿å—å¾ˆå¤§çš„å£“åŠ›ï¼Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ã€‚è€Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆçš„æŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½èƒ½å¹«åŠ©æˆ‘å€‘çš„ç´°èƒæŠµæŠ—é€™äº›å£“åŠ›ï¼Œä¿è­·è‚ºéƒ¨å¥åº·ï¼\n\né€™é …ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨äº†äººé¡çš„æ°£é“ç´°èƒå’Œå°é¼ ä¾†é€²è¡Œå¯¦é©—ã€‚ä»–å€‘æŠŠé€™äº›ç´°èƒæš´éœ²åœ¨å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ çš„æ··åˆç‰©ä¸­ï¼Œä¸¦è§€å¯Ÿç´°èƒçš„å­˜æ´»ç‡å’Œè€åŒ–æƒ…æ³ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæ¸›å°‘å¸ç…™å¼•èµ·çš„ç´°èƒæ¯’æ€§ï¼Œä¸¦æ”¹å–„å°é¼ çš„è‚ºéƒ¨å¥åº·ã€‚\n\né€™è£¡æœ‰å¹¾å€‹é‡é»ä½ å¯èƒ½æœƒæƒ³çŸ¥é“ï¼š\n1. è˜¿è””ç¡«ç´ èƒ½å¹«åŠ©æŠµæŠ—å¸ç…™é€ æˆçš„ç´°èƒè€åŒ–ã€‚\n2. å®ƒèƒ½æ”¹å–„è‚ºéƒ¨çš„ç—…ç†è®ŠåŒ–ï¼Œå°å¸ç…™è€…ä¾†èªªæˆ–è¨±æ˜¯ä¸€å€‹å¥½æ¶ˆæ¯ï¼\n3. é€éé£²é£Ÿè£œå……è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å¸ç…™çš„å‚·å®³ã€‚\n\næ‰€ä»¥ï¼Œåˆ¥å¿˜äº†åœ¨æ—¥å¸¸é£²é£Ÿä¸­å¤šåƒé»è˜¿è””ï¼Œè®“è‚ºéƒ¨æ›´å¥åº·ï¼",
    "image_prompt": "Create a simple and informative illustration explaining the experiment and main results of a study on the protective effects of sulforaphane from radishes against smoking-induced lung damage. Use a flat design style with a light background and soft colors. Include symbols representing sulforaphane (like broccoli or radish), simplified figures of human cells and mice, arrows or flow lines indicating the experimental steps, and a section highlighting the main results, such as protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºæ°£è…« Emphysema",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41341174/"
  },
  {
    "id": "41039785",
    "title_en": "Integrative Network Pharmacology and Proteomics Decipher the Immunomodulatory Mechanism of Sulforaphane Against Intrinsic Skin Aging.",
    "pub_date": "2025 Dec",
    "journal": "Molecular nutrition & food research",
    "abstract_en": "Skin aging is characterized by declines in structural functions, contributing to age-associated frailty. Sulforaphane (SFN), a natural anti-inflammatory substance, has been widely applied in multiple types of cancer therapies. However, its role in alleviating intrinsic skin aging remains to be elucidated. Integrative network pharmacology and proteomics were utilized to investigate the underlying mechanisms of SFN in intrinsic skin aging. Fifty-one anti-aging targets of SFN were identified, highlighting its promising regulatory impact on the aging process. Based on an 18-month-old natural aging mouse model, significant alleviation in skin structure, redox homeostasis, and immune cell composition was noted after 2 months of SFN supplementation. Additionally, proteomic analysis demonstrated that SFN reversed the proteomic profile of intrinsic skin aging, with 233 differentially expressed proteins (DEPs) identified in SFN-fed aging mice. Of note, the up-regulated DEPs were highly enriched in the apelin signaling pathway (pÂ =Â 0.010). Furthermore, immune cell infiltration and whole blood cell analysis revealed that SFN rescued T cells depletion in dermal tissue, which was strongly correlated with DEPs enriched in the SFN-activated apelin signaling pathway. SFN improves skin morphology and immune functions via activating the apelin signaling pathway, suggesting new prime targets in counteracting intrinsic skin aging.",
    "para1": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šçš„çµæ§‹åŠŸèƒ½æœƒé€æ¼¸ä¸‹é™ï¼Œé€™å¯èƒ½æœƒå°è‡´èˆ‡å¹´é½¡ç›¸é—œçš„è„†å¼±æ„Ÿã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶æŠ—ç™¼ç‚ç‰©è³ªåœ¨æ¸›ç·©çš®è†šè€åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚é›–ç„¶è˜¿è””ç¡«ç´ åœ¨å¤šç¨®ç™Œç—‡æ²»ç™‚ä¸­å·²ç¶“å»£æ³›æ‡‰ç”¨ï¼Œä½†å®ƒå°æ–¼å…§åœ¨çš®è†šè€åŒ–çš„å½±éŸ¿ä»éœ€é€²ä¸€æ­¥äº†è§£ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæˆ‘å€‘æä¾›æ–°çš„æ€è·¯ï¼Œä»¥æ”¹å–„çš®è†šå¥åº·å’Œé é˜²è€åŒ–ç›¸é—œçš„å•é¡Œã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–éç¨‹ä¸­çš„ä½œç”¨åŠå…¶æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿çš®è†šçš„çµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡ä»¥åŠå…ç–«ç´°èƒçš„çµ„æˆï¼Œä¸¦å°‹æ‰¾å…¶å¯èƒ½çš„æŠ—è€åŒ–é¶é»ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨çš®è†šè€åŒ–ä¸­çš„æ½›åœ¨ç›Šè™•ï¼Œä¸¦ç‚ºæœªä¾†çš„è­·è†šç”¢å“é–‹ç™¼æä¾›ä¾æ“šã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡åŠå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚é€éæ•´åˆæ€§ç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„åˆ†æï¼Œç ”ç©¶è€…è­˜åˆ¥å‡º51å€‹èˆ‡æŠ—è€åŒ–ç›¸é—œçš„é¶é»ï¼Œä¸¦é€²ä¸€æ­¥åˆ†æäº†è˜¿è””ç¡«ç´ å°é€™äº›é¶é»çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒçµ„æˆéƒ½æœ‰é¡¯è‘—æ”¹å–„ã€‚æ­¤å¤–ï¼Œè›‹ç™½è³ªçµ„å­¸åˆ†ææ­ç¤ºäº†233ç¨®ä¸åŒè¡¨é”çš„è›‹ç™½è³ªï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½å¤ é€†è½‰å…§åœ¨çš®è†šè€åŒ–çš„è›‹ç™½è³ªçµ„ç‰¹å¾µã€‚ç‰¹åˆ¥æ˜¯ï¼Œèˆ‡è˜¿è””ç¡«ç´ æ¿€æ´»çš„apelinä¿¡è™Ÿé€šè·¯ç›¸é—œçš„è›‹ç™½è³ªè¡¨é”ä¸Šèª¿ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½é€éé€™ä¸€ä¿¡è™Ÿé€šè·¯æ”¹å–„çš®è†šå½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œç‚ºå°æŠ—å…§åœ¨çš®è†šè€åŒ–æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "explanation_zh": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šçš„çµæ§‹åŠŸèƒ½æœƒé€æ¼¸ä¸‹é™ï¼Œé€™å¯èƒ½æœƒå°è‡´èˆ‡å¹´é½¡ç›¸é—œçš„è„†å¼±æ„Ÿã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶æŠ—ç™¼ç‚ç‰©è³ªåœ¨æ¸›ç·©çš®è†šè€åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚é›–ç„¶è˜¿è””ç¡«ç´ åœ¨å¤šç¨®ç™Œç—‡æ²»ç™‚ä¸­å·²ç¶“å»£æ³›æ‡‰ç”¨ï¼Œä½†å®ƒå°æ–¼å…§åœ¨çš®è†šè€åŒ–çš„å½±éŸ¿ä»éœ€é€²ä¸€æ­¥äº†è§£ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæˆ‘å€‘æä¾›æ–°çš„æ€è·¯ï¼Œä»¥æ”¹å–„çš®è†šå¥åº·å’Œé é˜²è€åŒ–ç›¸é—œçš„å•é¡Œã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–éç¨‹ä¸­çš„ä½œç”¨åŠå…¶æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿çš®è†šçš„çµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡ä»¥åŠå…ç–«ç´°èƒçš„çµ„æˆï¼Œä¸¦å°‹æ‰¾å…¶å¯èƒ½çš„æŠ—è€åŒ–é¶é»ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨çš®è†šè€åŒ–ä¸­çš„æ½›åœ¨ç›Šè™•ï¼Œä¸¦ç‚ºæœªä¾†çš„è­·è†šç”¢å“é–‹ç™¼æä¾›ä¾æ“šã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡åŠå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚é€éæ•´åˆæ€§ç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„åˆ†æï¼Œç ”ç©¶è€…è­˜åˆ¥å‡º51å€‹èˆ‡æŠ—è€åŒ–ç›¸é—œçš„é¶é»ï¼Œä¸¦é€²ä¸€æ­¥åˆ†æäº†è˜¿è””ç¡«ç´ å°é€™äº›é¶é»çš„å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒçµ„æˆéƒ½æœ‰é¡¯è‘—æ”¹å–„ã€‚æ­¤å¤–ï¼Œè›‹ç™½è³ªçµ„å­¸åˆ†ææ­ç¤ºäº†233ç¨®ä¸åŒè¡¨é”çš„è›‹ç™½è³ªï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½å¤ é€†è½‰å…§åœ¨çš®è†šè€åŒ–çš„è›‹ç™½è³ªçµ„ç‰¹å¾µã€‚ç‰¹åˆ¥æ˜¯ï¼Œèˆ‡è˜¿è””ç¡«ç´ æ¿€æ´»çš„apelinä¿¡è™Ÿé€šè·¯ç›¸é—œçš„è›‹ç™½è³ªè¡¨é”ä¸Šèª¿ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½é€éé€™ä¸€ä¿¡è™Ÿé€šè·¯æ”¹å–„çš®è†šå½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œç‚ºå°æŠ—å…§åœ¨çš®è†šè€åŒ–æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular nutrition & food researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿéš¨è‘—å¹´é½¡å¢é•·ï¼Œæˆ‘å€‘çš„çš®è†šæœƒè®Šå¾—è¶Šä¾†è¶Šè„†å¼±ï¼Œé€™æ˜¯è‡ªç„¶çš„ç¾è±¡ã€‚ä¸éï¼Œæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶ç‰©è³ªå¯èƒ½æœ‰åŠ©æ–¼æ¸›ç·©çš®è†šè€åŒ–ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨äº†è˜¿è””ç¡«ç´ å°çš®è†šçš„å½±éŸ¿ã€‚ç ”ç©¶è€…ç”¨ä¸€ç¨®18å€‹æœˆå¤§çš„å°é¼ ä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ï¼Œä¸¦çµ¦é€™äº›å°é¼ è£œå……äº†è˜¿è””ç¡«ç´ ï¼Œç„¶å¾Œè§€å¯Ÿå®ƒå€‘çš„çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡ï¼ˆç°¡å–®ä¾†èªªï¼Œå°±æ˜¯ç´°èƒçš„å¥åº·ç‹€æ…‹ï¼‰å’Œå…ç–«ç´°èƒçš„è®ŠåŒ–ã€‚\n\nçµæœé¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è£œå……ï¼Œé€™äº›å°é¼ çš„çš®è†šæ˜é¡¯æ”¹å–„äº†ï¼ä¸åƒ…çš®è†šçµæ§‹è®Šå¾—æ›´å¥½ï¼Œé€£ç´°èƒçš„å¥åº·ç‹€æ…‹å’Œå…ç–«åŠŸèƒ½ä¹Ÿæœ‰æ˜é¡¯æå‡ã€‚é€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½é€éæŸäº›ç”Ÿç‰©ä¿¡è™Ÿé€šè·¯ä¾†å¹«åŠ©æˆ‘å€‘çš„çš®è†šä¿æŒå¹´è¼•ã€‚\n\nç¸½çµä¾†èªªï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©æ¸›ç·©çš®è†šè€åŒ–ã€‚\n2. é€™é …ç ”ç©¶ä½¿ç”¨å°é¼ æ¨¡å‹ä¾†æ¨¡æ“¬çš®è†šè€åŒ–éç¨‹ã€‚\n3. ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æ”¹å–„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½ã€‚",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of a study on sulforaphane. Include symbolic illustrations of broccoli or sulforaphane, simplified representations of the experimental subjects (like mice), and arrows or flow lines indicating the steps of the experiment. Add a section that clearly highlights the main results, such as improvements in skin structure and immune function.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41039785/"
  },
  {
    "id": "41027171",
    "title_en": "Multi-omics analysis of gut-liver axis reveals the mechanism by which sulforaphane alleviates liver injury in Cyprinus carpio exposed to triphenyltin.",
    "pub_date": "2025 Dec",
    "journal": "Comparative biochemistry and physiology. Part D, Genomics & proteomics",
    "abstract_en": "This study investigates the protective effects of sulforaphane (SFN) against triphenyltin (TPT)-induced hepatotoxicity, immune dysfunction and gut microbiota dysbiosis in Cyprinus carpio. Cyprinus carpio were divided into three groups and exposed for 8Â weeks, including control, 10Â Î¼g/L TPT and 10Â Î¼g/L TPTÂ +Â 10Â mg/kg SFN group. This result showed that TPT exposure induced significantly (PÂ <Â 0.05) hepatotoxicity, evidenced by increasing hepatic total bile acid (TBA) and total cholesterol levels, while upregulating Hsp70/90 and downregulating lysozyme gene expression. SFN supplementation reduced TBA accumulation, normalized Hsp90 and lysozyme expression, mitigating TPT-induced lipid dysregulation and immunosuppression. Transcriptomic analysis revealed that TPT exposure activated lipid metabolism pathways (PPAR signaling and cholesterol metabolism), but suppressed immune-related pathways. SFN supplementation restored metabolic homeostasis by enriching glucose and amino acid metabolism pathways and activating AMPK signaling, while also modulating the expression of key genes (PLIN1, ME1, CPT1B). The microbiota composition were changed in SFNÂ +Â TPT, including the increased of beneficial Fusobacteriota and Cetobacterium, and the decreased of pathogenic Proteobacteria and Aeromonas. The gut transcriptome dysregulation were restored in SFNÂ +Â TPT by enhancing immune pathways in Toll-like/NOD-like receptors. The significant correlations linked were found in gut microbes (Kaistia, Vagococcus) to hepatic/intestinal gene expression in SFNÂ +Â TPT. Overall, these findings elucidate novel mechanisms underlying TPT-induced immunotoxicity in liver and intestine and demonstrate the protective role of SFN, providing a theoretical foundation for its application in toxicity mitigation strategies.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ç”±ä¸‰è‹¯éŒ«ï¼ˆTPTï¼‰å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½å¤±èª¿çš„æƒ…æ³ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨æ¸›å°‘é€™äº›æ¯’æ€§å½±éŸ¿æ–¹é¢ç™¼æ®ä¿è­·ä½œç”¨ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·ç®¡ç†å’Œç–¾ç—…é é˜²ç­–ç•¥å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éäº†è§£é€™äº›æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†ä¿è­·è‚è‡Ÿå¥åº·ï¼Œä¸¦æ”¹å–„å…ç–«ç³»çµ±çš„åŠŸèƒ½ï¼Œé€™å°æ–¼æå‡æ•´é«”å¥åº·ç‹€æ³æ˜¯éå¸¸é‡è¦çš„ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿ä»¥åŠè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ä¸‰è‹¯éŒ«é€™ç¨®åŒ–å­¸ç‰©è³ªå°é­šé¡ï¼ˆé¯‰é­šï¼‰é€ æˆçš„å¥åº·å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„åŠŸèƒ½ã€‚é€™äº›å•é¡Œä¸åƒ…é—œä¹æ°´ç”Ÿç”Ÿç‰©çš„å¥åº·ï¼Œä¹Ÿå¯èƒ½å°äººé¡å¥åº·æœ‰å•Ÿç¤ºï¼Œå› ç‚ºç’°å¢ƒä¸­çš„åŒ–å­¸ç‰©è³ªå°ç”Ÿæ…‹ç³»çµ±çš„å½±éŸ¿æ˜¯å»£æ³›çš„ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡é¯‰é­šåˆ†æˆä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸå…«é€±çš„å¯¦é©—ã€‚é€™ä¸‰çµ„åˆ†åˆ¥æ˜¯å°ç…§çµ„ã€æš´éœ²æ–¼10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„ï¼Œä»¥åŠåŒæ™‚æš´éœ²æ–¼10å¾®å…‹/å‡ä¸‰è‹¯éŒ«å’Œ10æ¯«å…‹/å…¬æ–¤è˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€‚ç ”ç©¶è€…é€šéè§€å¯Ÿé€™äº›é­šçš„è‚è‡ŸæŒ‡æ¨™ã€å…ç–«åŸºå› è¡¨é”å’Œè…¸é“å¾®ç”Ÿç‰©çµ„æˆï¼Œä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœï¼Œä¸¦åˆ†æå…¶å¯èƒ½çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿæ¯’æ€§ï¼Œè¡¨ç¾ç‚ºè‚è‡Ÿç¸½è†½é¹¼é…¸å’Œç¸½è†½å›ºé†‡æ°´å¹³çš„ä¸Šå‡ï¼Œä»¥åŠå…ç–«ç›¸é—œåŸºå› çš„è¡¨é”è®ŠåŒ–ã€‚è€Œè˜¿è””ç¡«ç´ çš„è£œå……å‰‡æœ‰åŠ©æ–¼æ¸›å°‘è†½é¹¼é…¸çš„ç©ç´¯ï¼Œæ¢å¾©åŸºå› è¡¨é”çš„æ­£å¸¸æ°´å¹³ï¼Œä¸¦æ”¹å–„ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è„‚è³ªå¤±èª¿å’Œå…ç–«æŠ‘åˆ¶ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆä¹Ÿç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å¢å¼·æœ‰ç›ŠèŒçš„æ¯”ä¾‹ï¼Œä¸¦æ¸›å°‘æœ‰å®³èŒçš„æ•¸é‡ã€‚é€™äº›çµæœç‚ºç†è§£ä¸‰è‹¯éŒ«å¼•èµ·çš„å…ç–«æ¯’æ€§æä¾›äº†æ–°çš„è¦‹è§£ï¼Œä¸¦é¡¯ç¤ºäº†è˜¿è””ç¡«ç´ çš„æ½›åœ¨ä¿è­·ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ç”±ä¸‰è‹¯éŒ«ï¼ˆTPTï¼‰å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½å¤±èª¿çš„æƒ…æ³ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨æ¸›å°‘é€™äº›æ¯’æ€§å½±éŸ¿æ–¹é¢ç™¼æ®ä¿è­·ä½œç”¨ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·ç®¡ç†å’Œç–¾ç—…é é˜²ç­–ç•¥å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éäº†è§£é€™äº›æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†ä¿è­·è‚è‡Ÿå¥åº·ï¼Œä¸¦æ”¹å–„å…ç–«ç³»çµ±çš„åŠŸèƒ½ï¼Œé€™å°æ–¼æå‡æ•´é«”å¥åº·ç‹€æ³æ˜¯éå¸¸é‡è¦çš„ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿ä»¥åŠè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ä¸‰è‹¯éŒ«é€™ç¨®åŒ–å­¸ç‰©è³ªå°é­šé¡ï¼ˆé¯‰é­šï¼‰é€ æˆçš„å¥åº·å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„åŠŸèƒ½ã€‚é€™äº›å•é¡Œä¸åƒ…é—œä¹æ°´ç”Ÿç”Ÿç‰©çš„å¥åº·ï¼Œä¹Ÿå¯èƒ½å°äººé¡å¥åº·æœ‰å•Ÿç¤ºï¼Œå› ç‚ºç’°å¢ƒä¸­çš„åŒ–å­¸ç‰©è³ªå°ç”Ÿæ…‹ç³»çµ±çš„å½±éŸ¿æ˜¯å»£æ³›çš„ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡é¯‰é­šåˆ†æˆä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸå…«é€±çš„å¯¦é©—ã€‚é€™ä¸‰çµ„åˆ†åˆ¥æ˜¯å°ç…§çµ„ã€æš´éœ²æ–¼10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„ï¼Œä»¥åŠåŒæ™‚æš´éœ²æ–¼10å¾®å…‹/å‡ä¸‰è‹¯éŒ«å’Œ10æ¯«å…‹/å…¬æ–¤è˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€‚ç ”ç©¶è€…é€šéè§€å¯Ÿé€™äº›é­šçš„è‚è‡ŸæŒ‡æ¨™ã€å…ç–«åŸºå› è¡¨é”å’Œè…¸é“å¾®ç”Ÿç‰©çµ„æˆï¼Œä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœï¼Œä¸¦åˆ†æå…¶å¯èƒ½çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿæ¯’æ€§ï¼Œè¡¨ç¾ç‚ºè‚è‡Ÿç¸½è†½é¹¼é…¸å’Œç¸½è†½å›ºé†‡æ°´å¹³çš„ä¸Šå‡ï¼Œä»¥åŠå…ç–«ç›¸é—œåŸºå› çš„è¡¨é”è®ŠåŒ–ã€‚è€Œè˜¿è””ç¡«ç´ çš„è£œå……å‰‡æœ‰åŠ©æ–¼æ¸›å°‘è†½é¹¼é…¸çš„ç©ç´¯ï¼Œæ¢å¾©åŸºå› è¡¨é”çš„æ­£å¸¸æ°´å¹³ï¼Œä¸¦æ”¹å–„ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è„‚è³ªå¤±èª¿å’Œå…ç–«æŠ‘åˆ¶ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆä¹Ÿç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å¢å¼·æœ‰ç›ŠèŒçš„æ¯”ä¾‹ï¼Œä¸¦æ¸›å°‘æœ‰å®³èŒçš„æ•¸é‡ã€‚é€™äº›çµæœç‚ºç†è§£ä¸‰è‹¯éŒ«å¼•èµ·çš„å…ç–«æ¯’æ€§æä¾›äº†æ–°çš„è¦‹è§£ï¼Œä¸¦é¡¯ç¤ºäº†è˜¿è””ç¡«ç´ çš„æ½›åœ¨ä¿è­·ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Part D, Genomics & proteomicsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“è˜¿è””ç¡«ç´ å…¶å¯¦å°æˆ‘å€‘çš„å¥åº·æœ‰å¹«åŠ©å—ï¼Ÿæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œé€™ç¨®ç‰©è³ªå¯èƒ½å°æŠ—æŸäº›ç’°å¢ƒæ±¡æŸ“ç‰©çš„æ¯’æ€§ï¼Œç‰¹åˆ¥æ˜¯ä¸‰è‹¯éŒ«ï¼ˆTPTï¼‰é€™ç¨®åŒ–å­¸ç‰©è³ªï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨ä¸‰è‹¯éŒ«å°é­šé¡è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œå› ç‚ºé€™ä¸åƒ…é—œä¹æ°´ä¸­çš„ç”Ÿç‰©ï¼Œä¹Ÿå¯èƒ½å½±éŸ¿åˆ°æˆ‘å€‘äººé¡çš„å¥åº·ã€‚ç ”ç©¶è€…æŠŠé¯‰é­šåˆ†æˆä¸‰çµ„ï¼Œåˆ†åˆ¥è§€å¯Ÿå°ç…§çµ„ã€æš´éœ²æ–¼ä¸‰è‹¯éŒ«çš„çµ„åˆ¥ï¼Œä»¥åŠåŒæ™‚è£œå……è˜¿è””ç¡«ç´ çš„çµ„åˆ¥ï¼Œå¯¦é©—æŒçºŒäº†å…«é€±ã€‚\n\nçµæœé¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«ç¢ºå¯¦å°é­šçš„è‚è‡Ÿé€ æˆäº†å‚·å®³ï¼Œä¸¦å½±éŸ¿å…ç–«ç³»çµ±ï¼Œä½†ç•¶åŠ å…¥è˜¿è””ç¡«ç´ å¾Œï¼Œé­šçš„è‚è‡ŸæŒ‡æ¨™å’Œå…ç–«åŸºå› è¡¨é”å¾—åˆ°äº†æ”¹å–„ï¼Œç”šè‡³è…¸é“ä¸­çš„æœ‰ç›ŠèŒä¹Ÿå¢åŠ äº†ï¼é€™äº›ç™¼ç¾è®“æˆ‘å€‘æ›´äº†è§£ç’°å¢ƒæ±¡æŸ“ç‰©å°å¥åº·çš„å½±éŸ¿ï¼Œä¹Ÿé¡¯ç¤ºäº†è˜¿è””ç¡«ç´ çš„æ½›åœ¨ä¿è­·ä½œç”¨ã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©æ¸›å°‘ç’°å¢ƒæ±¡æŸ“ç‰©çš„æ¯’æ€§å½±éŸ¿ã€‚\n2. æ”¹å–„è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±åŠŸèƒ½ã€‚\n3. ä¿ƒé€²è…¸é“å¾®ç”Ÿç‰©çš„å¥åº·ï¼Œå¢åŠ æœ‰ç›ŠèŒæ¯”ä¾‹ã€‚",
    "image_prompt": "Create a flat design infographic on a light background. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like fish or cells, and arrows indicating the experimental steps. Add a section clearly labeled 'Key Findings' showing protective effects and changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚è‡Ÿæ¯’æ€§ Hepatotoxicity",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41027171/"
  },
  {
    "id": "40714240",
    "title_en": "Gut microbiota-related glutathione metabolism is key mechanism for sulforaphane ameliorating ulcerative colitis.",
    "pub_date": "2025 Dec",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Gut barrier dysfunction is associated with dysbiosis of the gut microbiota and its metabolites, which is closely linked to the pathogenesis of ulcerative colitis (UC). Recent studies have demonstrated that Sulforaphane (SFN) exerts beneficial effects on UC. However, the role of the gut microbiota and microbial metabolism in the anti-UC mechanisms of SFN remains inadequately understood. In this study, we observed that SFN administration significantly improved the pathological phenotype, restored gut barrier integrity, and reduced colon inflammation in dextran sulfate sodium (DSS)-induced colitis mice. Gut microbiota analysis illustrated that SFN administration rebalances the alterations in gut microbiota composition, including genera such as Turicibacter, Lactobacillus and Bacteroides, in DSS-induced mice. Furthermore, untargeted metabolomics analysis indicated that the levels of microbial arachidonic acid metabolism, as well as the metabolism of alanine, aspartate, and glutamate, and glutathione metabolism in the gastrointestinal tract, were significantly altered in DSS-induced mice. Interestingly, SFN treatment significantly restore the alterations in glutathione metabolism and the levels of associated metabolites. Additionally, we observed that the MAPK/NF-ÎºB signaling pathway, regulated by glutathione metabolism, was inhibited in the colon of DSS-induced mice following SFN treatment. Collectively, these results suggest that SFN can alleviate DSS-induced colitis in mice by restoring dysregulated gut microbiota and glutathione metabolism, thereby modulating the MAPK/NF-ÎºB signaling pathway, enhancing intestinal barrier function and reducing colonic inflammation. Importantly, our findings elucidate a novel mechanism by which SFN improves gut barrier function, highlighting its potential to advance the development of SFN-derived therapeutics for the clinical management of colitis.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±è¡¡æœ‰é—œï¼Œé€™å¯èƒ½æœƒå°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼å±•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘è…¸é“ç‚ç—‡ï¼Œé€™å°æ–¼é é˜²å’Œæ²»ç™‚ç›¸é—œç–¾ç—…å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç”±æ–¼è…¸é“å¾®ç”Ÿç‰©å¤±è¡¡æ‰€å¼•èµ·çš„ç‚ç—‡åæ‡‰ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†èª˜å°æ½°ç˜æ€§çµè…¸ç‚çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ æ˜¯é€šéçµ¦äºˆç¡«é…¸å³æ—‹ç³–é…ï¼ˆDSSï¼‰ä¾†èª˜å°çš„ã€‚ç ”ç©¶è€…çµ¦äºˆå°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è…¸é“å±éšœçš„å®Œæ•´æ€§å’Œçµè…¸çš„ç‚ç—‡ç¨‹åº¦ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æå’Œä»£è¬çµ„å­¸åˆ†æï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†å°é¼ çš„è…¸é“ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆã€‚æ­¤å¤–ï¼Œä»£è¬çµ„å­¸åˆ†æé¡¯ç¤ºï¼Œèˆ‡è…¸é“ç›¸é—œçš„å¤šç¨®ä»£è¬é€”å¾‘åœ¨å°é¼ ä¸­ç™¼ç”Ÿäº†é¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œä»£è¬é€”å¾‘ä¾†æ”¹å–„è…¸é“å¥åº·ï¼Œä¸¦æ¸›å°‘ç‚ç—‡åæ‡‰ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±è¡¡æœ‰é—œï¼Œé€™å¯èƒ½æœƒå°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼å±•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘è…¸é“ç‚ç—‡ï¼Œé€™å°æ–¼é é˜²å’Œæ²»ç™‚ç›¸é—œç–¾ç—…å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç”±æ–¼è…¸é“å¾®ç”Ÿç‰©å¤±è¡¡æ‰€å¼•èµ·çš„ç‚ç—‡åæ‡‰ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†èª˜å°æ½°ç˜æ€§çµè…¸ç‚çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ æ˜¯é€šéçµ¦äºˆç¡«é…¸å³æ—‹ç³–é…ï¼ˆDSSï¼‰ä¾†èª˜å°çš„ã€‚ç ”ç©¶è€…çµ¦äºˆå°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è…¸é“å±éšœçš„å®Œæ•´æ€§å’Œçµè…¸çš„ç‚ç—‡ç¨‹åº¦ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æå’Œä»£è¬çµ„å­¸åˆ†æï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†å°é¼ çš„è…¸é“ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆã€‚æ­¤å¤–ï¼Œä»£è¬çµ„å­¸åˆ†æé¡¯ç¤ºï¼Œèˆ‡è…¸é“ç›¸é—œçš„å¤šç¨®ä»£è¬é€”å¾‘åœ¨å°é¼ ä¸­ç™¼ç”Ÿäº†é¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œä»£è¬é€”å¾‘ä¾†æ”¹å–„è…¸é“å¥åº·ï¼Œä¸¦æ¸›å°‘ç‚ç—‡åæ‡‰ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„è…¸é“å¥åº·å’Œæˆ‘å€‘çš„é£²é£Ÿæ¯æ¯ç›¸é—œï¼æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°è…¸é“å¥åº·æœ‰å¾ˆå¤§çš„å¹«åŠ©ã€‚ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼æ½°ç˜æ€§çµè…¸ç‚é€™ç¨®ç–¾ç—…ï¼Œé€™æ˜¯ä¸€ç¨®è…¸é“ç™¼ç‚çš„å•é¡Œã€‚ä»–å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ èƒ½å¦æ”¹å–„è…¸é“çš„å±éšœåŠŸèƒ½ï¼Œæ¸›å°‘ç”±è…¸é“å¾®ç”Ÿç‰©å¤±è¡¡å¼•èµ·çš„ç‚ç—‡ã€‚ \n\nåœ¨é€™é …å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®å°é¼ æ¨¡å‹ï¼Œé€šéç‰¹å®šçš„åŒ–å­¸ç‰©è³ªèª˜å°æ½°ç˜æ€§çµè…¸ç‚ï¼Œç„¶å¾Œçµ¦å°é¼ è˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿå…¶å°è…¸é“çš„å½±éŸ¿ã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„å°é¼ çš„è…¸é“å¥åº·ï¼Œæ¢å¾©è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘çµè…¸çš„ç‚ç—‡ã€‚æ›´æœ‰è¶£çš„æ˜¯ï¼Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆä¹Ÿéš¨ä¹‹å¾—åˆ°äº†èª¿æ•´ï¼ \n\né€™é …ç ”ç©¶çš„ä¸»è¦ç™¼ç¾åŒ…æ‹¬ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ”¹å–„è…¸é“çš„å±éšœåŠŸèƒ½ã€‚\n2. æ¸›å°‘çµè…¸çš„ç‚ç—‡åæ‡‰ã€‚\n3. èª¿æ•´è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¿ƒé€²è…¸é“å¥åº·ã€‚ \n\né›–ç„¶é€™äº›çµæœå¾ˆæœ‰å¸Œæœ›ï¼Œä½†æˆ‘å€‘ä»éœ€æ›´å¤šç ”ç©¶ä¾†æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼",
    "image_prompt": "Create a simple and informative illustration that explains the experiment and main results of a study on the effects of glucosinolate from radishes on gut health. The image should have a flat design style with a white or light background and soft colors. Include symbols representing glucosinolate or radishes, simplified illustrations of experimental subjects like mice, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40714240/"
  },
  {
    "id": "41291551",
    "title_en": "Nanoliposome-mediated delivery of sulforaphane suppresses Ehrlich ascites carcinoma growth and improves liver integrity and therapeutic outcomes in a murine model.",
    "pub_date": "2025 Nov",
    "journal": "BMC cancer",
    "abstract_en": "The anticancer activity of sulforaphane (SFN) involves multiple signaling pathways, but its mechanism against Ehrlich Ascites Carcinoma (EAC) in mice remains unclear. This study evaluated the antitumor efficacy of SFN-loaded nanoliposomes (SFN-NLPs). Ninety female Swiss albino mice were allocated into six groups: (1) untreated control, (2) SFN alone (50Â mg/kg/day, orally), (3) SFN-NLPs alone (50Â mg/kg/day, orally), (4) EAC-bearing mice (2.5â€‰Ã—â€‰10â¶ cells, intraperitoneally), (5) EACâ€‰+â€‰SFN, and (6) EACâ€‰+â€‰SFN-NLPs. with treatment lasting 20 days in tumor-bearing groups. SFN-NLPs significantly reduced EAC tumor volume, viable cell count, and tumor marker levels, while prolonging survival more effectively than free SFN. SFN-NLPs modulated key molecular pathways by suppressing inflammatory gene expression (NF-ÎºB, COX-2) and shifting the balance toward apoptosis via upregulation of TP53 and Bax and concomitant downregulation of Bcl-2. Regarding liver integrity, SFN-NLPs significantly reduced DNA fragmentation and hepatic oxidative stress, while modulating systemic inflammation through reductions in total leukocyte count, TNF-Î±, and C-reactive protein. In addition, SFN-NLPs conferred superior protection against both histopathological and ultrastructural liver damage. Furthermore, molecular docking analysis suggested plausible interactions of SFN with proteins associated with antioxidant defense, inflammation regulation, and apoptosis, indicating a potential modulatory role. In conclusion, nanoformulated SFN enhances stability, augments efficacy, and facilitates sustained release and bioavailability, thereby strengthening its antitumor, anti-inflammatory, antioxidant, and pro-apoptotic effects in EAC-bearing mice. These findings highlight the potential of SFN-NLPs to suppress tumor growth by modulating inflammatory and apoptotic gene expression while preserving liver integrity.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½é€éèª¿ç¯€èº«é«”å…§çš„å¤šç¨®ä¿¡è™Ÿé€šè·¯ï¼Œä¾†æŠ‘åˆ¶è…«ç˜¤çš„ç”Ÿé•·ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†åœ¨ç™Œç—‡æ²»ç™‚ä¸­ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€å€‹æœ‰æ½›åŠ›çš„è¼”åŠ©ç™‚æ³•ï¼Œå°¤å…¶æ˜¯é‡å°æŸäº›ç‰¹å®šé¡å‹çš„ç™Œç—‡ã€‚é€™é …ç ”ç©¶çš„çµæœä¹Ÿå¯èƒ½ä¿ƒä½¿æˆ‘å€‘é‡æ–°æ€è€ƒé£²é£Ÿä¸­é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©å°å¥åº·çš„å½±éŸ¿ï¼Œä¸¦é¼“å‹µæ›´å¤šäººå°‡é€™äº›é£Ÿç‰©ç´å…¥æ—¥å¸¸é£²é£Ÿä¸­ï¼Œä»¥æœŸé”åˆ°é é˜²ç–¾ç—…çš„æ•ˆæœã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ èº«ä¸Šå°Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•é€éä¸åŒçš„æ©Ÿåˆ¶ä¾†å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·ï¼Œä»¥åŠå®ƒåœ¨æ²»ç™‚éç¨‹ä¸­çš„å…·é«”ä½œç”¨ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æœ‰æ•ˆæ¸›å°‘è…«ç˜¤é«”ç©ã€æé«˜å­˜æ´»ç‡ï¼Œä¸¦ä¸”å°è‚è‡Ÿçš„å¥åº·æœ‰ä½•å½±éŸ¿ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°‡æœ‰åŠ©æ–¼æœªä¾†ç™Œç—‡æ²»ç™‚çš„ç™¼å±•ï¼Œä¸¦å¯èƒ½ç‚ºè‡¨åºŠæ‡‰ç”¨æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†æˆå…­çµ„é€²è¡Œå¯¦é©—ã€‚é€™äº›çµ„åˆ¥åŒ…æ‹¬æœªæ²»ç™‚çš„å°ç…§çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ã€ä»¥åŠå¸¶æœ‰EACçš„çµ„åˆ¥ã€‚æ²»ç™‚æŒçºŒäº†20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤çš„é«”ç©ã€å­˜æ´»ç‡ã€ä»¥åŠè‚è‡Ÿçš„å¥åº·ç‹€æ³ã€‚é€™æ¨£çš„è¨­è¨ˆè®“ç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒæ²»ç™‚æ–¹å¼çš„æ•ˆæœï¼Œä¸¦æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ åœ¨æŠ—è…«ç˜¤éç¨‹ä¸­çš„å…·é«”ä½œç”¨ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”ï¼ˆSFN-NLPsï¼‰åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜ç‰©æ°´å¹³æ–¹é¢ï¼Œè¡¨ç¾å¾—æ¯”å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆã€‚æ­¤å¤–ï¼ŒSFN-NLPsé‚„èƒ½æ”¹å–„è‚è‡Ÿçš„å¥åº·ï¼Œæ¸›å°‘DNAç‰‡æ®µåŒ–å’Œæ°§åŒ–å£“åŠ›ï¼Œä¸¦èª¿ç¯€å…¨èº«çš„ç‚ç—‡åæ‡‰ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”å¯èƒ½é€éèª¿ç¯€ç‚ç—‡å’Œå‡‹äº¡ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œä¾†æŠ‘åˆ¶è…«ç˜¤çš„ç”Ÿé•·ï¼ŒåŒæ™‚ä¿è­·è‚è‡Ÿçš„å®Œæ•´æ€§ã€‚é€™äº›ç™¼ç¾å¼·èª¿äº†è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½é€éèª¿ç¯€èº«é«”å…§çš„å¤šç¨®ä¿¡è™Ÿé€šè·¯ï¼Œä¾†æŠ‘åˆ¶è…«ç˜¤çš„ç”Ÿé•·ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†åœ¨ç™Œç—‡æ²»ç™‚ä¸­ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€å€‹æœ‰æ½›åŠ›çš„è¼”åŠ©ç™‚æ³•ï¼Œå°¤å…¶æ˜¯é‡å°æŸäº›ç‰¹å®šé¡å‹çš„ç™Œç—‡ã€‚é€™é …ç ”ç©¶çš„çµæœä¹Ÿå¯èƒ½ä¿ƒä½¿æˆ‘å€‘é‡æ–°æ€è€ƒé£²é£Ÿä¸­é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©å°å¥åº·çš„å½±éŸ¿ï¼Œä¸¦é¼“å‹µæ›´å¤šäººå°‡é€™äº›é£Ÿç‰©ç´å…¥æ—¥å¸¸é£²é£Ÿä¸­ï¼Œä»¥æœŸé”åˆ°é é˜²ç–¾ç—…çš„æ•ˆæœã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ èº«ä¸Šå°Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•é€éä¸åŒçš„æ©Ÿåˆ¶ä¾†å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·ï¼Œä»¥åŠå®ƒåœ¨æ²»ç™‚éç¨‹ä¸­çš„å…·é«”ä½œç”¨ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æœ‰æ•ˆæ¸›å°‘è…«ç˜¤é«”ç©ã€æé«˜å­˜æ´»ç‡ï¼Œä¸¦ä¸”å°è‚è‡Ÿçš„å¥åº·æœ‰ä½•å½±éŸ¿ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°‡æœ‰åŠ©æ–¼æœªä¾†ç™Œç—‡æ²»ç™‚çš„ç™¼å±•ï¼Œä¸¦å¯èƒ½ç‚ºè‡¨åºŠæ‡‰ç”¨æä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†æˆå…­çµ„é€²è¡Œå¯¦é©—ã€‚é€™äº›çµ„åˆ¥åŒ…æ‹¬æœªæ²»ç™‚çš„å°ç…§çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ã€ä»¥åŠå¸¶æœ‰EACçš„çµ„åˆ¥ã€‚æ²»ç™‚æŒçºŒäº†20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤çš„é«”ç©ã€å­˜æ´»ç‡ã€ä»¥åŠè‚è‡Ÿçš„å¥åº·ç‹€æ³ã€‚é€™æ¨£çš„è¨­è¨ˆè®“ç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒæ²»ç™‚æ–¹å¼çš„æ•ˆæœï¼Œä¸¦æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ åœ¨æŠ—è…«ç˜¤éç¨‹ä¸­çš„å…·é«”ä½œç”¨ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”ï¼ˆSFN-NLPsï¼‰åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜ç‰©æ°´å¹³æ–¹é¢ï¼Œè¡¨ç¾å¾—æ¯”å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆã€‚æ­¤å¤–ï¼ŒSFN-NLPsé‚„èƒ½æ”¹å–„è‚è‡Ÿçš„å¥åº·ï¼Œæ¸›å°‘DNAç‰‡æ®µåŒ–å’Œæ°§åŒ–å£“åŠ›ï¼Œä¸¦èª¿ç¯€å…¨èº«çš„ç‚ç—‡åæ‡‰ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”å¯èƒ½é€éèª¿ç¯€ç‚ç—‡å’Œå‡‹äº¡ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œä¾†æŠ‘åˆ¶è…«ç˜¤çš„ç”Ÿé•·ï¼ŒåŒæ™‚ä¿è­·è‚è‡Ÿçš„å®Œæ•´æ€§ã€‚é€™äº›ç™¼ç¾å¼·èª¿äº†è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC cancerã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ å¯èƒ½å°å¥åº·æœ‰å¤§å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°ç™Œç—‡çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨å°é¼ èº«ä¸Šçš„æ•ˆæœã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“è˜¿è””ç¡«ç´ å¦‚ä½•å¹«åŠ©æ¸›å°‘è…«ç˜¤ç”Ÿé•·ï¼Œç”šè‡³æé«˜å­˜æ´»ç‡ã€‚  \n  \nä»–å€‘é€²è¡Œäº†ä¸€å€‹ç‚ºæœŸ20å¤©çš„å¯¦é©—ï¼Œä½¿ç”¨äº†90éš»å°é¼ ï¼Œä¸¦æŠŠå®ƒå€‘åˆ†æˆå¹¾çµ„é€²è¡Œä¸åŒçš„æ²»ç™‚ã€‚ç ”ç©¶è€…è§€å¯Ÿåˆ°ï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”ï¼ˆé€™æ˜¯ä¸€ç¨®èƒ½æ›´å¥½è¢«èº«é«”å¸æ”¶çš„å½¢å¼ï¼‰åœ¨æ¸›å°‘è…«ç˜¤é«”ç©å’Œæ”¹å–„è‚è‡Ÿå¥åº·æ–¹é¢ï¼Œæ¯”å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆï¼  \n  \né€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°ï¼Œè˜¿è””ç¡«ç´ æˆ–è¨±æˆç‚ºç™Œç—‡æ²»ç™‚çš„è¼”åŠ©é¸æ“‡ï¼Œä½†ä»éœ€æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå…·é«”æ•ˆæœã€‚  \n  \nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ã€‚  \n2. è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘è…«ç˜¤å’Œä¿è­·è‚è‡Ÿæ–¹é¢æ•ˆæœæ›´ä½³ã€‚  \n3. å¥åº·é£²é£Ÿä¸­åŠ å…¥é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå°å¥åº·æœ‰ç›Šï¼",
    "image_prompt": "Create a flat design infographic on a light background that visually explains a study on sulforaphane (SFN) and its effects on cancer. Include simplified icons of broccoli and sulforaphane. Show simplified representations of mice as experimental subjects. Use arrows or flow lines to indicate the experimental steps. Include a section labeled 'Main Results' highlighting protective effects and changes observed, such as tumor reduction and liver health improvement.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "Ehrlichè…¹æ°´ç™Œ Ehrlich Ascites Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41291551/"
  },
  {
    "id": "41135276",
    "title_en": "Sulforaphane targets STAT3-CKMT2-AS1 to suppress gastric cancer via PSMB8 downregulation and AIMP1 stabilization.",
    "pub_date": "2025 Nov",
    "journal": "Phytomedicine : international journal of phytotherapy and phytopharmacology",
    "abstract_en": "Gastric cancer (GC) remains one of the most formidable threats to human health with limited therapeutic options. Sulforaphane (SFN), a natural isothiocyanate, exhibits antitumor activity; however, its molecular mechanisms of action in GC remain unclear. To investigate the mechanism of action of SFN in gastric cancer. The antitumor effects of SFN were comprehensively assessed in vitro and in vivo, followed by sequencing analysis to identify the targeted lncRNA. Subsequently, the mechanical verification experiments were carried out to determine the upstream and downstream regulatory components involved in the STAT3-CKMT2-AS1 regulatory axis. We demonstrated that SFN strongly inhibits GC. SFN downregulated the expression of the lncRNA CKMT2-AS1. Elevated expression levels of CKMT2-AS1 in human GC tissues are correlated with poor patient survival rates. Knockdown of CKMT2-AS1 significantly inhibited GC proliferation and migration both in vivo and in vitro, whereas CKMT2-AS1 overexpression enhanced malignant phenotypes. Mechanistically, we identified STAT3 as the transcriptional activator driving CKMT2-AS1 expression, with SFN directly binding to, and inhibiting, STAT3 phosphorylation to decrease its transcriptional activity. Interestingly, cytoplasmic CKMT2-AS1 competitively adsorbs miR-451a, leading to the expression of PSMB8, ultimately promoting the progression of the malignant phenotype of GC. Moreover, we discovered that CKMT2-AS1 directly binds to the RNA-binding protein (RBP) AIMP1, promoting ubiquitination-mediated degradation of AIMP1 protein via the proteasomal pathway. The highly expressed AIMP1 protein, in turn, inhibits the phosphorylation of the PI3K/AKT signaling pathway, which is hyperactivated in virtually all solid tumors. Our findings not only elucidate a novel SFN-mediated tumor-suppressive mechanism via the STAT3/CKMT2-AS1 regulatory axis, but also validate CKMT2-AS1 as a promising therapeutic target for GC intervention.",
    "para1": "èƒƒç™Œä»ç„¶æ˜¯å°äººé¡å¥åº·çš„ä¸€å¤§å¨è„…ï¼Œæ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ–è¨±èƒ½å¹«åŠ©æˆ‘å€‘æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ–¹æ³•ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œç‰¹åˆ¥æ˜¯å®ƒå°æŸäº›é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰çš„èª¿æ§ä½œç”¨ï¼Œé€™äº›RNAå¯èƒ½èˆ‡ç™Œç—‡çš„ç™¼å±•å’Œé å¾Œæœ‰é—œã€‚",
    "para3": "ç ”ç©¶åœ˜éšŠé€²è¡Œäº†ä¸€ç³»åˆ—çš„å¯¦é©—ï¼ŒåŒ…æ‹¬é«”å¤–å’Œé«”å…§çš„æ¸¬è©¦ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ä»–å€‘é‚„é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥èˆ‡è˜¿è””ç¡«ç´ ä½œç”¨ç›¸é—œçš„ç›®æ¨™lncRNAã€‚æ¥è‘—ï¼Œç ”ç©¶è€…é€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šåœ¨STAT3-CKMT2-AS1èª¿æ§è»¸ä¸­ï¼Œä¸Šæ¸¸å’Œä¸‹æ¸¸çš„èª¿æ§æˆåˆ†ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œçš„å¢æ®–å’Œè½‰ç§»ï¼Œä¸¦ä¸‹èª¿äº†CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚é€²ä¸€æ­¥çš„åˆ†æè¡¨æ˜ï¼ŒSTAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè€Œè˜¿è””ç¡«ç´ å‰‡èƒ½ç›´æ¥çµåˆä¸¦æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œé™ä½å…¶è½‰éŒ„æ´»æ€§ã€‚é€™äº›ç™¼ç¾æ­ç¤ºäº†è˜¿è””ç¡«ç´ é€šéSTAT3/CKMT2-AS1èª¿æ§è»¸ç™¼æ®è…«ç˜¤æŠ‘åˆ¶ä½œç”¨çš„å…¨æ–°æ©Ÿåˆ¶ï¼Œä¸¦ç¢ºèªCKMT2-AS1ä½œç‚ºèƒƒç™Œå¹²é çš„æ½›åœ¨æ²»ç™‚é¶é»ã€‚",
    "explanation_zh": "èƒƒç™Œä»ç„¶æ˜¯å°äººé¡å¥åº·çš„ä¸€å¤§å¨è„…ï¼Œæ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ–è¨±èƒ½å¹«åŠ©æˆ‘å€‘æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ–¹æ³•ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œç‰¹åˆ¥æ˜¯å®ƒå°æŸäº›é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰çš„èª¿æ§ä½œç”¨ï¼Œé€™äº›RNAå¯èƒ½èˆ‡ç™Œç—‡çš„ç™¼å±•å’Œé å¾Œæœ‰é—œã€‚\n\nç ”ç©¶åœ˜éšŠé€²è¡Œäº†ä¸€ç³»åˆ—çš„å¯¦é©—ï¼ŒåŒ…æ‹¬é«”å¤–å’Œé«”å…§çš„æ¸¬è©¦ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ä»–å€‘é‚„é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥èˆ‡è˜¿è””ç¡«ç´ ä½œç”¨ç›¸é—œçš„ç›®æ¨™lncRNAã€‚æ¥è‘—ï¼Œç ”ç©¶è€…é€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šåœ¨STAT3-CKMT2-AS1èª¿æ§è»¸ä¸­ï¼Œä¸Šæ¸¸å’Œä¸‹æ¸¸çš„èª¿æ§æˆåˆ†ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œçš„å¢æ®–å’Œè½‰ç§»ï¼Œä¸¦ä¸‹èª¿äº†CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚é€²ä¸€æ­¥çš„åˆ†æè¡¨æ˜ï¼ŒSTAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè€Œè˜¿è””ç¡«ç´ å‰‡èƒ½ç›´æ¥çµåˆä¸¦æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œé™ä½å…¶è½‰éŒ„æ´»æ€§ã€‚é€™äº›ç™¼ç¾æ­ç¤ºäº†è˜¿è””ç¡«ç´ é€šéSTAT3/CKMT2-AS1èª¿æ§è»¸ç™¼æ®è…«ç˜¤æŠ‘åˆ¶ä½œç”¨çš„å…¨æ–°æ©Ÿåˆ¶ï¼Œä¸¦ç¢ºèªCKMT2-AS1ä½œç‚ºèƒƒç™Œå¹²é çš„æ½›åœ¨æ²»ç™‚é¶é»ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPhytomedicine : international journal of phytotherapy and phytopharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­æœ‰äº›å¤©ç„¶æˆåˆ†å¯èƒ½å°æŠ—ç™Œç—‡æœ‰å¹«åŠ©ï¼æœ€è¿‘ä¸€é …ç ”ç©¶èšç„¦æ–¼ä¸€ç¨®å«è˜¿è””ç¡«ç´ çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œé€™å¯èƒ½æˆç‚ºèƒƒç™Œæ²»ç™‚çš„æ–°å¸Œæœ›ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æƒ³äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œå°¤å…¶æ˜¯å®ƒå°æŸäº›RNAçš„å½±éŸ¿ã€‚é€™äº›RNAèˆ‡ç™Œç—‡çš„ç™¼å±•å’Œé å¾Œæœ‰é—œï¼Œäº†è§£å®ƒå€‘çš„ä½œç”¨å°æ–¼æ²»ç™‚éå¸¸é‡è¦ã€‚\n\nç ”ç©¶åœ˜éšŠé€²è¡Œäº†å¤šç¨®å¯¦é©—ï¼ŒåŒ…æ‹¬åœ¨å¯¦é©—å®¤å’Œå‹•ç‰©èº«ä¸Šçš„æ¸¬è©¦ï¼Œä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ•ˆæœã€‚ä»–å€‘é‚„åˆ†æäº†åŸºå› è³‡æ–™ï¼Œæ‰¾å‡ºèˆ‡è˜¿è””ç¡«ç´ æœ‰é—œçš„ç‰¹å®šRNAï¼Œä¸¦ç¢ºå®šäº†å®ƒå€‘çš„èª¿æ§æ©Ÿåˆ¶ã€‚\n\nçµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œç´°èƒçš„å¢æ®–å’Œè½‰ç§»ï¼Œä¸¦ä¸”é™ä½äº†ä¸€ç¨®åç‚ºCKMT2-AS1çš„RNAçš„è¡¨é”ï¼Œé€™ç¨®RNAçš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒSTAT3é€™å€‹å› å­æœƒä¿ƒé€²CKMT2-AS1çš„è¡¨é”ï¼Œè€Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥å½±éŸ¿STAT3ï¼Œé™ä½å…¶æ´»æ€§ã€‚\n\nğŸ”é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºèƒƒç™Œæ²»ç™‚çš„æ–°å·¥å…·ã€‚\n2. å®ƒèƒ½æŠ‘åˆ¶ç™Œç´°èƒå¢æ®–å’Œè½‰ç§»ã€‚\n3. CKMT2-AS1å¯èƒ½æ˜¯æœªä¾†æ²»ç™‚çš„æ½›åœ¨é¶é»ã€‚",
    "image_prompt": "Create a flat design infographic that explains the experimental methods and main results of a study on the anti-cancer effects of a natural compound called sulforaphane. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like cells or animals, and arrows or flow lines to indicate experimental steps. Add a section highlighting the main results, such as protective effects or changes observed in cancer cell behavior.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41135276/"
  },
  {
    "id": "41275316",
    "title_en": "Investigating the clinical efficacy, safety and molecular mechanism of sulforaphane in autism spectrum disorder: an integrated study combining meta-analysis, network pharmacology, and computational biology.",
    "pub_date": "2025 Nov",
    "journal": "BMC pharmacology & toxicology",
    "abstract_en": "Sulforaphane, a natural antioxidant rich in cruciferous vegetables, has emerged as a promising dietary supplement for autism spectrum disorder (ASD). However, its therapeutic efficacy remains controversial, and the pharmacological mechanisms are not fully elucidated. Eligible randomized controlled trials were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Review Manager 5.4 was used for meta-analysis and bias risk assessment. Network pharmacology, Mendelian randomization, GEO data analyses, molecular docking, and molecular dynamics simulation were employed to explore the mechanisms of sulforaphane in ASD. Six trials involving 333 participants were included in the meta-analysis. Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls. No significant difference was observed in the incidence of adverse events. Network pharmacology identified 10 core targets of sulforaphane in ASD, including AKT1, EGFR, HSP90AA1, SRC, CASP3, STAT1, MAPK1, MMP9, MAPK8, and JAK2. These targets were implicated in the PI3K-Akt signaling pathway, MAPK signaling pathway, Chemokine signaling pathway, Chemical carcinogenesis - reactive oxygen species, TNF signaling pathway, Th17 cell differentiation, mTOR signaling pathway, and IL-17 signaling pathway. Mendelian randomization further revealed an inverse association between STAT1 levels and ASD risk. GEO transcriptomic data provided independent validation for the network pharmacology predictions. The binding energies between sulforaphane and the top 10 core targets are all â‰¤ -4.0Â kcal/mol. Molecular dynamics simulations further validated the stable interaction between MMP-9 and sulforaphane. Sulforaphane may serve as an efficacious and safe adjunctive therapy for ASD, mediated by its anti-oxidant and anti-inflammatory effects along with the modulation of autophagy. CRD42025635045.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é›–ç„¶æœ‰ä¸€äº›ç ”ç©¶é¡¯ç¤ºå®ƒå¯èƒ½æœ‰ç›Šï¼Œä½†å…¶ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œä¸”å…·é«”çš„è—¥ç†æ©Ÿåˆ¶å°šæœªå®Œå…¨æ˜ç­ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºè‡ªé–‰ç—‡çš„é£²é£Ÿè£œå……æä¾›æ–°çš„æ€è·¯ï¼Œå¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°ç†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†æ”¹å–„å¥åº·ç‹€æ³æˆ–é é˜²ç–¾ç—…ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œä¸¦é€²ä¸€æ­¥åˆ†æå…¶å¯èƒ½çš„ä½œç”¨æ©Ÿåˆ¶ã€‚è‡ªé–‰ç—‡æ˜¯ä¸€ç¨®å½±éŸ¿ç¤¾äº¤äº’å‹•å’Œæºé€šèƒ½åŠ›çš„ç¥ç¶“ç™¼å±•éšœç¤™ï¼Œå°æ‚£è€…åŠå…¶å®¶åº­é€ æˆé‡å¤§æŒ‘æˆ°ï¼Œå› æ­¤å°‹æ‰¾æœ‰æ•ˆçš„è¼”åŠ©ç™‚æ³•æ˜¯ç•¶å‰çš„ç ”ç©¶é‡é»ã€‚",
    "para3": "ç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …æ¶‰åŠ333ååƒèˆ‡è€…çš„è©¦é©—é€²è¡Œç¶œåˆåˆ†æã€‚ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€GEOæ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœåŠå…¶èˆ‡ç”Ÿç‰©æ¨™è¨˜çš„é—œè¯ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œé€™æ„å‘³è‘—ä»–å€‘çš„ç¤¾äº¤èƒ½åŠ›æœ‰æ‰€æ”¹å–„ã€‚ç ”ç©¶ä¸­ä¸¦æœªç™¼ç¾é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½æ˜¯ä¸€ç¨®å®‰å…¨çš„è¼”åŠ©ç™‚æ³•ã€‚æ­¤å¤–ï¼Œç¶²çµ¡è—¥ç†å­¸åˆ†æç¢ºå®šäº†è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„åå€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»æ¶‰åŠå¤šæ¢ä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œé€²ä¸€æ­¥æ”¯æŒäº†è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é›–ç„¶æœ‰ä¸€äº›ç ”ç©¶é¡¯ç¤ºå®ƒå¯èƒ½æœ‰ç›Šï¼Œä½†å…¶ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œä¸”å…·é«”çš„è—¥ç†æ©Ÿåˆ¶å°šæœªå®Œå…¨æ˜ç­ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºè‡ªé–‰ç—‡çš„é£²é£Ÿè£œå……æä¾›æ–°çš„æ€è·¯ï¼Œå¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°ç†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†æ”¹å–„å¥åº·ç‹€æ³æˆ–é é˜²ç–¾ç—…ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œä¸¦é€²ä¸€æ­¥åˆ†æå…¶å¯èƒ½çš„ä½œç”¨æ©Ÿåˆ¶ã€‚è‡ªé–‰ç—‡æ˜¯ä¸€ç¨®å½±éŸ¿ç¤¾äº¤äº’å‹•å’Œæºé€šèƒ½åŠ›çš„ç¥ç¶“ç™¼å±•éšœç¤™ï¼Œå°æ‚£è€…åŠå…¶å®¶åº­é€ æˆé‡å¤§æŒ‘æˆ°ï¼Œå› æ­¤å°‹æ‰¾æœ‰æ•ˆçš„è¼”åŠ©ç™‚æ³•æ˜¯ç•¶å‰çš„ç ”ç©¶é‡é»ã€‚\n\nç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …æ¶‰åŠ333ååƒèˆ‡è€…çš„è©¦é©—é€²è¡Œç¶œåˆåˆ†æã€‚ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€GEOæ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœåŠå…¶èˆ‡ç”Ÿç‰©æ¨™è¨˜çš„é—œè¯ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œé€™æ„å‘³è‘—ä»–å€‘çš„ç¤¾äº¤èƒ½åŠ›æœ‰æ‰€æ”¹å–„ã€‚ç ”ç©¶ä¸­ä¸¦æœªç™¼ç¾é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½æ˜¯ä¸€ç¨®å®‰å…¨çš„è¼”åŠ©ç™‚æ³•ã€‚æ­¤å¤–ï¼Œç¶²çµ¡è—¥ç†å­¸åˆ†æç¢ºå®šäº†è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„åå€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»æ¶‰åŠå¤šæ¢ä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œé€²ä¸€æ­¥æ”¯æŒäº†è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC pharmacology & toxicologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“è˜¿è””è£¡çš„ç§˜å¯†å—ï¼Ÿå®ƒä¸åƒ…ç¾å‘³ï¼Œé‚„å¯èƒ½å°è‡ªé–‰ç—‡æœ‰å¹«åŠ©ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ ï¼ˆå°±æ˜¯è˜¿è””è£¡çš„å¤©ç„¶æˆåˆ†ï¼‰å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶äººå“¡æƒ³çŸ¥é“ï¼Œé€™ç¨®å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ã€‚è‡ªé–‰ç—‡æœƒå½±éŸ¿äººå€‘çš„ç¤¾äº¤äº’å‹•å’Œæºé€šï¼Œå°æ‚£è€…å’Œå®¶åº­ä¾†èªªéƒ½æ˜¯ä¸€å€‹æŒ‘æˆ°ï¼Œæ‰€ä»¥æ‰¾åˆ°æœ‰æ•ˆçš„è¼”åŠ©ç™‚æ³•éå¸¸é‡è¦ã€‚\n\né€™é …ç ”ç©¶åˆ†æäº†å…­å€‹æ¶‰åŠ333ååƒèˆ‡è€…çš„è©¦é©—ï¼Œä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ä¾†æ¢ç´¢è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚çµæœé¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œè¡¨ç¤ºä»–å€‘çš„ç¤¾äº¤èƒ½åŠ›æœ‰æ‰€æ”¹å–„ï¼è€Œä¸”ï¼Œç ”ç©¶ä¸­ä¸¦æœªç™¼ç¾æ˜é¡¯çš„å‰¯ä½œç”¨ï¼Œé€™è®“äººæ„Ÿåˆ°å®‰å¿ƒã€‚\n\nâœ¨ ç¸½çµä¾†èªªï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ã€‚\n2. é€™é …ç ”ç©¶é¡¯ç¤ºè˜¿è””ç¡«ç´ çš„å®‰å…¨æ€§ã€‚\n3. ç ”ç©¶æ­ç¤ºäº†è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„å¤šå€‹ä½œç”¨é¶é»ã€‚\n\né€™æ˜¯ä¸€å€‹ä»¤äººæŒ¯å¥®çš„é–‹å§‹ï¼Œè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æœªä¾†æ›´å¤šçš„ç ”ç©¶ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of the study on sulforaphane and autism. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like people or cells), arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' showing improvements in social response scores.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé–‰ç—‡è­œç³»éšœç¤™ Autism Spectrum Disorder",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41275316/"
  },
  {
    "id": "41265122",
    "title_en": "Synergistic strategies of sulforaphane biosynthesis and functional properties in broccoli sprouts powder obtained from sucrose stress modulation coupled with vacuum freeze-drying.",
    "pub_date": "2025 Nov",
    "journal": "Food chemistry",
    "abstract_en": "This study investigated methionine-sucrose stress treatments on glucoraphanin biosynthesis in broccoli sprouts and the impact of vacuum freeze-drying (VFD) on sprout powder quality. Results showed that sucrose treatment elevated glucoraphanin content by 316.30Â % in 4-day sprouts compared to the control (9.72Â mg/g), accompanied by increases of 42.65Â % in total isothiocyanates (ITCs) and 70.00Â % in anthocyanins. The treatment enhanced myrosinase activity and upregulated osmotic regulators. PCA confirmed that sucrose stress optimized the nutritional quality of broccoli sprouts and exhibited potential in sulforaphane enrichment. The VFD broccoli sprout powder exhibited high retention of sulforaphane (6.00Â mg/g dw) and total ITCs (7.00Â mg/g dw), with optimal water-holding capacity, oil-holding capacity, and swelling capacity. The sulforaphane extract exhibited significant antimicrobial activity against E. coli (16.00Â mm inhibition zone) and Staphylococcus aureus (10.02Â mm). The synergistic application of sucrose stress and VFD presents a promising approach for developing functional foods.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼æ–¹é¢ã€‚é’èŠ±æ¤°èœå«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç–¾ç—…ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥æé«˜é’èŠ±æ¤°èœä¸­è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œé€™å¯èƒ½å°æ–¼æƒ³è¦å¢å¼·å…ç–«åŠ›æˆ–æ”¹å–„å¥åº·ç‹€æ³çš„äººä¾†èªªï¼Œå…·æœ‰æ½›åœ¨çš„å¥½è™•ã€‚é€™äº›ç™¼ç¾å¯èƒ½ä¿ƒä½¿äººå€‘æ›´åŠ é‡è¦–é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–ï¼Œä¸¦æ¢ç´¢å¦‚ä½•é€éé£²é£Ÿä¾†å¢é€²å¥åº·ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„åˆæˆå½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éä¸åŒçš„è™•ç†æ–¹æ³•ä¾†æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ã€‚é€™äº›æˆåˆ†ä¸åƒ…å°æ¤ç‰©æœ¬èº«çš„ç”Ÿé•·æœ‰å¹«åŠ©ï¼Œé‚„å¯èƒ½å°äººé¡å¥åº·ç”¢ç”Ÿæ­£é¢çš„å½±éŸ¿ï¼Œå› æ­¤é€™é …ç ”ç©¶å…·æœ‰é‡è¦çš„å¯¦ç”¨åƒ¹å€¼ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°é’èŠ±æ¤°èœèŠ½é€²è¡Œäº†ç”²ç¡«æ°¨é…¸-è”—ç³–çš„å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶å°è‘¡è„ç³–è‹·åˆæˆçš„å½±éŸ¿ã€‚ç ”ç©¶å°è±¡æ˜¯4å¤©å¤§çš„é’èŠ±æ¤°èœèŠ½ï¼Œé€éæ¯”è¼ƒè™•ç†çµ„èˆ‡å°ç…§çµ„çš„çµæœï¼Œä¾†è©•ä¼°è”—ç³–è™•ç†å°é’èŠ±æ¤°èœèŠ½ç‡Ÿé¤Šæˆåˆ†çš„æå‡æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æ¢è¨äº†çœŸç©ºå†·å‡ä¹¾ç‡¥æŠ€è¡“å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªå½±éŸ¿ï¼Œé€™äº›æ–¹æ³•çš„çµåˆæ—¨åœ¨å„ªåŒ–é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†ä½¿é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–è‹·å«é‡å¢åŠ äº†316.30%ï¼ŒåŒæ™‚ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰é¡¯è‘—æå‡ã€‚æ­¤å¤–ï¼ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½çš„ä¿ç•™ä¸Šè¡¨ç¾è‰¯å¥½ï¼Œä¸¦ä¸”å…·æœ‰å„ªè‰¯çš„æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æå–ç‰©å°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒå…·æœ‰é¡¯è‘—çš„æŠ—èŒæ´»æ€§ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„çµåˆï¼Œå¯èƒ½ç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†ä¸€ç¨®æœ‰å‰æ™¯çš„æ–¹æ³•ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼æ–¹é¢ã€‚é’èŠ±æ¤°èœå«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç–¾ç—…ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥æé«˜é’èŠ±æ¤°èœä¸­è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œé€™å¯èƒ½å°æ–¼æƒ³è¦å¢å¼·å…ç–«åŠ›æˆ–æ”¹å–„å¥åº·ç‹€æ³çš„äººä¾†èªªï¼Œå…·æœ‰æ½›åœ¨çš„å¥½è™•ã€‚é€™äº›ç™¼ç¾å¯èƒ½ä¿ƒä½¿äººå€‘æ›´åŠ é‡è¦–é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–ï¼Œä¸¦æ¢ç´¢å¦‚ä½•é€éé£²é£Ÿä¾†å¢é€²å¥åº·ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„åˆæˆå½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éä¸åŒçš„è™•ç†æ–¹æ³•ä¾†æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ã€‚é€™äº›æˆåˆ†ä¸åƒ…å°æ¤ç‰©æœ¬èº«çš„ç”Ÿé•·æœ‰å¹«åŠ©ï¼Œé‚„å¯èƒ½å°äººé¡å¥åº·ç”¢ç”Ÿæ­£é¢çš„å½±éŸ¿ï¼Œå› æ­¤é€™é …ç ”ç©¶å…·æœ‰é‡è¦çš„å¯¦ç”¨åƒ¹å€¼ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°é’èŠ±æ¤°èœèŠ½é€²è¡Œäº†ç”²ç¡«æ°¨é…¸-è”—ç³–çš„å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶å°è‘¡è„ç³–è‹·åˆæˆçš„å½±éŸ¿ã€‚ç ”ç©¶å°è±¡æ˜¯4å¤©å¤§çš„é’èŠ±æ¤°èœèŠ½ï¼Œé€éæ¯”è¼ƒè™•ç†çµ„èˆ‡å°ç…§çµ„çš„çµæœï¼Œä¾†è©•ä¼°è”—ç³–è™•ç†å°é’èŠ±æ¤°èœèŠ½ç‡Ÿé¤Šæˆåˆ†çš„æå‡æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æ¢è¨äº†çœŸç©ºå†·å‡ä¹¾ç‡¥æŠ€è¡“å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªå½±éŸ¿ï¼Œé€™äº›æ–¹æ³•çš„çµåˆæ—¨åœ¨å„ªåŒ–é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†ä½¿é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–è‹·å«é‡å¢åŠ äº†316.30%ï¼ŒåŒæ™‚ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰é¡¯è‘—æå‡ã€‚æ­¤å¤–ï¼ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½çš„ä¿ç•™ä¸Šè¡¨ç¾è‰¯å¥½ï¼Œä¸¦ä¸”å…·æœ‰å„ªè‰¯çš„æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æå–ç‰©å°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒå…·æœ‰é¡¯è‘—çš„æŠ—èŒæ´»æ€§ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„çµåˆï¼Œå¯èƒ½ç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†ä¸€ç¨®æœ‰å‰æ™¯çš„æ–¹æ³•ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood chemistryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“é’èŠ±æ¤°èœä¸åƒ…å¥½åƒï¼Œé‚„å¯èƒ½å°å¥åº·æœ‰å¹«åŠ©å—ï¼Ÿæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œé’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®æˆåˆ†â€”â€”è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½åœ¨ç–¾ç—…é é˜²ä¸Šæœ‰æ½›åŠ›ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼å¦‚ä½•ç”¨ç‰¹å®šçš„æ–¹æ³•ä¾†æå‡é’èŠ±æ¤°èœèŠ½ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œå°¤å…¶æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ã€‚ ç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®å«åšç”²ç¡«æ°¨é…¸-è”—ç³–çš„è™•ç†æ–¹å¼ï¼Œå°4å¤©å¤§çš„é’èŠ±æ¤°èœèŠ½é€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿé€™ç¨®è™•ç†å°ç‡Ÿé¤Šæˆåˆ†çš„å½±éŸ¿ã€‚çµæœé¡¯ç¤ºï¼Œé€™ç¨®è™•ç†è®“é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–è‹·å«é‡å¢åŠ äº†316.30%ï¼è€Œä¸”ï¼Œç¶“éçœŸç©ºå†·å‡ä¹¾ç‡¥è™•ç†çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨ä¿ç•™ç‡Ÿé¤Šæˆåˆ†ä¸Šè¡¨ç¾ä¹Ÿå¾ˆä¸éŒ¯ï¼Œé‚„å°æŸäº›ç´°èŒæœ‰æŠ—èŒæ•ˆæœã€‚ é€™äº›ç™¼ç¾è®“æˆ‘å€‘æ›´åŠ é‡è¦–é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–ï¼Œå› ç‚ºå®ƒå€‘ä¸åƒ…ç¾å‘³ï¼Œé‚„å¯èƒ½å¢é€²å¥åº·ï¼ ä¸»è¦é‡é»ï¼š\n1. é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å¥åº·ã€‚\n2. ç‰¹å®šè™•ç†æ–¹æ³•èƒ½é¡¯è‘—æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šåƒ¹å€¼ã€‚\n3. é’èŠ±æ¤°èœèŠ½ç²‰å°æŸäº›ç´°èŒæœ‰æŠ—èŒæ•ˆæœã€‚",
    "image_prompt": "Create a simple infographic that explains the experiment and main results of a study on broccoli sprouts. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli and sulforaphane, simplified illustrations of the experimental subjects (like people or cells), arrows or flow lines to indicate the experimental steps, and a section highlighting the main results, such as the increase in certain nutrients and antibacterial effects.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41265122/"
  },
  {
    "id": "41159773",
    "title_en": "Sulforaphane-Loaded Hydrogel Prolongs Fully MHC-Mismatched Skin Allograft Survival.",
    "pub_date": "2025 Nov",
    "journal": "ACS applied bio materials",
    "abstract_en": "Despite immunosuppression, acute rejection (AR) is still a common setback among transplantation patients and is a risk factor for graft survival. Sulforaphane (SFN), a phytochemical present in crucifers, has been shown to have anti-inflammatory and immunoregulatory properties, yet its influences on immune cell activation as well as in graft survival are still unknown. Thus, the aim was to evaluate SFN's effect, and to improve efficacy, efficiency, and availability, it was incorporated into thermosensitive polymeric hydrogels, to prevent AR in skin transplant (Tx) model mice. A thermosensitive hydrogel containing SFN (0.1%) and hyaluronic acid (HA) (0.5%) dispersed in a poloxamer matrix (PL407 at 20% w/v) was developed (GS-PL407 20%, HA and SFN) and characterized as a liquid-viscous hydrogel. The fully MHC-incompatible skin Tx procedure was performed by using donor skin Balb/c mice, transplanted into C57BL/6 recipient mice. The cytotoxicity test of GS was performed using in vitro assays with bone marrow-derived dendritic cells (BMDC). Treatment of BMDC with GS for 24 h presents no cytotoxicity. Untreated allograft mice present 100% of graft loss at day 9 post Tx. Remarkably, subcutaneous GS injection every 3 days promoted 80% of allograft survival for more than 14 days when compared with untreated recipients (<i>p</i> < 0.001). Histological analysis showed a lower level of inflammatory cells in the skin Tx of GS-treated mice. Flow cytometry analysis of draining lymph nodes at day 5 post Tx revealed that GS treatment reduced the frequency of DC and subtypes and function of the CD4<sup>+</sup> T cells. In vitro GS-treated lipopolysaccharide-activated BMDC present less activation of costimulatory markers. Taken together, GS treatment reduced immune cell activation, postponing AR onset and prolonging allograft survival in Tx animals. This strategy highlights the role of SFN as a promising candidate for further studies in organ transplantation experiments and being tested combined with current immunosuppression protocols.",
    "para1": "åœ¨å™¨å®˜ç§»æ¤çš„éç¨‹ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™æœƒå½±éŸ¿åˆ°ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æ½›åœ¨å¥½è™•ï¼Œå› ç‚ºå®ƒå…·æœ‰æŠ—ç™¼ç‚å’Œèª¿ç¯€å…ç–«çš„ç‰¹æ€§ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯èƒ½èƒ½æ‰¾åˆ°æ”¹å–„å™¨å®˜ç§»æ¤æˆåŠŸç‡çš„æ–°æ–¹æ³•ï¼Œé€²è€Œæå‡ç—…äººçš„å¥åº·ç‹€æ³ï¼Œæ¸›å°‘æ’æ–¥åæ‡‰çš„é¢¨éšªï¼Œé€™å°æ–¼å™¨å®˜ç§»æ¤æ‚£è€…ä¾†èªªæ˜¯éå¸¸é‡è¦çš„å•Ÿç¤ºã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»è¦ç›®çš„æ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ä»¥åŠç§»æ¤å™¨å®˜çš„å­˜æ´»æƒ…æ³ã€‚ç”±æ–¼ç›®å‰å°æ–¼è˜¿è””ç¡«ç´ åœ¨é€™æ–¹é¢çš„å½±éŸ¿ä»ä¸æ˜ç¢ºï¼Œå› æ­¤é€™é …ç ”ç©¶çš„çµæœå°‡æœ‰åŠ©æ–¼å¡«è£œé€™ä¸€çŸ¥è­˜ç©ºç™½ã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†çš®è†šç§»æ¤æ¨¡å‹çš„å°é¼ ï¼Œä¸¦å°‡è˜¿è””ç¡«ç´ èˆ‡é€æ˜è³ªé…¸è£½æˆç†±æ•èšåˆç‰©æ°´å‡è† ï¼Œä»¥æé«˜å…¶æ•ˆæœå’Œå¯ç”¨æ€§ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶è€…é–‹ç™¼äº†ä¸€ç¨®å«æœ‰0.1%è˜¿è””ç¡«ç´ å’Œ0.5%é€æ˜è³ªé…¸çš„æ°´å‡è† ï¼Œä¸¦é€²è¡Œäº†ç›¸é—œçš„å¯¦é©—ä¾†è©•ä¼°å…¶å°å…ç–«ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶ä¸­é‚„é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿é€™ç¨®æ°´å‡è† å°å…ç–«ç´°èƒä¸æœƒé€ æˆå‚·å®³ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ æ°´å‡è† æ²»ç™‚çš„å°é¼ ï¼Œå…¶ç§»æ¤çš®è†šçš„å­˜æ´»ç‡é¡¯è‘—æé«˜ï¼Œé”åˆ°80%ä»¥ä¸Šï¼Œä¸”å­˜æ´»æ™‚é–“è¶…é14å¤©ï¼Œé€™èˆ‡æœªæ¥å—æ²»ç™‚çš„å°é¼ ç›¸æ¯”æœ‰æ˜é¡¯å·®ç•°ã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—æ²»ç™‚çš„å°é¼ å…¶çš®è†šä¸­çš„ç‚ç—‡ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æœ‰æ•ˆæ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿï¼Œä¸¦å»¶é•·ç§»æ¤å™¨å®˜çš„å­˜æ´»æ™‚é–“ã€‚é€™äº›çµæœç‚ºæœªä¾†åœ¨å™¨å®˜ç§»æ¤ä¸­çš„æ‡‰ç”¨æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "åœ¨å™¨å®˜ç§»æ¤çš„éç¨‹ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™æœƒå½±éŸ¿åˆ°ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æ½›åœ¨å¥½è™•ï¼Œå› ç‚ºå®ƒå…·æœ‰æŠ—ç™¼ç‚å’Œèª¿ç¯€å…ç–«çš„ç‰¹æ€§ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯èƒ½èƒ½æ‰¾åˆ°æ”¹å–„å™¨å®˜ç§»æ¤æˆåŠŸç‡çš„æ–°æ–¹æ³•ï¼Œé€²è€Œæå‡ç—…äººçš„å¥åº·ç‹€æ³ï¼Œæ¸›å°‘æ’æ–¥åæ‡‰çš„é¢¨éšªï¼Œé€™å°æ–¼å™¨å®˜ç§»æ¤æ‚£è€…ä¾†èªªæ˜¯éå¸¸é‡è¦çš„å•Ÿç¤ºã€‚\n\né€™é …ç ”ç©¶çš„ä¸»è¦ç›®çš„æ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ä»¥åŠç§»æ¤å™¨å®˜çš„å­˜æ´»æƒ…æ³ã€‚ç”±æ–¼ç›®å‰å°æ–¼è˜¿è””ç¡«ç´ åœ¨é€™æ–¹é¢çš„å½±éŸ¿ä»ä¸æ˜ç¢ºï¼Œå› æ­¤é€™é …ç ”ç©¶çš„çµæœå°‡æœ‰åŠ©æ–¼å¡«è£œé€™ä¸€çŸ¥è­˜ç©ºç™½ã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†çš®è†šç§»æ¤æ¨¡å‹çš„å°é¼ ï¼Œä¸¦å°‡è˜¿è””ç¡«ç´ èˆ‡é€æ˜è³ªé…¸è£½æˆç†±æ•èšåˆç‰©æ°´å‡è† ï¼Œä»¥æé«˜å…¶æ•ˆæœå’Œå¯ç”¨æ€§ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶è€…é–‹ç™¼äº†ä¸€ç¨®å«æœ‰0.1%è˜¿è””ç¡«ç´ å’Œ0.5%é€æ˜è³ªé…¸çš„æ°´å‡è† ï¼Œä¸¦é€²è¡Œäº†ç›¸é—œçš„å¯¦é©—ä¾†è©•ä¼°å…¶å°å…ç–«ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶ä¸­é‚„é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿é€™ç¨®æ°´å‡è† å°å…ç–«ç´°èƒä¸æœƒé€ æˆå‚·å®³ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ æ°´å‡è† æ²»ç™‚çš„å°é¼ ï¼Œå…¶ç§»æ¤çš®è†šçš„å­˜æ´»ç‡é¡¯è‘—æé«˜ï¼Œé”åˆ°80%ä»¥ä¸Šï¼Œä¸”å­˜æ´»æ™‚é–“è¶…é14å¤©ï¼Œé€™èˆ‡æœªæ¥å—æ²»ç™‚çš„å°é¼ ç›¸æ¯”æœ‰æ˜é¡¯å·®ç•°ã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—æ²»ç™‚çš„å°é¼ å…¶çš®è†šä¸­çš„ç‚ç—‡ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æœ‰æ•ˆæ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿï¼Œä¸¦å»¶é•·ç§»æ¤å™¨å®˜çš„å­˜æ´»æ™‚é–“ã€‚é€™äº›çµæœç‚ºæœªä¾†åœ¨å™¨å®˜ç§»æ¤ä¸­çš„æ‡‰ç”¨æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS applied bio materialsã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿåœ¨å™¨å®˜ç§»æ¤éç¨‹ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰å¸¸å¸¸æœƒè®“é†«ç”Ÿå‚·é€è…¦ç­‹ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶æ¤ç‰©æˆåˆ†å¯èƒ½æœƒå¹«åŠ©æ”¹å–„é€™å€‹å•é¡Œã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æƒ³çœ‹çœ‹è˜¿è””ç¡«ç´ å°æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨å°é¼ çš„çš®è†šç§»æ¤æ¨¡å‹ä¸­ã€‚ç ”ç©¶è€…å€‘è£½ä½œäº†ä¸€ç¨®å«æœ‰è˜¿è””ç¡«ç´ çš„æ°´å‡è† ï¼Œç„¶å¾Œè§€å¯Ÿå®ƒå°å…ç–«ç´°èƒçš„å½±éŸ¿ã€‚çµæœç™¼ç¾ï¼Œé€™ç¨®æ°´å‡è† èƒ½é¡¯è‘—æé«˜ç§»æ¤çš®è†šçš„å­˜æ´»ç‡ï¼Œç”šè‡³é”åˆ°80%ä»¥ä¸Šï¼Œä¸¦ä¸”å­˜æ´»æ™‚é–“è¶…é14å¤©ï¼\n\nä¸åƒ…å¦‚æ­¤ï¼Œæ¥å—æ²»ç™‚çš„å°é¼ çš®è†šä¸­çš„ç‚ç—‡ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å…ç–«ç³»çµ±çš„éåº¦åæ‡‰ï¼Œå»¶é•·ç§»æ¤å™¨å®˜çš„å­˜æ´»æ™‚é–“ã€‚\n\nğŸ”é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æ€¥æ€§æ’æ–¥åæ‡‰ã€‚\n2. ä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ°´å‡è† èƒ½é¡¯è‘—æé«˜ç§»æ¤çš®è†šçš„å­˜æ´»ç‡ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†å™¨å®˜ç§»æ¤çš„æ”¹å–„æä¾›äº†æ–°æ€è·¯ï¼",
    "image_prompt": "Create an informative illustration that explains the experiment and main results of the research on sulforaphane and acute rejection in organ transplantation. Use a flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice or cells, arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Results' highlighting the protective effects and outcomes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§æ’æ–¥åæ‡‰ Acute Rejection",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41159773/"
  },
  {
    "id": "41196460",
    "title_en": "Sulforaphane: a natural organosulfur having potential to modulate apoptosis and survival signalling in cancer.",
    "pub_date": "2025 Nov",
    "journal": "Discover oncology",
    "abstract_en": "Owing to its ever-growing range of pharmacological advantages, sulforaphane, an isothiocyanate from cruciferous vegetables such as broccoli, is becoming increasingly popular. This review aims to provide a thorough understanding and a current update on the application of sulforaphane in cancer treatment. Sulforaphane interacts with many signaling molecules that control various pathways in malignant cells, including angiogenesis, apoptosis, cell cycle arrest, metastasis, and inflammation pathways. This review examines the effects of this isothiocyanate on inflammatory mediators, caspases, MMPs, cytokines, and the proteins Bax and Bcl-2. Furthermore, the advantages of nanotechnology and synergistic effects in sulforaphane applications are also reviewed. As per evidence, sulforaphane is a shining example of how ethno-pharmacological expertise can be used to create modern medications.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ä¸åŒç”Ÿç‰©é€”å¾‘ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†é é˜²æˆ–è¼”åŠ©æ²»ç™‚ç™Œç—‡ï¼Œé€™å°æ–¼æå‡äººé¡å¥åº·æ°´å¹³æ˜¯éå¸¸æœ‰æ„ç¾©çš„ã€‚",
    "para2": "é€™ç¯‡ç¶œè¿°çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒå…§çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™ç¯‡æ–‡ç« æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èª¿æ§è…«ç˜¤ç›¸é—œçš„ç”Ÿç‰©é€”å¾‘ï¼Œå¦‚è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»å’Œç‚ç—‡ç­‰æ–¹é¢çš„ä½œç”¨ï¼Œé€™äº›éƒ½æ˜¯ç™Œç—‡ç™¼å±•éç¨‹ä¸­é‡è¦çš„ç’°ç¯€ã€‚",
    "para3": "é€™é …ç ”ç©¶ä¸»è¦æ˜¯é€éæ–‡ç»å›é¡§çš„æ–¹å¼é€²è¡Œï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ å°æ–¼å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€åŠèƒ±å¤©å†¬é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ï¼Œä»¥åŠèˆ‡ç´°èƒå‡‹äº¡ç›¸é—œçš„è›‹ç™½è³ªå¦‚Baxå’ŒBcl-2ã€‚ç ”ç©¶è€…ä¹Ÿæ¢è¨äº†ç´ç±³æŠ€è¡“å’Œè˜¿è””ç¡«ç´ çš„å”åŒæ•ˆæ‡‰åœ¨æ‡‰ç”¨ä¸Šçš„å„ªå‹¢ï¼Œé€™äº›æ–¹æ³•èƒ½å¤ å¹«åŠ©æˆ‘å€‘æ›´æ·±å…¥åœ°ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åŠ›ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿æ§ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©é€”å¾‘ä¸Šå…·æœ‰æ½›åœ¨çš„æ•ˆæœï¼Œé€™å¯èƒ½ç‚ºç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨æŸäº›æ–¹é¢å…·æœ‰è‰¯å¥½çš„æ‡‰ç”¨æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œå®‰å…¨æ€§ã€‚é€™é …ç ”ç©¶å¼·èª¿äº†å‚³çµ±è—¥ç†çŸ¥è­˜åœ¨ç¾ä»£é†«è—¥é–‹ç™¼ä¸­çš„é‡è¦æ€§ï¼Œä¸¦å±•ç¤ºäº†è˜¿è””ç¡«ç´ çš„æ‡‰ç”¨å‰æ™¯ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ä¸åŒç”Ÿç‰©é€”å¾‘ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†é é˜²æˆ–è¼”åŠ©æ²»ç™‚ç™Œç—‡ï¼Œé€™å°æ–¼æå‡äººé¡å¥åº·æ°´å¹³æ˜¯éå¸¸æœ‰æ„ç¾©çš„ã€‚\n\né€™ç¯‡ç¶œè¿°çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒå…§çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™ç¯‡æ–‡ç« æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èª¿æ§è…«ç˜¤ç›¸é—œçš„ç”Ÿç‰©é€”å¾‘ï¼Œå¦‚è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»å’Œç‚ç—‡ç­‰æ–¹é¢çš„ä½œç”¨ï¼Œé€™äº›éƒ½æ˜¯ç™Œç—‡ç™¼å±•éç¨‹ä¸­é‡è¦çš„ç’°ç¯€ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ˜¯é€éæ–‡ç»å›é¡§çš„æ–¹å¼é€²è¡Œï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ å°æ–¼å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€åŠèƒ±å¤©å†¬é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ï¼Œä»¥åŠèˆ‡ç´°èƒå‡‹äº¡ç›¸é—œçš„è›‹ç™½è³ªå¦‚Baxå’ŒBcl-2ã€‚ç ”ç©¶è€…ä¹Ÿæ¢è¨äº†ç´ç±³æŠ€è¡“å’Œè˜¿è””ç¡«ç´ çš„å”åŒæ•ˆæ‡‰åœ¨æ‡‰ç”¨ä¸Šçš„å„ªå‹¢ï¼Œé€™äº›æ–¹æ³•èƒ½å¤ å¹«åŠ©æˆ‘å€‘æ›´æ·±å…¥åœ°ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åŠ›ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿æ§ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©é€”å¾‘ä¸Šå…·æœ‰æ½›åœ¨çš„æ•ˆæœï¼Œé€™å¯èƒ½ç‚ºç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨æŸäº›æ–¹é¢å…·æœ‰è‰¯å¥½çš„æ‡‰ç”¨æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œå®‰å…¨æ€§ã€‚é€™é …ç ”ç©¶å¼·èª¿äº†å‚³çµ±è—¥ç†çŸ¥è­˜åœ¨ç¾ä»£é†«è—¥é–‹ç™¼ä¸­çš„é‡è¦æ€§ï¼Œä¸¦å±•ç¤ºäº†è˜¿è””ç¡«ç´ çš„æ‡‰ç”¨å‰æ™¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠDiscover oncologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡é¢æœ‰ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„æˆåˆ†ï¼Œæœ€è¿‘ç§‘å­¸å®¶å€‘å°å®ƒçš„ç ”ç©¶å¯æœ‰è¶£äº†ï¼é€™ç¨®å¤©ç„¶åŒ–åˆç‰©ä¸åƒ…èƒ½è®“æˆ‘å€‘çš„é¤ç›¤æ›´ç¾å‘³ï¼Œé‚„å¯èƒ½åœ¨ç™Œç—‡æ²»ç™‚ä¸Šç™¼æ®é‡è¦ä½œç”¨ã€‚ğŸ¤”\n\né€™ç¯‡ç ”ç©¶ä¸»è¦é—œå¿ƒè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ã€‚ç ”ç©¶äººå“¡é€éæ–‡ç»å›é¡§ï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ å°ä¸åŒç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼Œåƒæ˜¯ç‚ç—‡ä»‹è³ªå’Œèˆ‡ç´°èƒæ­»äº¡æœ‰é—œçš„è›‹ç™½è³ªã€‚ä»–å€‘ä¹Ÿæ¢è¨äº†ç´ç±³æŠ€è¡“å’Œè˜¿è””ç¡«ç´ çš„å”åŒæ•ˆæ‡‰ï¼Œé€™å¯èƒ½å¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°ç†è§£é€™å€‹åŒ–åˆç‰©çš„æ½›åŠ›ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿æ§ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©é€”å¾‘ä¸Šæœ‰æ½›åœ¨çš„æ•ˆæœï¼Œé€™ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚ä¸éï¼Œé‚„éœ€è¦æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªå®ƒçš„å…·é«”ç™‚æ•ˆå’Œå®‰å…¨æ€§ã€‚\n\nğŸ”é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ç™Œç—‡æ²»ç™‚ã€‚\n2. ç ”ç©¶é¡¯ç¤ºå®ƒèƒ½å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ã€‚\n3. é‚„éœ€é€²ä¸€æ­¥ç ”ç©¶ç¢ºèªå…¶ç™‚æ•ˆå’Œå®‰å…¨æ€§ã€‚",
    "image_prompt": "Create a flat design infographic with a light background illustrating the study of sulforaphane. Include symbols of broccoli and sulforaphane, simplified representations of experimental subjects like humans or cells, and arrows or flow lines indicating the experimental process. Add a section labeled 'Main Results' highlighting protective effects or changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41196460/"
  },
  {
    "id": "41184790",
    "title_en": "Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.",
    "pub_date": "2025 Nov",
    "journal": "BMC psychiatry",
    "abstract_en": "Sulforaphane, an isothiocyanate derived from cruciferous vegetables (e.g., broccoli sprouts), has been explored for its antioxidant and anti-inflammatory properties. This is the first systematic review and meta-analysis to explore the therapeutic potentials of sulforaphane in schizophrenia. We searched PubMed, Scopus, Web of Science, and Cochrane Central for studies from inception to April 2025. We included randomized controlled trials (RCTs) evaluating the efficacy of sulforaphane in schizophrenia. The primary outcomes were changes in the Positive and Negative Syndrome Scale (PANSS) total and its subscales. Secondary outcomes included cognitive measures, metabolic markers, and safety. Four RCTs with 369 schizophrenia patients were included. Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point. However, a modest improvement in negative symptoms was found at 12 week- time point (MD= -1.06; 95% CI: -1.95 to -0.16; pâ€‰=â€‰0.02), which was not maintained at the latest follow-up. General psychopathology scores improved significantly (MD= -1.5; 95% CI: -2.78 to -0.23; pâ€‰=â€‰0.02). No cognitive benefits were observed. Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol. Discontinuation rates were lower in the sulforaphane group (RRâ€‰=â€‰0.68; 95% CI: 0.49 to 0.95; pâ€‰=â€‰0.02). The study provides initial insights into sulforaphane's potential therapeutic effects in schizophrenia, showing modest improvements in general psychopathology and negative symptoms, with favorable metabolic changes and lower discontinuation rates. Due to limited data and heterogeneity, the study findings should be interpreted with caution. Not applicable.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼ˆå¦‚é’èŠ±æ¤°èœï¼‰çš„åŒ–åˆç‰©ï¼Œå› å…¶æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§è€Œå—åˆ°é—œæ³¨ã€‚é›–ç„¶é€™é …ç ”ç©¶ä¸»è¦é‡å°ç²¾ç¥åˆ†è£‚ç—‡ï¼Œä½†å®ƒä¹Ÿå¯èƒ½ç‚ºå…¶ä»–ç²¾ç¥å¥åº·å•é¡Œçš„é é˜²å’Œæ²»ç™‚æä¾›ä¸€äº›æ–°çš„æ€è·¯ã€‚é€™è¡¨æ˜ï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¯èƒ½åœ¨æ”¹å–„å¿ƒç†å¥åº·æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œå€¼å¾—é€²ä¸€æ­¥æ¢ç´¢ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç ”ç©¶è€…é€²è¡Œäº†ä¸€é …ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œæ—¨åœ¨è©•ä¼°è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„å½±éŸ¿ã€‚é€™æ˜¯é¦–æ¬¡é‡å°é€™ä¸€ä¸»é¡Œé€²è¡Œçš„ç³»çµ±æ€§åˆ†æï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„ç—‡ç‹€ï¼Œä¸¦æä¾›ä¸€äº›æœ‰é—œå…¶ç™‚æ•ˆçš„ç§‘å­¸è­‰æ“šã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æœå°‹ç›¸é—œçš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTï¼‰ï¼Œä¸¦ç´å…¥äº†369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ã€‚é€™äº›è©¦é©—è©•ä¼°äº†è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œä¸»è¦é—œæ³¨çš„çµæœåŒ…æ‹¬æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰çš„ç¸½åˆ†åŠå…¶å­é‡è¡¨çš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è€ƒé‡äº†èªçŸ¥æ¸¬é‡ã€ä»£è¬æ¨™è¨˜å’Œå®‰å…¨æ€§ç­‰æ¬¡è¦çµæœã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶èƒ½å¤ å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨å½±éŸ¿ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„PANSSç¸½åˆ†æˆ–æ­£ç—‡ç‹€æ–¹é¢ä¸¦æ²’æœ‰é¡¯è‘—æ•ˆæœï¼Œä½†åœ¨12é€±çš„æ™‚é–“é»ä¸Šï¼Œè² ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚ä¸€èˆ¬ç²¾ç¥ç—…ç†å­¸çš„è©•åˆ†ä¹Ÿé¡¯ç¤ºå‡ºé¡¯è‘—æ”¹å–„ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ å°ä»£è¬æ¨™è¨˜ï¼ˆå¦‚ä½å¯†åº¦è„‚è›‹ç™½ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼‰æœ‰é¡¯è‘—çš„é™ä½æ•ˆæœï¼Œä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„ä¸­æ­¢ç‡è¼ƒä½ã€‚å„˜ç®¡çµæœé¡¯ç¤ºå‡ºä¸€äº›æ½›åœ¨çš„å¥½è™•ï¼Œä½†ç”±æ–¼æ•¸æ“šæœ‰é™ä¸”å­˜åœ¨ç•°è³ªæ€§ï¼Œé€™äº›ç™¼ç¾éœ€è¦è¬¹æ…è§£è®€ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼ˆå¦‚é’èŠ±æ¤°èœï¼‰çš„åŒ–åˆç‰©ï¼Œå› å…¶æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§è€Œå—åˆ°é—œæ³¨ã€‚é›–ç„¶é€™é …ç ”ç©¶ä¸»è¦é‡å°ç²¾ç¥åˆ†è£‚ç—‡ï¼Œä½†å®ƒä¹Ÿå¯èƒ½ç‚ºå…¶ä»–ç²¾ç¥å¥åº·å•é¡Œçš„é é˜²å’Œæ²»ç™‚æä¾›ä¸€äº›æ–°çš„æ€è·¯ã€‚é€™è¡¨æ˜ï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¯èƒ½åœ¨æ”¹å–„å¿ƒç†å¥åº·æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œå€¼å¾—é€²ä¸€æ­¥æ¢ç´¢ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç ”ç©¶è€…é€²è¡Œäº†ä¸€é …ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œæ—¨åœ¨è©•ä¼°è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„å½±éŸ¿ã€‚é€™æ˜¯é¦–æ¬¡é‡å°é€™ä¸€ä¸»é¡Œé€²è¡Œçš„ç³»çµ±æ€§åˆ†æï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„ç—‡ç‹€ï¼Œä¸¦æä¾›ä¸€äº›æœ‰é—œå…¶ç™‚æ•ˆçš„ç§‘å­¸è­‰æ“šã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æœå°‹ç›¸é—œçš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTï¼‰ï¼Œä¸¦ç´å…¥äº†369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ã€‚é€™äº›è©¦é©—è©•ä¼°äº†è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œä¸»è¦é—œæ³¨çš„çµæœåŒ…æ‹¬æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰çš„ç¸½åˆ†åŠå…¶å­é‡è¡¨çš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è€ƒé‡äº†èªçŸ¥æ¸¬é‡ã€ä»£è¬æ¨™è¨˜å’Œå®‰å…¨æ€§ç­‰æ¬¡è¦çµæœã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶èƒ½å¤ å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨å½±éŸ¿ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„PANSSç¸½åˆ†æˆ–æ­£ç—‡ç‹€æ–¹é¢ä¸¦æ²’æœ‰é¡¯è‘—æ•ˆæœï¼Œä½†åœ¨12é€±çš„æ™‚é–“é»ä¸Šï¼Œè² ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚ä¸€èˆ¬ç²¾ç¥ç—…ç†å­¸çš„è©•åˆ†ä¹Ÿé¡¯ç¤ºå‡ºé¡¯è‘—æ”¹å–„ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ å°ä»£è¬æ¨™è¨˜ï¼ˆå¦‚ä½å¯†åº¦è„‚è›‹ç™½ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼‰æœ‰é¡¯è‘—çš„é™ä½æ•ˆæœï¼Œä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„ä¸­æ­¢ç‡è¼ƒä½ã€‚å„˜ç®¡çµæœé¡¯ç¤ºå‡ºä¸€äº›æ½›åœ¨çš„å¥½è™•ï¼Œä½†ç”±æ–¼æ•¸æ“šæœ‰é™ä¸”å­˜åœ¨ç•°è³ªæ€§ï¼Œé€™äº›ç™¼ç¾éœ€è¦è¬¹æ…è§£è®€ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC psychiatryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ å¯èƒ½å°å¿ƒç†å¥åº·æœ‰å¹«åŠ©å—ï¼Ÿé€™é …ç ”ç©¶è®“æˆ‘å€‘å°é€™ç¨®å¤©ç„¶æˆåˆ†æœ‰äº†æ–°èªè­˜ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨æ•ˆæœã€‚ç ”ç©¶è€…é€²è¡Œäº†ç³»çµ±æ€§çš„å›é¡§ï¼Œåˆ†æäº†369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„è³‡æ–™ï¼Œæƒ³äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„ä»–å€‘çš„ç—‡ç‹€ã€‚\n\né›–ç„¶çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨æ”¹å–„ä¸€äº›ç—‡ç‹€æ–¹é¢ä¸¦æ²’æœ‰é¡¯è‘—æ•ˆæœï¼Œä½†åœ¨12é€±å¾Œï¼Œè² é¢ç—‡ç‹€æœ‰è¼•å¾®çš„æ”¹å–„ï¼Œä¸¦ä¸”ä¸€èˆ¬ç²¾ç¥ç—…ç†å­¸çš„è©•åˆ†ä¹Ÿæœ‰æ‰€æå‡ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„å°ä¸€äº›ä»£è¬æŒ‡æ¨™ï¼ˆå¦‚è†½å›ºé†‡ï¼‰æœ‰é¡¯è‘—é™ä½çš„æ•ˆæœï¼Œä¸¦ä¸”åƒèˆ‡è€…çš„ä¸­æ­¢ç‡è¼ƒä½ã€‚é€™äº›ç™¼ç¾é›–ç„¶æœ‰æ½›åœ¨çš„å¥½è™•ï¼Œä½†ä»éœ€è¬¹æ…è§£è®€ã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„è² ç—‡ç‹€æœ‰è¼•å¾®æ•ˆæœã€‚\n2. ç ”ç©¶é¡¯ç¤ºå…¶å°æŸäº›ä»£è¬æŒ‡æ¨™æœ‰æ­£é¢å½±éŸ¿ã€‚\n3. çµæœéœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªã€‚  \nè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æ›´å¤šçš„ç§‘å­¸ç™¼ç¾å§ï¼",
    "image_prompt": "Create an infographic that explains the experimental method and main results of a study on sulforaphane. The image should have a flat design style with a white or light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of human figures as study participants, and arrows or flow lines indicating the experimental steps. There should be a section labeled 'Main Results' highlighting key findings, such as slight improvements in negative symptoms and effects on metabolic markers.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç²¾ç¥åˆ†è£‚ç—‡ Schizophrenia",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41184790/"
  },
  {
    "id": "40992247",
    "title_en": "Assessing the transplacental passage and breastmilk levels of broccoli sprout-derived sulforaphane.",
    "pub_date": "2025 Nov",
    "journal": "Placenta",
    "abstract_en": "Preeclampsia is characterised by hypertension with maternal end-organ dysfunction and/or fetal growth restriction. Sulforaphane, an antioxidant found in broccoli sprouts, has potential as a future therapeutic. With its ability to attenuate the injurious impacts of endothelial dysfunction in vitro, sulforaphane is uniquely positioned to protect against the harmful effects of preeclampsia. However, the transferability of sulforaphane from mother to fetus/baby remains unknown in humans. Uncomplicated pregnant patients (nÂ =Â 8) scheduled for elective caesarean sections (>37 weeks gestation) provided written and informed consent. A single oral dose of EnduraCell, a broccoli sprout extract (equivalent to 21Â mg of sulforaphane), was administered prior to caesarean section. Baseline blood pressure, blood and urine were collected and again at time of operation, alongside umbilical cord blood (vein and artery) and placental samples. 2-4 days post-delivery, a second dose was administered. Two hours later, maternal bloods and breast milk were collected. Samples were processed and analysed by liquid-chromatography mass-spectrometry to measure sulforaphane. Besides an increase in peripheral diastolic blood pressure on the day of caesarean section (pÂ =Â 0.028), there were no changes in maternal blood pressure or heart rate after ingestion of EnduraCell. Sulforaphane was found in maternal serum (70.10Â ng/mlÂ Â±Â 11.90), umbilical cord blood (vein: 25.18Â ng/mLÂ Â±Â 3.11, artery: 18.81Â ng/mLÂ Â±Â 2.36), urine (5726.00Â ng/mLÂ Â±Â 1175.00), placental tissue (10.99Â ng/mgÂ Â±Â 2.11) and breast milk (1.33Â ng/mLÂ Â±Â 2.29). Sulforaphane is present in the umbilical cord and breast milk, providing the world's first evidence of sulforaphane maternal-fetal transfer in humans, and opening avenues for future research into relevant fetal implications.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå¦Šå¨ æ¯’è¡€ç—‡ï¼‰çš„é é˜²å’Œæ²»ç™‚ä¸­æ‰®æ¼”é‡è¦è§’è‰²ã€‚å¦Šå¨ é«˜è¡€å£“ç—‡æ˜¯ä¸€ç¨®å¦Šå¨ æœŸé–“å¸¸è¦‹çš„ä½µç™¼ç—‡ï¼Œå¯èƒ½å°æ¯è¦ªå’Œèƒå…’é€ æˆåš´é‡å½±éŸ¿ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å…·æœ‰æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œèƒ½å¤ æ¸›è¼•å…§çš®åŠŸèƒ½éšœç¤™çš„å‚·å®³ï¼Œé€™ä½¿å¾—å®ƒåœ¨ä¿è­·å­•å©¦å’Œèƒå…’æ–¹é¢å…·æœ‰æ½›åŠ›ã€‚é›–ç„¶é€™é …ç ”ç©¶çš„çµæœä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥æ¢è¨å…¶åœ¨è‡¨åºŠæ‡‰ç”¨ä¸­çš„å¯¦éš›æ•ˆæœå’Œå®‰å…¨æ€§ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒæ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’æˆ–å¬°å…’ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘æ˜¯å¦èƒ½åœ¨å¦Šå¨ æœŸé–“æä¾›ä¿è­·ï¼Œä¸¦ä¸”æ˜¯å¦èƒ½å¤ é€éè‡å¸¶è¡€å’Œæ¯ä¹³å‚³éçµ¦èƒå…’ã€‚é€™é …ç ”ç©¶çš„é‡è¦æ€§åœ¨æ–¼ï¼Œå®ƒä¸åƒ…é—œæ³¨æ¯è¦ªçš„å¥åº·ï¼Œä¹Ÿé—œå¿ƒèƒå…’çš„ç™¼å±•ï¼Œå°¤å…¶æ˜¯åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡çš„èƒŒæ™¯ä¸‹ã€‚",
    "para3": "ç ”ç©¶å°è±¡ç‚ºå…«åè¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢çš„å¥åº·å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨å¦Šå¨ 37é€±ä»¥ä¸Šï¼Œä¸¦ä¸”å·²ç¶“ç°½ç½²çŸ¥æƒ…åŒæ„æ›¸ã€‚ç ”ç©¶ä¸­ï¼Œå­•å©¦åœ¨å‰–è…¹ç”¢å‰å£æœä¸€åŠ‘è˜¿è””ç¡«ç´ æå–ç‰©ï¼ˆç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ï¼‰ã€‚åœ¨æ‰‹è¡“å‰ï¼Œç ”ç©¶åœ˜éšŠæ”¶é›†äº†å­•å©¦çš„åŸºç·šè¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦åœ¨æ‰‹è¡“æ™‚æ”¶é›†è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚ç”¢å¾Œ2è‡³4å¤©ï¼Œå­•å©¦å†æ¬¡æœç”¨è˜¿è””ç¡«ç´ æå–ç‰©ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œé€²è¡Œåˆ†æä»¥æ¸¬é‡è˜¿è””ç¡«ç´ çš„å«é‡ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’çš„è­‰æ“šã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œå­•å©¦çš„å‘¨é‚Šèˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†æ•´é«”ä¸Šæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ‡‰ç”¨æä¾›äº†æ–°çš„æ–¹å‘ï¼Œä¸¦å¼•ç™¼äº†å°å…¶å°èƒå…’å½±éŸ¿çš„é€²ä¸€æ­¥æ¢è¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå¦Šå¨ æ¯’è¡€ç—‡ï¼‰çš„é é˜²å’Œæ²»ç™‚ä¸­æ‰®æ¼”é‡è¦è§’è‰²ã€‚å¦Šå¨ é«˜è¡€å£“ç—‡æ˜¯ä¸€ç¨®å¦Šå¨ æœŸé–“å¸¸è¦‹çš„ä½µç™¼ç—‡ï¼Œå¯èƒ½å°æ¯è¦ªå’Œèƒå…’é€ æˆåš´é‡å½±éŸ¿ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å…·æœ‰æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œèƒ½å¤ æ¸›è¼•å…§çš®åŠŸèƒ½éšœç¤™çš„å‚·å®³ï¼Œé€™ä½¿å¾—å®ƒåœ¨ä¿è­·å­•å©¦å’Œèƒå…’æ–¹é¢å…·æœ‰æ½›åŠ›ã€‚é›–ç„¶é€™é …ç ”ç©¶çš„çµæœä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥æ¢è¨å…¶åœ¨è‡¨åºŠæ‡‰ç”¨ä¸­çš„å¯¦éš›æ•ˆæœå’Œå®‰å…¨æ€§ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒæ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’æˆ–å¬°å…’ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘æ˜¯å¦èƒ½åœ¨å¦Šå¨ æœŸé–“æä¾›ä¿è­·ï¼Œä¸¦ä¸”æ˜¯å¦èƒ½å¤ é€éè‡å¸¶è¡€å’Œæ¯ä¹³å‚³éçµ¦èƒå…’ã€‚é€™é …ç ”ç©¶çš„é‡è¦æ€§åœ¨æ–¼ï¼Œå®ƒä¸åƒ…é—œæ³¨æ¯è¦ªçš„å¥åº·ï¼Œä¹Ÿé—œå¿ƒèƒå…’çš„ç™¼å±•ï¼Œå°¤å…¶æ˜¯åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡çš„èƒŒæ™¯ä¸‹ã€‚\n\nç ”ç©¶å°è±¡ç‚ºå…«åè¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢çš„å¥åº·å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨å¦Šå¨ 37é€±ä»¥ä¸Šï¼Œä¸¦ä¸”å·²ç¶“ç°½ç½²çŸ¥æƒ…åŒæ„æ›¸ã€‚ç ”ç©¶ä¸­ï¼Œå­•å©¦åœ¨å‰–è…¹ç”¢å‰å£æœä¸€åŠ‘è˜¿è””ç¡«ç´ æå–ç‰©ï¼ˆç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ï¼‰ã€‚åœ¨æ‰‹è¡“å‰ï¼Œç ”ç©¶åœ˜éšŠæ”¶é›†äº†å­•å©¦çš„åŸºç·šè¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦åœ¨æ‰‹è¡“æ™‚æ”¶é›†è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚ç”¢å¾Œ2è‡³4å¤©ï¼Œå­•å©¦å†æ¬¡æœç”¨è˜¿è””ç¡«ç´ æå–ç‰©ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œé€²è¡Œåˆ†æä»¥æ¸¬é‡è˜¿è””ç¡«ç´ çš„å«é‡ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’çš„è­‰æ“šã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œå­•å©¦çš„å‘¨é‚Šèˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†æ•´é«”ä¸Šæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ‡‰ç”¨æä¾›äº†æ–°çš„æ–¹å‘ï¼Œä¸¦å¼•ç™¼äº†å°å…¶å°èƒå…’å½±éŸ¿çš„é€²ä¸€æ­¥æ¢è¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPlacentaã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡çš„ç¥å¥‡æˆåˆ†ï¼Œå¯èƒ½å°å­•å©¦å’Œå¯¶å¯¶çš„å¥åº·æœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼ğŸŒ±é€™é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œç§‘å­¸å®¶å€‘æƒ³çŸ¥é“å®ƒæ˜¯å¦èƒ½å¹«åŠ©é é˜²å¦Šå¨ é«˜è¡€å£“ç—‡ï¼Œé€™æ˜¯ä¸€ç¨®åœ¨æ‡·å­•æœŸé–“å¯èƒ½å½±éŸ¿æ¯è¦ªå’Œèƒå…’å¥åº·çš„ä½µç™¼ç—‡ã€‚\n\nç ”ç©¶ä¸­ï¼Œå…«ä½å³å°‡å‰–è…¹ç”¢çš„å­•å©¦åƒèˆ‡äº†å¯¦é©—ï¼Œå¥¹å€‘åœ¨æ‰‹è¡“å‰å’Œç”¢å¾Œæœç”¨äº†è˜¿è””ç¡«ç´ æå–ç‰©ã€‚ç§‘å­¸å®¶å€‘æ”¶é›†äº†å¥¹å€‘çš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦åœ¨æ‰‹è¡“æ™‚æ”¶é›†äº†è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬é€²è¡Œåˆ†æã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…åœ¨å­•å©¦çš„è¡€æ¶²ä¸­è¢«æª¢æ¸¬åˆ°ï¼Œé‚„èƒ½å¤ å‚³éåˆ°èƒå…’èº«ä¸Šï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦çš„ï¼é›–ç„¶å­•å©¦çš„è¡€å£“åœ¨æ‰‹è¡“ç•¶å¤©æœ‰äº›è®ŠåŒ–ï¼Œä½†æ•´é«”ä¸Šä¸¦æœªå‡ºç¾é¡¯è‘—çš„å•é¡Œã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ‡‰ç”¨æä¾›äº†æ–°çš„æ–¹å‘ã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°å­•å©¦å’Œèƒå…’çš„å¥åº·æœ‰ç›Šã€‚\n2. ç ”ç©¶è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create an infographic that explains the experimental method and main results of a study on sulforaphane. Include simplified illustrations of broccoli or sulforaphane, representations of human subjects (pregnant women), and arrows or flow lines to show the steps of the experiment. Add a section highlighting the main results, such as the protective effects observed and the transfer of sulforaphane from mother to fetus. Use a flat design style with a light background and soft colors.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¦Šå¨ é«˜è¡€å£“ç—‡ Preeclampsia",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40992247/"
  },
  {
    "id": "40633511",
    "title_en": "Synthesis and biological evaluation of Sulforaphane derivatives with dual functions: Ischemia-reperfusion injury protection and antitumor effects.",
    "pub_date": "2025 Nov",
    "journal": "Bioorganic & medicinal chemistry",
    "abstract_en": "Reperfusion therapy for the treatment of acute myocardial infarction (AMI) often leads to ischemia-reperfusion (I/R) injuries, characterized by excessive ROS. Sulforaphane (SFN) homologous, known for their anti-inflammatory and antioxidant properties, activate the nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway and reduce mitochondrial ROS but are limited by poor stability and short half-life. SFN derivatives were synthesized through structural modifications of the dithiocarbamate and thiourea moieties at the isothiocyanate group, aiming to enhance stability and maintain therapeutic efficacy. Compound 3g emerged as a promising candidate, demonstrating superior protection against hypoxia-reoxygenation (H/R) injury in cardiac microvascular endothelial cells (CMECs) and exhibiting good antitumor activity. Specifically, 3g reduced ROS levels by 24.5Â % (compared to nifedipine at 17.8Â %), increased NO production to 48.0Â Î¼M (vs. 44.0Â Î¼M), lowered TNF-Î± secretion to 22.6Â pg/mL (vs. 23.9Â pg/mL). Concurrently, 3g showed potent antiproliferative activity (IC<sub>50</sub>Â =Â 7.5Â Î¼M), with 3.8-fold greater potency than 5-fluorouracil (IC<sub>50</sub>Â =Â 28.2Â Î¼M). Stability studies showed enhanced resistance in both protic and aprotic solvents. Density functional theory (DFT) was applied to characterize the molecular properties of the optimal compounds. Molecular docking and ADMET analysis revealed that aromatic substitution and sulfur oxidation significantly improved Nrf2/Keap1 pathway targeting, highlighting the derivative's potential for stability and therapeutic efficacy. These findings suggest that 3g is a promising candidate for treating I/R-induced injury and oxidative stress-related cardiovascular conditions.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œæ€¥æ€§å¿ƒè‚Œæ¢—å¡çš„é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œï¼Œå¸¸æœƒç™¼ç”Ÿç¼ºè¡€å†çŒæ³¨æå‚·ï¼Œé€™ç¨®æƒ…æ³æœƒå°è‡´éå¤šçš„æ´»æ€§æ°§ï¼ˆROSï¼‰ç”¢ç”Ÿï¼Œé€²è€Œæå®³å¿ƒè‡Ÿç´°èƒã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ï¼Œå› ç‚ºå…·æœ‰æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æå‚·ï¼Œå¾è€Œä¿è­·å¿ƒè‡Ÿå¥åº·ã€‚é€™é¡¯ç¤ºå‡ºé€éæ”¹å–„é€™äº›åŒ–åˆç‰©çš„ç©©å®šæ€§å’Œç™‚æ•ˆï¼Œå¯èƒ½èƒ½å¤ åœ¨å¿ƒè¡€ç®¡ç–¾ç—…çš„æ²»ç™‚ä¸Šå¸¶ä¾†æ–°çš„å¸Œæœ›ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„ç¼ºè¡€å†çŒæ³¨æå‚·é€²è¡Œæ¢è¨ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ä¾†æ¸›å°‘é€™ç¨®æå‚·ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•é€šéæ”¹è‰¯é€™äº›åŒ–åˆç‰©çš„çµæ§‹ä¾†æé«˜å…¶ç©©å®šæ€§å’Œç™‚æ•ˆï¼Œé€²è€Œæœ‰æ•ˆæ¸›å°‘å¿ƒè‡Ÿç´°èƒå—åˆ°çš„æ°§åŒ–å£“åŠ›å’Œæå‚·ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£å¿ƒè‡Ÿç—…çš„ç—…ç†æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¹¾ç¨®è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯é€šéå°äºŒç¡«æ°¨åŸºç”²é…¸é¹½å’Œç¡«è„²åŸºåœ˜é€²è¡Œçµæ§‹ä¿®é£¾ï¼Œä¾†æé«˜é€™äº›åŒ–åˆç‰©çš„ç©©å®šæ€§ã€‚å¯¦é©—ä¸»è¦é‡å°å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒé€²è¡Œï¼Œæ¸¬è©¦é€™äº›åŒ–åˆç‰©åœ¨ç¼ºæ°§å†çŒæ³¨æå‚·ä¸­çš„ä¿è­·æ•ˆæœã€‚ç ”ç©¶è€…ä½¿ç”¨äº†åˆ†å­å°æ¥å’ŒADMETåˆ†æç­‰æ–¹æ³•ï¼Œä¾†è©•ä¼°é€™äº›åŒ–åˆç‰©çš„åˆ†å­ç‰¹æ€§å’Œè—¥ç‰©ä»£è¬å‹•åŠ›å­¸ï¼Œå¾è€Œæ‰¾å‡ºæœ€å…·æ½›åŠ›çš„å€™é¸åŒ–åˆç‰©ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œåˆæˆçš„åŒ–åˆç‰©3gåœ¨æ¸›å°‘ç¼ºæ°§å†çŒæ³¨æå‚·æ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œèƒ½æœ‰æ•ˆé™ä½æ´»æ€§æ°§çš„æ°´å¹³ï¼Œä¸¦æé«˜ä¸€æ°§åŒ–æ°®çš„ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œ3gåœ¨æŠ—è…«ç˜¤æ´»æ€§æ–¹é¢ä¹Ÿé¡¯ç¤ºå‡ºè‰¯å¥½çš„æ•ˆæœï¼Œå°ç´°èƒå¢æ®–çš„æŠ‘åˆ¶åŠ›æ¯”å¸¸ç”¨çš„åŒ–ç™‚è—¥ç‰©5-æ°Ÿå°¿å˜§å•¶æ›´å¼·ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œ3gå¯èƒ½æˆç‚ºæ²»ç™‚ç¼ºè¡€å†çŒæ³¨æå‚·åŠç›¸é—œå¿ƒè¡€ç®¡ç–¾ç—…çš„æœ‰å‰æ™¯çš„å€™é¸è—¥ç‰©ï¼Œé›–ç„¶ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œæ€¥æ€§å¿ƒè‚Œæ¢—å¡çš„é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œï¼Œå¸¸æœƒç™¼ç”Ÿç¼ºè¡€å†çŒæ³¨æå‚·ï¼Œé€™ç¨®æƒ…æ³æœƒå°è‡´éå¤šçš„æ´»æ€§æ°§ï¼ˆROSï¼‰ç”¢ç”Ÿï¼Œé€²è€Œæå®³å¿ƒè‡Ÿç´°èƒã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ï¼Œå› ç‚ºå…·æœ‰æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æå‚·ï¼Œå¾è€Œä¿è­·å¿ƒè‡Ÿå¥åº·ã€‚é€™é¡¯ç¤ºå‡ºé€éæ”¹å–„é€™äº›åŒ–åˆç‰©çš„ç©©å®šæ€§å’Œç™‚æ•ˆï¼Œå¯èƒ½èƒ½å¤ åœ¨å¿ƒè¡€ç®¡ç–¾ç—…çš„æ²»ç™‚ä¸Šå¸¶ä¾†æ–°çš„å¸Œæœ›ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„ç¼ºè¡€å†çŒæ³¨æå‚·é€²è¡Œæ¢è¨ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ä¾†æ¸›å°‘é€™ç¨®æå‚·ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•é€šéæ”¹è‰¯é€™äº›åŒ–åˆç‰©çš„çµæ§‹ä¾†æé«˜å…¶ç©©å®šæ€§å’Œç™‚æ•ˆï¼Œé€²è€Œæœ‰æ•ˆæ¸›å°‘å¿ƒè‡Ÿç´°èƒå—åˆ°çš„æ°§åŒ–å£“åŠ›å’Œæå‚·ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£å¿ƒè‡Ÿç—…çš„ç—…ç†æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¹¾ç¨®è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯é€šéå°äºŒç¡«æ°¨åŸºç”²é…¸é¹½å’Œç¡«è„²åŸºåœ˜é€²è¡Œçµæ§‹ä¿®é£¾ï¼Œä¾†æé«˜é€™äº›åŒ–åˆç‰©çš„ç©©å®šæ€§ã€‚å¯¦é©—ä¸»è¦é‡å°å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒé€²è¡Œï¼Œæ¸¬è©¦é€™äº›åŒ–åˆç‰©åœ¨ç¼ºæ°§å†çŒæ³¨æå‚·ä¸­çš„ä¿è­·æ•ˆæœã€‚ç ”ç©¶è€…ä½¿ç”¨äº†åˆ†å­å°æ¥å’ŒADMETåˆ†æç­‰æ–¹æ³•ï¼Œä¾†è©•ä¼°é€™äº›åŒ–åˆç‰©çš„åˆ†å­ç‰¹æ€§å’Œè—¥ç‰©ä»£è¬å‹•åŠ›å­¸ï¼Œå¾è€Œæ‰¾å‡ºæœ€å…·æ½›åŠ›çš„å€™é¸åŒ–åˆç‰©ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œåˆæˆçš„åŒ–åˆç‰©3gåœ¨æ¸›å°‘ç¼ºæ°§å†çŒæ³¨æå‚·æ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œèƒ½æœ‰æ•ˆé™ä½æ´»æ€§æ°§çš„æ°´å¹³ï¼Œä¸¦æé«˜ä¸€æ°§åŒ–æ°®çš„ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œ3gåœ¨æŠ—è…«ç˜¤æ´»æ€§æ–¹é¢ä¹Ÿé¡¯ç¤ºå‡ºè‰¯å¥½çš„æ•ˆæœï¼Œå°ç´°èƒå¢æ®–çš„æŠ‘åˆ¶åŠ›æ¯”å¸¸ç”¨çš„åŒ–ç™‚è—¥ç‰©5-æ°Ÿå°¿å˜§å•¶æ›´å¼·ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œ3gå¯èƒ½æˆç‚ºæ²»ç™‚ç¼ºè¡€å†çŒæ³¨æå‚·åŠç›¸é—œå¿ƒè¡€ç®¡ç–¾ç—…çš„æœ‰å‰æ™¯çš„å€™é¸è—¥ç‰©ï¼Œé›–ç„¶ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "fb_post": "æ ¹æ“šã€ŠBioorganic & medicinal chemistryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡çš„æˆåˆ†å¯èƒ½å°å¿ƒè‡Ÿå¥åº·æœ‰å¤§å¹«åŠ©ï¼é€™é …æœ€æ–°ç ”ç©¶å°ˆæ³¨æ–¼æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„å¿ƒè‡Ÿæå‚·ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ ä¾†æ¸›å°‘é€™äº›æå‚·ã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å’Œå®ƒçš„è¡ç”Ÿç‰©èƒ½å¹«åŠ©ä¿è­·å¿ƒè‡Ÿç´°èƒï¼Œæ¸›å°‘ç”±ç¼ºæ°§å†çŒæ³¨é€ æˆçš„æå‚·ã€‚ \n\nåœ¨å¯¦é©—ä¸­ï¼Œç§‘å­¸å®¶å€‘åˆæˆäº†å¹¾ç¨®è˜¿è””ç¡«ç´ çš„è®Šé«”ï¼Œä¸¦æ¸¬è©¦å®ƒå€‘å°å¿ƒè‡Ÿå¾®è¡€ç®¡ç´°èƒçš„ä¿è­·æ•ˆæœã€‚ä»–å€‘ä½¿ç”¨äº†å„ç¨®åˆ†ææ–¹æ³•ï¼Œæ‰¾å‡ºæœ€æœ‰æ½›åŠ›çš„åŒ–åˆç‰©ã€‚æœ€çµ‚ï¼Œä»–å€‘ç™¼ç¾ä¸€ç¨®åç‚º3gçš„åŒ–åˆç‰©åœ¨æ¸›å°‘å¿ƒè‡Ÿæå‚·æ–¹é¢ç‰¹åˆ¥æœ‰æ•ˆï¼Œé‚„èƒ½æå‡ä¸€æ°§åŒ–æ°®çš„ç”¢ç”Ÿï¼Œç”šè‡³åœ¨æŠ—è…«ç˜¤æ–¹é¢çš„æ•ˆæœä¹Ÿè¶…éäº†å¸¸è¦‹çš„åŒ–ç™‚è—¥ç‰©ï¼ \n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†å¿ƒè¡€ç®¡ç–¾ç—…çš„æ²»ç™‚å……æ»¿æœŸå¾…ï¼Œä½†ä»éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªé€™äº›æ•ˆæœã€‚ \n\nğŸ” ç ”ç©¶é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å¿ƒè‡Ÿå¥åº·ã€‚\n2. åˆæˆçš„åŒ–åˆç‰©3gåœ¨æ¸›å°‘å¿ƒè‡Ÿæå‚·æ–¹é¢æ•ˆæœé¡¯è‘—ã€‚\n3. 3gåœ¨æŠ—è…«ç˜¤æ–¹é¢çš„æ•ˆæœè¶…éå‚³çµ±åŒ–ç™‚è—¥ç‰©ã€‚",
    "image_prompt": "Create a flat design infographic with a light background that explains the experimental process and main results of a study on the protective effects of a compound derived from cruciferous vegetables (like radish) on heart cells. Include simplified illustrations of the compound, heart cells, and the experimental setup. Use arrows or flow lines to indicate the steps of the experiment. Highlight a section labeled 'Main Results' showcasing the protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¿ƒè‚Œæ¢—å¡ Myocardial Infarction",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40633511/"
  },
  {
    "id": "40617372",
    "title_en": "Antioxidant effect of esculin and sulforaphane in zebrafish larvae: A comparative study.",
    "pub_date": "2025 Nov",
    "journal": "Comparative biochemistry and physiology. Toxicology & pharmacology : CBP",
    "abstract_en": "Antioxidants are crucial for maintaining cellular redox homeostasis by neutralizing free radicals, including reactive oxygen species (ROS). Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor that activates various cytoprotective genes to counteract oxidative damage. The present study aimed to compare the antioxidant potential of natural phytochemicals, esculin (ESC), and sulforaphane (SFN) in zebrafish larvae, focusing on Nrf2 activation. Zebrafish larvae were treated with ESC (100Â Î¼M) and SFN (40Â Î¼M) along with control for 6Â h. The levels of ROS, lipid peroxidation (LPO), nitric oxide (NO), glutathione S-transferase (GST), glutathione peroxidase (GPx), catalase (CAT), and reduced glutathione (GSH) were measured. Further, RT-PCR and Western blotting methods were employed to determine the antioxidant genes and protein levels, respectively. In addition, Nrf2 localization within the cell was assessed using nuclear/cytosolic fractionation assay and wholemount immunohistochemistry method. Our results demonstrate that ESC treatment significantly increased antioxidant enzyme activities (GST, GPx, CAT), similar to the effects observed with SFN. Further, ESC enhanced the mRNA levels of antioxidant genes expression, such as nrf2, gstp1, hmox1a, prdx1, nqo1, gss, gsr, sqstm1, hsp90aa1.2 than SFN. Antioxidant proteins Nrf2, Gstp1, Cat, and Sod2 were upregulated in the ESC-treated groups. Subsequently, nuclear localization of Nrf2 was detected in both SFN- and ESC-treated groups, confirming Nrf2 translocation into the nucleus. Our findings suggest that ESC possesses potent antioxidant activity as SFN in 72-hpf zebrafish larvae through the Keap1-Nrf2 signaling pathway.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†é—œæ–¼æŠ—æ°§åŒ–åŠ‘åœ¨å¥åº·ç¶­è­·å’Œç–¾ç—…é é˜²æ–¹é¢çš„é‡è¦å•Ÿç¤ºã€‚æŠ—æ°§åŒ–åŠ‘èƒ½å¤ ä¸­å’Œè‡ªç”±åŸºï¼Œæ¸›å°‘æ°§åŒ–æå‚·ï¼Œé€™å°æ–¼ç¶­æŒç´°èƒçš„å¥åº·è‡³é—œé‡è¦ã€‚ç ”ç©¶ä¸­æåˆ°çš„Nrf2æ˜¯ä¸€ç¨®è½‰éŒ„å› å­ï¼Œèƒ½å•Ÿå‹•å¤šç¨®ä¿è­·æ€§åŸºå› ï¼Œå¹«åŠ©æŠµæŠ—æ°§åŒ–æå®³ã€‚é€™æ„å‘³è‘—é€éå¢åŠ æŠ—æ°§åŒ–åŠ‘çš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„æˆ‘å€‘çš„å¥åº·ç‹€æ³ï¼Œä¸¦é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªï¼Œå°¤å…¶æ˜¯èˆ‡æ°§åŒ–å£“åŠ›ç›¸é—œçš„ç–¾ç—…ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜‡å…‹æ—ï¼ˆesculin, ESCï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆsulforaphane, SFNï¼‰åœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­çš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å°Nrf2çš„æ¿€æ´»æ•ˆæœã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™å…©ç¨®åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œä»¥åŠå®ƒå€‘åœ¨ç´°èƒå…§çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå¾è€Œç‚ºæœªä¾†çš„å¥åº·ç ”ç©¶æä¾›ä¾æ“šã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†72å°æ™‚çš„æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥æ¥å—è˜‡å…‹æ—ï¼ˆ100Î¼Mï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆ40Î¼Mï¼‰çš„è™•ç†ï¼ŒæŒçºŒ6å°æ™‚ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬æ´»æ€§æ°§ï¼ˆROSï¼‰ã€è„‚è³ªéæ°§åŒ–ï¼ˆLPOï¼‰ã€ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰ç­‰ï¼Œä¸¦ä½¿ç”¨RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†åˆ†ææŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„æ°´å¹³ã€‚æ­¤å¤–ï¼Œé‚„è©•ä¼°äº†Nrf2åœ¨ç´°èƒå…§çš„å®šä½ï¼Œé€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ·±å…¥äº†è§£é€™äº›åŒ–åˆç‰©çš„æŠ—æ°§åŒ–æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜‡å…‹æ—è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œè˜‡å…‹æ—é‚„ä¿ƒé€²äº†å¤šç¨®æŠ—æ°§åŒ–åŸºå› çš„è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ã€‚ç ”ç©¶ä¸­ç™¼ç¾ï¼ŒNrf2åœ¨è˜‡å…‹æ—å’Œè˜¿è””ç¡«ç´ è™•ç†çµ„ä¸­å‡æœ‰æ ¸å…§å®šä½ï¼Œé€™è¡¨æ˜é€™å…©ç¨®åŒ–åˆç‰©éƒ½èƒ½æœ‰æ•ˆä¿ƒé€²Nrf2é€²å…¥ç´°èƒæ ¸ï¼Œé€²ä¸€æ­¥æ”¯æŒäº†å®ƒå€‘åœ¨æŠ—æ°§åŒ–éç¨‹ä¸­çš„ä½œç”¨ã€‚é€™äº›çµæœæš—ç¤ºè˜‡å…‹æ—åœ¨æŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†é—œæ–¼æŠ—æ°§åŒ–åŠ‘åœ¨å¥åº·ç¶­è­·å’Œç–¾ç—…é é˜²æ–¹é¢çš„é‡è¦å•Ÿç¤ºã€‚æŠ—æ°§åŒ–åŠ‘èƒ½å¤ ä¸­å’Œè‡ªç”±åŸºï¼Œæ¸›å°‘æ°§åŒ–æå‚·ï¼Œé€™å°æ–¼ç¶­æŒç´°èƒçš„å¥åº·è‡³é—œé‡è¦ã€‚ç ”ç©¶ä¸­æåˆ°çš„Nrf2æ˜¯ä¸€ç¨®è½‰éŒ„å› å­ï¼Œèƒ½å•Ÿå‹•å¤šç¨®ä¿è­·æ€§åŸºå› ï¼Œå¹«åŠ©æŠµæŠ—æ°§åŒ–æå®³ã€‚é€™æ„å‘³è‘—é€éå¢åŠ æŠ—æ°§åŒ–åŠ‘çš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„æˆ‘å€‘çš„å¥åº·ç‹€æ³ï¼Œä¸¦é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªï¼Œå°¤å…¶æ˜¯èˆ‡æ°§åŒ–å£“åŠ›ç›¸é—œçš„ç–¾ç—…ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜‡å…‹æ—ï¼ˆesculin, ESCï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆsulforaphane, SFNï¼‰åœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­çš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å°Nrf2çš„æ¿€æ´»æ•ˆæœã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™å…©ç¨®åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œä»¥åŠå®ƒå€‘åœ¨ç´°èƒå…§çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå¾è€Œç‚ºæœªä¾†çš„å¥åº·ç ”ç©¶æä¾›ä¾æ“šã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†72å°æ™‚çš„æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥æ¥å—è˜‡å…‹æ—ï¼ˆ100Î¼Mï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆ40Î¼Mï¼‰çš„è™•ç†ï¼ŒæŒçºŒ6å°æ™‚ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬æ´»æ€§æ°§ï¼ˆROSï¼‰ã€è„‚è³ªéæ°§åŒ–ï¼ˆLPOï¼‰ã€ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰ç­‰ï¼Œä¸¦ä½¿ç”¨RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†åˆ†ææŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„æ°´å¹³ã€‚æ­¤å¤–ï¼Œé‚„è©•ä¼°äº†Nrf2åœ¨ç´°èƒå…§çš„å®šä½ï¼Œé€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ·±å…¥äº†è§£é€™äº›åŒ–åˆç‰©çš„æŠ—æ°§åŒ–æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜‡å…‹æ—è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œè˜‡å…‹æ—é‚„ä¿ƒé€²äº†å¤šç¨®æŠ—æ°§åŒ–åŸºå› çš„è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ã€‚ç ”ç©¶ä¸­ç™¼ç¾ï¼ŒNrf2åœ¨è˜‡å…‹æ—å’Œè˜¿è””ç¡«ç´ è™•ç†çµ„ä¸­å‡æœ‰æ ¸å…§å®šä½ï¼Œé€™è¡¨æ˜é€™å…©ç¨®åŒ–åˆç‰©éƒ½èƒ½æœ‰æ•ˆä¿ƒé€²Nrf2é€²å…¥ç´°èƒæ ¸ï¼Œé€²ä¸€æ­¥æ”¯æŒäº†å®ƒå€‘åœ¨æŠ—æ°§åŒ–éç¨‹ä¸­çš„ä½œç”¨ã€‚é€™äº›çµæœæš—ç¤ºè˜‡å…‹æ—åœ¨æŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Toxicology & pharmacology : CBPã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿåƒé’èŠ±æ¤°èœå¯èƒ½ä¸åªæ˜¯è®“ä½ è®Šå¾—æ›´å¥åº·ï¼Œé‚„èƒ½å¹«åŠ©å°æŠ—æ°§åŒ–å£“åŠ›ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ¢è¨äº†å…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼šè˜‡å…‹æ—å’Œè˜¿è””ç¡«ç´ ï¼Œçœ‹çœ‹å®ƒå€‘å°å°é­šï¼ˆæ–‘é¦¬é­šå¹¼é«”ï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘æƒ³äº†è§£é€™äº›åŒ–åˆç‰©å¦‚ä½•æ¿€æ´»æˆ‘å€‘é«”å…§çš„ä¿è­·åŸºå› ï¼Œç‰¹åˆ¥æ˜¯Nrf2ï¼Œé€™æ˜¯ä¸€å€‹å¹«åŠ©æˆ‘å€‘æŠµæŠ—æ°§åŒ–æå®³çš„é—œéµè§’è‰²ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œä»–å€‘çµ¦æ–‘é¦¬é­šå¹¼é«”ä¸åŒçš„è™•ç†ï¼Œç„¶å¾Œæ¸¬é‡äº†æ´»æ€§æ°§ã€è„‚è³ªéæ°§åŒ–ç­‰æŒ‡æ¨™ï¼Œé‚„åˆ†æäº†æŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨ç¾ã€‚çµæœé¡¯ç¤ºï¼Œè˜‡å…‹æ—å’Œè˜¿è””ç¡«ç´ éƒ½èƒ½æœ‰æ•ˆæé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œä¸¦ä¿ƒé€²Nrf2é€²å…¥ç´°èƒæ ¸ï¼Œé€™æ„å‘³è‘—å®ƒå€‘åœ¨ä¿è­·ç´°èƒæ–¹é¢çš„æ½›åŠ›ã€‚\n\nç¸½çµä¾†èªªï¼š\n1. è˜‡å…‹æ—å’Œè˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æé«˜èº«é«”çš„æŠ—æ°§åŒ–èƒ½åŠ›ã€‚\n2. Nrf2åœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚\n3. é€™äº›ç ”ç©¶çµæœç‚ºæˆ‘å€‘æœªä¾†çš„å¥åº·ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental methods and main results of a study comparing the antioxidant effects of two natural compounds, esculin and sulforaphane, on zebrafish larvae. Include simple icons representing broccoli or sulforaphane, simplified images of zebrafish or cells, arrows or flow lines indicating the experimental steps, and a section highlighting the main results, such as increased antioxidant enzyme activity and the role of Nrf2 in cellular protection.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40617372/"
  },
  {
    "id": "40533430",
    "title_en": "Monovalent glycoconjugates of sulforaphane prevent inflammation induced by lipopolysaccharide in human dendritic cells by inhibiting NF-Ä¸B signalling pathway.",
    "pub_date": "2025 Nov",
    "journal": "British journal of pharmacology",
    "abstract_en": "Sulforaphane (SFN) has notable health benefits but faces challenges due to its poor solubility and delivery. This study investigates SFN-glycoconjugates effects on lipopolysaccharide (LPS)-induced inflammation in dendritic cells (DCs). With the aiming to enhance their therapeutic potential against inflammatory diseases. Novel monovalent SFN-glycoconjugates with mannose (Man) and fucose (0Fuc) were developed and tested for their anti-inflammatory and immune-modulatory properties in DCs from healthy donors under chronic LPS exposure. By leveraging therapeutic strategies, SFN-glycoconjugates significantly improved the solubility and bioavailability of SFN, thereby overcoming the limitations of traditional delivery methods. Monocyte-derived DCs were treated with SFN-glycoconjugates and subsequently exposed to a chronic inflammatory environment induced by LPS. Our results showed that SFN-glycoconjugates enhance effectiveness in suppressing inflammation by targeting the p65 NF-ÎºB pathway, without affecting MAPK signalling. SFN-glycoconjugates induce a tolerogenic immune response, characterized by increased IL-10 production and enhanced regulatory T- and B-cell proliferation. These effects surpass those of p65 NF-ÎºB inhibition alone, highlighting a distinct and potent regulatory mechanism independent of MAPK pathways. The integration of food therapeutic strategies not only enhances the stability and delivery of bioactive compounds but also broadens their potential applications in functional foods and therapeutic approaches. In particular, SFN-glycoconjugates represent a promising option as biologically active compounds for inflammatory diseases, offering enhanced anti-inflammatory and immunomodulatory effects through optimized delivery systems and the activation of specific molecular pathways.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†æ–°çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰é¡¯è‘—å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£æ€§å·®å’Œå‚³éå›°é›£ï¼Œé™åˆ¶äº†å…¶æ‡‰ç”¨ã€‚é€éæ”¹è‰¯çš„å‚³éç³»çµ±ï¼Œé€™é …ç ”ç©¶æ¢ç´¢äº†å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œä¸¦å¯èƒ½å°æŠ—ç™¼ç‚æ€§ç–¾ç—…æœ‰å¹«åŠ©ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼æ”¹å–„ç›¸é—œç–¾ç—…çš„æ²»ç™‚ï¼Œä¹Ÿç‚ºæœªä¾†çš„åŠŸèƒ½æ€§é£Ÿå“é–‹ç™¼æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©å°æ–¼ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç™¼ç‚åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•åˆ©ç”¨é€™äº›æ–°å‹çš„ç³–è‹·çµåˆç‰©ä¾†å¢å¼·è˜¿è””ç¡«ç´ çš„æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€ç‰¹æ€§ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ…¢æ€§ç™¼ç‚çš„ç’°å¢ƒä¸­ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯å¸Œæœ›èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†å°æŠ—èˆ‡ç™¼ç‚ç›¸é—œçš„ç–¾ç—…ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªå¥åº·æè´ˆè€…çš„æ¨¹çªç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼æ…¢æ€§LPSç’°å¢ƒä¸­ã€‚ç ”ç©¶åœ˜éšŠé–‹ç™¼äº†æ–°å‹çš„å–®åƒ¹è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ï¼Œä¸¦æ¸¬è©¦å…¶åœ¨æ¨¹çªç´°èƒä¸­çš„æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€æ•ˆæœã€‚é€™äº›ç³–è‹·çµåˆç‰©çš„è¨­è¨ˆæ—¨åœ¨æ”¹å–„è˜¿è””ç¡«ç´ çš„æº¶è§£æ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œä»¥å…‹æœå‚³çµ±å‚³éæ–¹æ³•çš„é™åˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç™¼ç‚æ–¹é¢çš„æ•ˆæœé¡¯è‘—ï¼Œç‰¹åˆ¥æ˜¯é€šéé‡å°p65 NF-ÎºBé€”å¾‘ä¾†é”æˆï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿå‚³éã€‚é€™äº›ç³–è‹·çµåˆç‰©èƒ½å¤ èª˜å°è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…è¶Šäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„ä½œç”¨ï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·å¤§çš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œç‚ºæœªä¾†çš„æŠ—ç™¼ç‚æ²»ç™‚æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†æ–°çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰é¡¯è‘—å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£æ€§å·®å’Œå‚³éå›°é›£ï¼Œé™åˆ¶äº†å…¶æ‡‰ç”¨ã€‚é€éæ”¹è‰¯çš„å‚³éç³»çµ±ï¼Œé€™é …ç ”ç©¶æ¢ç´¢äº†å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œä¸¦å¯èƒ½å°æŠ—ç™¼ç‚æ€§ç–¾ç—…æœ‰å¹«åŠ©ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼æ”¹å–„ç›¸é—œç–¾ç—…çš„æ²»ç™‚ï¼Œä¹Ÿç‚ºæœªä¾†çš„åŠŸèƒ½æ€§é£Ÿå“é–‹ç™¼æä¾›äº†æ–°çš„æ€è·¯ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©å°æ–¼ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç™¼ç‚åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•åˆ©ç”¨é€™äº›æ–°å‹çš„ç³–è‹·çµåˆç‰©ä¾†å¢å¼·è˜¿è””ç¡«ç´ çš„æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€ç‰¹æ€§ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ…¢æ€§ç™¼ç‚çš„ç’°å¢ƒä¸­ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯å¸Œæœ›èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†å°æŠ—èˆ‡ç™¼ç‚ç›¸é—œçš„ç–¾ç—…ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªå¥åº·æè´ˆè€…çš„æ¨¹çªç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼æ…¢æ€§LPSç’°å¢ƒä¸­ã€‚ç ”ç©¶åœ˜éšŠé–‹ç™¼äº†æ–°å‹çš„å–®åƒ¹è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ï¼Œä¸¦æ¸¬è©¦å…¶åœ¨æ¨¹çªç´°èƒä¸­çš„æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€æ•ˆæœã€‚é€™äº›ç³–è‹·çµåˆç‰©çš„è¨­è¨ˆæ—¨åœ¨æ”¹å–„è˜¿è””ç¡«ç´ çš„æº¶è§£æ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œä»¥å…‹æœå‚³çµ±å‚³éæ–¹æ³•çš„é™åˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç™¼ç‚æ–¹é¢çš„æ•ˆæœé¡¯è‘—ï¼Œç‰¹åˆ¥æ˜¯é€šéé‡å°p65 NF-ÎºBé€”å¾‘ä¾†é”æˆï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿå‚³éã€‚é€™äº›ç³–è‹·çµåˆç‰©èƒ½å¤ èª˜å°è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…è¶Šäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„ä½œç”¨ï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·å¤§çš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œç‚ºæœªä¾†çš„æŠ—ç™¼ç‚æ²»ç™‚æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBritish journal of pharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡çš„ç§˜å¯†æˆåˆ†å¯èƒ½æœƒå¹«åŠ©æˆ‘å€‘å°æŠ—ç™¼ç‚ï¼é€™é …ç ”ç©¶è®“æˆ‘å€‘å°è˜¿è””ç¡«ç´ æœ‰äº†æ–°çš„äº†è§£ï¼Œç‰¹åˆ¥æ˜¯åœ¨å¥åº·å’Œç–¾ç—…é é˜²æ–¹é¢ã€‚\n\nç ”ç©¶äººå“¡å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©çš„å‰µæ–°åŒ–åˆç‰©ï¼Œé€™ç¨®çµåˆç‰©èƒ½å¢å¼·è˜¿è””ç¡«ç´ çš„æŠ—ç™¼ç‚æ•ˆæœã€‚ä»–å€‘ä½¿ç”¨å¥åº·æè´ˆè€…çš„æ¨¹çªç´°èƒï¼Œæ¨¡æ“¬æ…¢æ€§ç™¼ç‚çš„ç’°å¢ƒï¼Œæ¸¬è©¦é€™äº›æ–°å‹çµåˆç‰©çš„æ•ˆæœã€‚\n\nçµæœé¡¯ç¤ºï¼Œé€™äº›è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç™¼ç‚æ–¹é¢éå¸¸æœ‰æ•ˆï¼Œå°¤å…¶æ˜¯é€éä¸€ç¨®ç‰¹å®šçš„é€”å¾‘ä¾†ç™¼æ®ä½œç”¨ï¼Œä¸¦ä¸”èƒ½ä¿ƒé€²å…ç–«ç³»çµ±çš„èª¿ç¯€åæ‡‰ï¼Œé€™å°æ–¼æœªä¾†çš„æŠ—ç™¼ç‚æ²»ç™‚å¯èƒ½æœ‰é‡è¦çš„å•Ÿç¤ºã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ä½ å¯èƒ½æœƒæƒ³çŸ¥é“ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼å°æŠ—ç™¼ç‚ï¼Œé€™å°å¥åº·æœ‰ç›Šï¼\n2. æ–°å‹çš„ç³–è‹·çµåˆç‰©èƒ½æé«˜è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n3. é€™é …ç ”ç©¶å¯èƒ½ç‚ºæœªä¾†çš„åŠŸèƒ½æ€§é£Ÿå“é–‹ç™¼æä¾›æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental method and main results of a study on a compound called Raphanus sativus sulforaphane-glycoside. Include symbols representing broccoli or Raphanus sativus sulforaphane, simplified illustrations of experimental subjects like humans or cells, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed in the study.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™¼ç‚æ€§ç–¾ç—… Inflammatory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40533430/"
  },
  {
    "id": "41171476",
    "title_en": "Online solid-phase extraction of glucoraphanin and sulforaphane from non-edible plants based on amino acid-functionalized covalent organic frameworks.",
    "pub_date": "2025 Oct",
    "journal": "Mikrochimica acta",
    "abstract_en": "Glucoraphanin (GR) and sulforaphane (SFN) are sulfur-containing compounds with diverse medicinal applications. However, cruciferous vegetables are a single source of GR and SFN, which limits development and utilization in natural resources. Herein, amino acid covalent organic framework (COF-Cys) was synthesized via click reactions and employed as an adsorbent in online solid-phase extraction (online SPE) to determine GR and SFN in non-edible plant samples. The adsorption mechanism was analyzed using density functional theory, revealing that adsorption occurred via electrostatic interaction and hydrogen bonding. Under the optimum conditions, good linearity (4-2500Â ng/mL; R<sup>2</sup>â€‰=â€‰0.9922 and 0.9968) and lower limits of detection (1.0Â ng/mL and 0.6Â ng/mL) were observed. GR and SFN were found in 18 non-edible plant samples, and recoveries of spiked samples were 89.1-109.3% with RSDâ€‰â‰¤â€‰6.9%. The COF-Cys-online SPE-UPLC-MS/MS approach displays great potential for application to detect GR and SFN in non-edible plants and provide valuable support for the development of functional products.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©åœ¨è¨±å¤šæ¤ç‰©ä¸­å­˜åœ¨ï¼Œé€™å¯èƒ½ç‚ºæˆ‘å€‘æä¾›äº†æ–°çš„å¤©ç„¶è³‡æºä¾†é–‹ç™¼å¥åº·ç”¢å“ã€‚é€™äº›åŒ–åˆç‰©å…·æœ‰æ½›åœ¨çš„è—¥ç”¨åƒ¹å€¼ï¼Œèƒ½å¤ å¹«åŠ©æˆ‘å€‘é é˜²æŸäº›ç–¾ç—…ï¼Œå°¤å…¶æ˜¯èˆ‡æ°§åŒ–å£“åŠ›å’Œç™¼ç‚æœ‰é—œçš„ç–¾ç—…ã€‚å› æ­¤ï¼Œæ¢ç´¢éå¯é£Ÿç”¨æ¤ç‰©ä¸­çš„é€™äº›åŒ–åˆç‰©ï¼Œå¯èƒ½æœƒç‚ºæˆ‘å€‘çš„å¥åº·å¸¶ä¾†æ–°çš„æ©Ÿæœƒï¼Œä¸¦ä¿ƒé€²åŠŸèƒ½æ€§é£Ÿå“çš„ç™¼å±•ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•å¾éå¯é£Ÿç”¨æ¤ç‰©ä¸­æå–è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©â€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•æœ‰æ•ˆåœ°æª¢æ¸¬é€™äº›åŒ–åˆç‰©ï¼Œä¸¦äº†è§£å®ƒå€‘åœ¨éå¯é£Ÿç”¨æ¤ç‰©ä¸­çš„å­˜åœ¨æƒ…æ³ã€‚ç”±æ–¼é€™äº›åŒ–åˆç‰©ä¸»è¦ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æ‰¾åˆ°å…¶ä»–ä¾†æºï¼Œä»¥æ“´å¤§å…¶æ‡‰ç”¨ç¯„åœã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…ä½¿ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€šééœé›»ç›¸äº’ä½œç”¨å’Œæ°«éµé€²è¡Œçš„ã€‚åœ¨æœ€ä½³æ¢ä»¶ä¸‹ï¼Œå¯¦é©—é¡¯ç¤ºå‡ºè‰¯å¥½çš„ç·šæ€§é—œä¿‚å’Œè¼ƒä½çš„æª¢æ¸¬é™ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼Œåœ¨18ç¨®éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­æª¢æ¸¬åˆ°äº†è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ï¼Œä¸”æ¨£æœ¬çš„å›æ”¶ç‡åœ¨89.1%åˆ°109.3%ä¹‹é–“ï¼Œè®Šç•°ä¿‚æ•¸å°æ–¼6.9%ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–çµåˆè¶…é«˜æ•ˆæ¶²ç›¸è‰²è­œè³ªè­œï¼ˆUPLC-MS/MSï¼‰çš„æ–¹æ³•åœ¨æª¢æ¸¬é€™äº›åŒ–åˆç‰©æ–¹é¢å…·æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼Œä¸¦å¯èƒ½ç‚ºåŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©åœ¨è¨±å¤šæ¤ç‰©ä¸­å­˜åœ¨ï¼Œé€™å¯èƒ½ç‚ºæˆ‘å€‘æä¾›äº†æ–°çš„å¤©ç„¶è³‡æºä¾†é–‹ç™¼å¥åº·ç”¢å“ã€‚é€™äº›åŒ–åˆç‰©å…·æœ‰æ½›åœ¨çš„è—¥ç”¨åƒ¹å€¼ï¼Œèƒ½å¤ å¹«åŠ©æˆ‘å€‘é é˜²æŸäº›ç–¾ç—…ï¼Œå°¤å…¶æ˜¯èˆ‡æ°§åŒ–å£“åŠ›å’Œç™¼ç‚æœ‰é—œçš„ç–¾ç—…ã€‚å› æ­¤ï¼Œæ¢ç´¢éå¯é£Ÿç”¨æ¤ç‰©ä¸­çš„é€™äº›åŒ–åˆç‰©ï¼Œå¯èƒ½æœƒç‚ºæˆ‘å€‘çš„å¥åº·å¸¶ä¾†æ–°çš„æ©Ÿæœƒï¼Œä¸¦ä¿ƒé€²åŠŸèƒ½æ€§é£Ÿå“çš„ç™¼å±•ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•å¾éå¯é£Ÿç”¨æ¤ç‰©ä¸­æå–è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©â€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•æœ‰æ•ˆåœ°æª¢æ¸¬é€™äº›åŒ–åˆç‰©ï¼Œä¸¦äº†è§£å®ƒå€‘åœ¨éå¯é£Ÿç”¨æ¤ç‰©ä¸­çš„å­˜åœ¨æƒ…æ³ã€‚ç”±æ–¼é€™äº›åŒ–åˆç‰©ä¸»è¦ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æ‰¾åˆ°å…¶ä»–ä¾†æºï¼Œä»¥æ“´å¤§å…¶æ‡‰ç”¨ç¯„åœã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…ä½¿ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€šééœé›»ç›¸äº’ä½œç”¨å’Œæ°«éµé€²è¡Œçš„ã€‚åœ¨æœ€ä½³æ¢ä»¶ä¸‹ï¼Œå¯¦é©—é¡¯ç¤ºå‡ºè‰¯å¥½çš„ç·šæ€§é—œä¿‚å’Œè¼ƒä½çš„æª¢æ¸¬é™ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼Œåœ¨18ç¨®éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­æª¢æ¸¬åˆ°äº†è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ï¼Œä¸”æ¨£æœ¬çš„å›æ”¶ç‡åœ¨89.1%åˆ°109.3%ä¹‹é–“ï¼Œè®Šç•°ä¿‚æ•¸å°æ–¼6.9%ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–çµåˆè¶…é«˜æ•ˆæ¶²ç›¸è‰²è­œè³ªè­œï¼ˆUPLC-MS/MSï¼‰çš„æ–¹æ³•åœ¨æª¢æ¸¬é€™äº›åŒ–åˆç‰©æ–¹é¢å…·æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼Œä¸¦å¯èƒ½ç‚ºåŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "fb_post": "æ ¹æ“šã€ŠMikrochimica actaã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„æ—¥å¸¸é£²é£Ÿä¸­ï¼Œç”šè‡³ä¸€äº›éå¯é£Ÿç”¨çš„æ¤ç‰©ä¸­ï¼Œå¯èƒ½éš±è—è‘—å¥åº·çš„å¯¶è—ï¼æœ€è¿‘ä¸€é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å’Œå®ƒçš„å‰èº«åŒ–åˆç‰©â€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ï¼Œé€™äº›ç‰©è³ªå¯èƒ½å°æˆ‘å€‘çš„å¥åº·å¤§æœ‰å¹«åŠ©ï¼\n\nç ”ç©¶è€…å€‘çš„ç›®æ¨™æ˜¯äº†è§£å¦‚ä½•å¾ä¸€äº›ä¸å¸¸è¦‹çš„æ¤ç‰©ä¸­æå–é€™äº›åŒ–åˆç‰©ï¼Œä¸¦æª¢æ¸¬å®ƒå€‘çš„å­˜åœ¨ã€‚ä»–å€‘ç™¼ç¾ï¼Œé€™äº›åŒ–åˆç‰©ä¸»è¦ä¾†è‡ªåå­—èŠ±ç§‘çš„è”¬èœï¼Œä½†ä¹Ÿå¸Œæœ›èƒ½æ‰¾åˆ°å…¶ä»–ä¾†æºã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶åœ˜éšŠåˆæˆäº†ä¸€ç¨®ç‰¹æ®Šçš„ææ–™ï¼Œèƒ½æœ‰æ•ˆåœ°æª¢æ¸¬é€™äº›åŒ–åˆç‰©ã€‚ä»–å€‘ç™¼ç¾ï¼Œé€™ç¨®ææ–™èƒ½å¤ å¾ˆå¥½åœ°å¸é™„è˜¿è””ç¡«ç´ ï¼Œä¸¦ä¸”åœ¨æœ€ä½³æ¢ä»¶ä¸‹ï¼Œæª¢æ¸¬çš„æº–ç¢ºæ€§éå¸¸é«˜ã€‚\n\næœ€ä»¤äººèˆˆå¥®çš„æ˜¯ï¼Œåœ¨18ç¨®éå¯é£Ÿç”¨æ¤ç‰©ä¸­ï¼Œä»–å€‘æˆåŠŸæª¢æ¸¬åˆ°äº†é€™äº›åŒ–åˆç‰©ï¼Œå›æ”¶ç‡ä¹Ÿç›¸ç•¶ç†æƒ³ï¼é€™æ„å‘³è‘—ï¼Œæœªä¾†æˆ‘å€‘å¯èƒ½èƒ½åˆ©ç”¨é€™äº›æ¤ç‰©ä¾†é–‹ç™¼æ–°çš„å¥åº·ç”¢å“ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å’Œè‘¡è„ç³–è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼é é˜²èˆ‡æ°§åŒ–å£“åŠ›å’Œç™¼ç‚æœ‰é—œçš„ç–¾ç—…ã€‚\n2. ç ”ç©¶è€…æˆåŠŸå¾éå¯é£Ÿç”¨æ¤ç‰©ä¸­æå–é€™äº›åŒ–åˆç‰©ï¼Œæœªä¾†æ‡‰ç”¨æ½›åŠ›å·¨å¤§ã€‚\n3. ä½¿ç”¨æ–°ææ–™é€²è¡Œæª¢æ¸¬ï¼Œæº–ç¢ºæ€§å’Œå¯é æ€§éƒ½å¾ˆé«˜ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental method and main results of a study on sulforaphane and its precursor, glucoraphanin. The image should have a light background with soft colors. Include symbols for broccoli or sulforaphane, simplified illustrations of experimental subjects (like people, animals, or cells), and arrows or flow lines to indicate the experimental steps. There should be a section labeled 'Main Results' highlighting key findings such as protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41171476/"
  },
  {
    "id": "41246347",
    "title_en": "Sulforaphane in cancer precision medicine: from biosynthetic origins to multiscale mechanisms and clinical translation.",
    "pub_date": "2025",
    "journal": "Frontiers in immunology",
    "abstract_en": "Sulforaphane (SFN), an isothiocyanate derived from glucoraphanin in cruciferous vegetables, has evolved from a dietary antioxidant to a sophisticated multi-target agent in oncology. While its roles in nuclear factor erythroid 2-related factor 2 (Nrf2) activation and histone deacetylase (HDAC) inhibition are well-established, this review provides a novel synthesis by integrating disparate research scales-a multiscale perspective that spans from the genetic and epigenetic regulation of glucoraphanin biosynthesis in plants to SFN's recently elucidated effects on ferroptosis, cancer stem cells (CSCs), and the tumor immune microenvironment in humans. We critically evaluate how key host factors, such as gut microbiota composition and glutathione S-transferase (GST) polymorphisms, dictate SFN bioavailability and efficacy, thereby framing a precision nutrition paradigm for its application. Furthermore, we move beyond generic claims of synergy to detail SFN's specific mechanisms in enhancing conventional therapies, including the modulation of drug transporters and immune checkpoints. By integrating advances from plant biochemistry to molecular oncology, this review establishes an updated and mechanism-oriented framework for realizing SFN's compelling potential in cancer prevention and therapy through a precision medicine approach.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºå°å¥åº·æœ‰æ½›åœ¨çš„ç›Šè™•ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡é é˜²æ–¹é¢ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡çš„ç™¼å±•ï¼Œä¸¦å¼·èª¿äº†å®ƒåœ¨ä¿ƒé€²å¥åº·å’Œé é˜²ç–¾ç—…æ–¹é¢çš„å¤šé‡ä½œç”¨ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†å°æŠ—ç™Œç—‡ï¼Œé€™å°æ–¼å¸Œæœ›æ”¹å–„å¥åº·ç‹€æ³çš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„è©±é¡Œã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„æ½›åœ¨ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·ã€ç™Œç—‡å¹¹ç´°èƒçš„è¡Œç‚ºï¼Œä»¥åŠè…«ç˜¤å…ç–«å¾®ç’°å¢ƒçš„è®ŠåŒ–ã€‚é€™äº›å› ç´ éƒ½å¯èƒ½å½±éŸ¿ç™Œç—‡çš„ç™¼å±•å’Œæ²»ç™‚æ•ˆæœï¼Œå› æ­¤æ·±å…¥äº†è§£é€™äº›æ©Ÿåˆ¶å°æ–¼æœªä¾†çš„ç™Œç—‡ç ”ç©¶å’Œæ²»ç™‚ç­–ç•¥è‡³é—œé‡è¦ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…æ¡ç”¨äº†å¤šç¨®ç ”ç©¶æ–¹æ³•ï¼Œå¾æ¤ç‰©çš„åŸºå› å’Œè¡¨è§€éºå‚³å­¸å…¥æ‰‹ï¼Œæ¢è¨è˜¿è””ç¡«ç´ çš„åˆæˆéç¨‹ï¼Œä¸¦é€²ä¸€æ­¥åˆ†æå…¶åœ¨äººé«”ä¸­çš„ä½œç”¨ã€‚ä»–å€‘è©•ä¼°äº†å®¿ä¸»å› ç´ ï¼Œå¦‚è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆå’Œè°·èƒ±ç”˜è‚½S-è½‰ç§»é…¶çš„å¤šæ…‹æ€§ï¼Œé€™äº›å› ç´ æœƒå½±éŸ¿è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©åˆ©ç”¨åº¦å’Œç™‚æ•ˆã€‚é€™æ¨£çš„å¤šå±¤æ¬¡ç ”ç©¶æ–¹æ³•æœ‰åŠ©æ–¼å»ºç«‹ä¸€å€‹ç²¾æº–ç‡Ÿé¤Šçš„æ¡†æ¶ï¼Œä»¥ä¾¿æ›´å¥½åœ°æ‡‰ç”¨è˜¿è””ç¡«ç´ ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¢å¼·å‚³çµ±ç™Œç—‡æ²»ç™‚æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œé€™åŒ…æ‹¬èª¿ç¯€è—¥ç‰©é‹è¼¸è›‹ç™½å’Œå…ç–«æª¢æŸ¥é»çš„ä½œç”¨ã€‚ç ”ç©¶è€…å¼·èª¿ï¼Œè˜¿è””ç¡«ç´ çš„å…·é«”ä½œç”¨æ©Ÿåˆ¶ä¸åƒ…é™æ–¼ä¸€èˆ¬çš„å”åŒæ•ˆæ‡‰ï¼Œè€Œæ˜¯æ¶‰åŠæ›´è¤‡é›œçš„ç”Ÿç‰©åŒ–å­¸éç¨‹ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„ç™Œç—‡é é˜²å’Œæ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼Œä¸¦å¼·èª¿äº†ç²¾æº–é†«ç™‚åœ¨é€™ä¸€é ˜åŸŸçš„é‡è¦æ€§ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºå°å¥åº·æœ‰æ½›åœ¨çš„ç›Šè™•ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡é é˜²æ–¹é¢ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡çš„ç™¼å±•ï¼Œä¸¦å¼·èª¿äº†å®ƒåœ¨ä¿ƒé€²å¥åº·å’Œé é˜²ç–¾ç—…æ–¹é¢çš„å¤šé‡ä½œç”¨ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†å°æŠ—ç™Œç—‡ï¼Œé€™å°æ–¼å¸Œæœ›æ”¹å–„å¥åº·ç‹€æ³çš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„è©±é¡Œã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„æ½›åœ¨ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·ã€ç™Œç—‡å¹¹ç´°èƒçš„è¡Œç‚ºï¼Œä»¥åŠè…«ç˜¤å…ç–«å¾®ç’°å¢ƒçš„è®ŠåŒ–ã€‚é€™äº›å› ç´ éƒ½å¯èƒ½å½±éŸ¿ç™Œç—‡çš„ç™¼å±•å’Œæ²»ç™‚æ•ˆæœï¼Œå› æ­¤æ·±å…¥äº†è§£é€™äº›æ©Ÿåˆ¶å°æ–¼æœªä¾†çš„ç™Œç—‡ç ”ç©¶å’Œæ²»ç™‚ç­–ç•¥è‡³é—œé‡è¦ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…æ¡ç”¨äº†å¤šç¨®ç ”ç©¶æ–¹æ³•ï¼Œå¾æ¤ç‰©çš„åŸºå› å’Œè¡¨è§€éºå‚³å­¸å…¥æ‰‹ï¼Œæ¢è¨è˜¿è””ç¡«ç´ çš„åˆæˆéç¨‹ï¼Œä¸¦é€²ä¸€æ­¥åˆ†æå…¶åœ¨äººé«”ä¸­çš„ä½œç”¨ã€‚ä»–å€‘è©•ä¼°äº†å®¿ä¸»å› ç´ ï¼Œå¦‚è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆå’Œè°·èƒ±ç”˜è‚½S-è½‰ç§»é…¶çš„å¤šæ…‹æ€§ï¼Œé€™äº›å› ç´ æœƒå½±éŸ¿è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©åˆ©ç”¨åº¦å’Œç™‚æ•ˆã€‚é€™æ¨£çš„å¤šå±¤æ¬¡ç ”ç©¶æ–¹æ³•æœ‰åŠ©æ–¼å»ºç«‹ä¸€å€‹ç²¾æº–ç‡Ÿé¤Šçš„æ¡†æ¶ï¼Œä»¥ä¾¿æ›´å¥½åœ°æ‡‰ç”¨è˜¿è””ç¡«ç´ ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¢å¼·å‚³çµ±ç™Œç—‡æ²»ç™‚æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œé€™åŒ…æ‹¬èª¿ç¯€è—¥ç‰©é‹è¼¸è›‹ç™½å’Œå…ç–«æª¢æŸ¥é»çš„ä½œç”¨ã€‚ç ”ç©¶è€…å¼·èª¿ï¼Œè˜¿è””ç¡«ç´ çš„å…·é«”ä½œç”¨æ©Ÿåˆ¶ä¸åƒ…é™æ–¼ä¸€èˆ¬çš„å”åŒæ•ˆæ‡‰ï¼Œè€Œæ˜¯æ¶‰åŠæ›´è¤‡é›œçš„ç”Ÿç‰©åŒ–å­¸éç¨‹ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„ç™Œç—‡é é˜²å’Œæ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼Œä¸¦å¼·èª¿äº†ç²¾æº–é†«ç™‚åœ¨é€™ä¸€é ˜åŸŸçš„é‡è¦æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in immunologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ é€™å€‹å°å°çš„åŒ–åˆç‰©ï¼Œå¯èƒ½å°æˆ‘å€‘çš„å¥åº·å¤§æœ‰å¹«åŠ©ï¼Œå°¤å…¶æ˜¯åœ¨ç™Œç—‡é é˜²æ–¹é¢ï¼é€™ç¯‡ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡çš„ç™¼å±•ï¼Œè®“æˆ‘å€‘ä¸€èµ·ä¾†çœ‹çœ‹å§ï¼\n\nç ”ç©¶è€…å€‘æƒ³çŸ¥é“è˜¿è””ç¡«ç´ æ˜¯å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·ï¼Œé‚„æœ‰å®ƒåœ¨è…«ç˜¤å…ç–«ç’°å¢ƒä¸­çš„è§’è‰²ã€‚ä»–å€‘æ¡ç”¨äº†è¨±å¤šä¸åŒçš„ç ”ç©¶æ–¹æ³•ï¼Œåƒæ˜¯åˆ†ææ¤ç‰©çš„åŸºå› ï¼Œé‚„æœ‰ç ”ç©¶äººé«”å…§çš„ä½œç”¨ï¼ŒåŒ…æ‹¬è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆç­‰ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…è®“æˆ‘å€‘æ›´äº†è§£è˜¿è””ç¡«ç´ ï¼Œé‚„èƒ½å¹«åŠ©æˆ‘å€‘æ‰¾åˆ°æ›´å¥½çš„å¥åº·æ–¹æ³•ï¼\n\næœ€æœ‰è¶£çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½èƒ½å¢å¼·å‚³çµ±ç™Œç—‡æ²»ç™‚çš„æ•ˆæœï¼Œé€™æ„å‘³è‘—å®ƒä¸åƒ…åƒ…æ˜¯ç°¡å–®çš„å”åŒä½œç”¨ï¼Œè€Œæ˜¯æ¶‰åŠæ›´è¤‡é›œçš„ç”Ÿç‰©éç¨‹ã€‚é€™äº›çµæœç‚ºæœªä¾†çš„ç™Œç—‡é é˜²å’Œæ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼\n\nâœ¨ é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°ç™Œç—‡é é˜²æœ‰æ½›åœ¨å¹«åŠ©ã€‚\n2. ç ”ç©¶æ­ç¤ºäº†è˜¿è””ç¡«ç´ å½±éŸ¿ç™Œç´°èƒçš„å¤šç¨®æ©Ÿåˆ¶ã€‚\n3. é€™ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic on a light background that explains the experiment methods and main results of a study on sulforaphane. Include simple icons representing broccoli or sulforaphane, simplified figures of humans, animals, or cells as experimental subjects, and arrows or flow lines indicating the experimental steps. Add a section labeled 'Main Results' with simple bullet points highlighting protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41246347/"
  },
  {
    "id": "41056875",
    "title_en": "Sulforaphane inhibits gastric cancer progression by regulating the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis.",
    "pub_date": "2025 Oct",
    "journal": "Biochemical and biophysical research communications",
    "abstract_en": "Sulforaphane (SFN) plays a vital role in many types of cancer as a natural extract from plants. However, whether SFN can inhibit gastric carcinogenesis by regulating the lncRNA-miRNA-mRNA axis is unclear. In the current work, the significantly differentially expressed lncRNA PSMB8AS1 was obtained by performing high-throughput sequencing of gastric cancer cells treated with SFN. The qRT-PCR assay results confirmed the inhibitory effect of SFN on PSM8AS1. Subsequently, using gastric cancer data from TCGA and 11 pairs of clinical samples from gastric and paracancerous tissues, we found that PSMB8-AS1 was upregulated in gastric cancer, and high expression of PSMB8-AS1 was associated with low survival of patients with gastric cancer. MTT, cell colony formation, scratch healing, flow cytometry, and qRT-PCR assays showed that the knockdown of PSMB8-AS1 significantly reduced the proliferation and migration of gastric cancer cells as well as promoted apoptosis. Dual luciferase reporter gene and RNA immunoprecipitation (RIP) assay confirmed that PSMB8-AS1 can function as the molecular sponge for miR-888-5p. Meanwhile, bioinformatics analysis and dual-luciferase reporter gene assay showed that miR-888-5p regulates SLC4A7. Overexpression of miR-888-5p or knockdown of SLC4A7 reduced the proliferation and migration of gastric cancer cells. In addition, rescue experiments confirmed that the inhibitory effects of the knockdown of PSMB8-AS1 or the knockdown of SLC4A7 on the proliferation and migration of gastric cancer cells could be reversed by miR-888-5p inhibitor treatment. Subcutaneous tumor formation experiments in nude mice demonstrated that the tumor volume of nude mice transplanted with PSMB8-AS1-knockdown gastric cancer cells was significantly reduced compared with that of the control group. Transcription factors can usually bind to the promoter regions of lncRNAs and regulate the transcription of lncRNAs. We demonstrated through website prediction and experiments that SFN can inhibit the level of PSMB8-AS1 by regulating the transcription factor YY1. These results suggest that SFN inhibits gastric cancer growth through the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis. Therefore, SFN might be a promising therapeutical agent for GC prevention and therapy.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é˜²æ²»æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½èƒƒç™Œçš„é¢¨éšªï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚é›–ç„¶é€™äº›çµæœä»¤äººæŒ¯å¥®ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªé€™äº›ç™¼ç¾çš„å…·é«”æ‡‰ç”¨åŠå…¶åœ¨è‡¨åºŠä¸Šçš„æœ‰æ•ˆæ€§ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ é€éèª¿ç¯€é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰-å¾®å°RNAï¼ˆmiRNAï¼‰-ä¿¡ä½¿RNAï¼ˆmRNAï¼‰è»¸ä¾†æŠ‘åˆ¶èƒƒç™Œçš„å½¢æˆã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯ä¸€ç¨®åç‚ºPSMB8-AS1çš„lncRNAï¼Œä¸¦è©¦åœ–äº†è§£å…¶åœ¨èƒƒç™Œç´°èƒä¸­çš„è¡¨é”è®ŠåŒ–åŠå…¶å°ç™Œç´°èƒå¢æ®–å’Œè½‰ç§»çš„å½±éŸ¿ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨èƒƒç™Œé˜²æ²»ä¸­çš„æ½›åœ¨æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›ä¾æ“šã€‚",
    "para3": "ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆå°æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒé€²è¡Œé«˜é€šé‡æ¸¬åºï¼Œä»¥æ‰¾å‡ºé¡¯è‘—å·®ç•°è¡¨é”çš„lncRNAã€‚æ¥è‘—ï¼Œä½¿ç”¨qRT-PCRç­‰æ–¹æ³•ç¢ºèªè˜¿è””ç¡«ç´ å°PSMB8-AS1çš„æŠ‘åˆ¶ä½œç”¨ã€‚ç ”ç©¶è€…é‚„åˆ†æäº†ä¾†è‡ªTCGAçš„èƒƒç™Œæ•¸æ“šåŠ11å°è‡¨åºŠæ¨£æœ¬ï¼Œç™¼ç¾PSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œä¸¦èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡å‘ˆè² ç›¸é—œã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„é€²è¡Œäº†ç´°èƒå¢æ®–ã€é·ç§»å’Œå‡‹äº¡çš„å¯¦é©—ï¼Œä»¥è©•ä¼°PSMB8-AS1çš„åŠŸèƒ½ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œé™ä½PSMB8-AS1çš„è¡¨é”èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒPSMB8-AS1å¯ä»¥ä½œç‚ºmiR-888-5pçš„åˆ†å­æµ·ç¶¿ï¼Œè€ŒmiR-888-5på‰‡èª¿æ§SLC4A7çš„è¡¨é”ã€‚é€²ä¸€æ­¥çš„å¯¦é©—è­‰å¯¦ï¼Œéè¡¨é”miR-888-5pæˆ–é™ä½SLC4A7çš„è¡¨é”éƒ½èƒ½æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ã€‚æ­¤å¤–ï¼Œè£¸é¼ å¯¦é©—é¡¯ç¤ºï¼Œç§»æ¤PSMB8-AS1æ•²é™¤çš„èƒƒç™Œç´°èƒå¾Œï¼Œè…«ç˜¤é«”ç©é¡¯è‘—æ¸›å°‘ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éYY1/PSMB8-AS1/miR-888-5p/SLC4A7è»¸ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œé¡¯ç¤ºå…¶åœ¨èƒƒç™Œé é˜²å’Œæ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é˜²æ²»æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½èƒƒç™Œçš„é¢¨éšªï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚é›–ç„¶é€™äº›çµæœä»¤äººæŒ¯å¥®ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªé€™äº›ç™¼ç¾çš„å…·é«”æ‡‰ç”¨åŠå…¶åœ¨è‡¨åºŠä¸Šçš„æœ‰æ•ˆæ€§ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ é€éèª¿ç¯€é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰-å¾®å°RNAï¼ˆmiRNAï¼‰-ä¿¡ä½¿RNAï¼ˆmRNAï¼‰è»¸ä¾†æŠ‘åˆ¶èƒƒç™Œçš„å½¢æˆã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯ä¸€ç¨®åç‚ºPSMB8-AS1çš„lncRNAï¼Œä¸¦è©¦åœ–äº†è§£å…¶åœ¨èƒƒç™Œç´°èƒä¸­çš„è¡¨é”è®ŠåŒ–åŠå…¶å°ç™Œç´°èƒå¢æ®–å’Œè½‰ç§»çš„å½±éŸ¿ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨èƒƒç™Œé˜²æ²»ä¸­çš„æ½›åœ¨æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›ä¾æ“šã€‚\n\nç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆå°æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒé€²è¡Œé«˜é€šé‡æ¸¬åºï¼Œä»¥æ‰¾å‡ºé¡¯è‘—å·®ç•°è¡¨é”çš„lncRNAã€‚æ¥è‘—ï¼Œä½¿ç”¨qRT-PCRç­‰æ–¹æ³•ç¢ºèªè˜¿è””ç¡«ç´ å°PSMB8-AS1çš„æŠ‘åˆ¶ä½œç”¨ã€‚ç ”ç©¶è€…é‚„åˆ†æäº†ä¾†è‡ªTCGAçš„èƒƒç™Œæ•¸æ“šåŠ11å°è‡¨åºŠæ¨£æœ¬ï¼Œç™¼ç¾PSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œä¸¦èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡å‘ˆè² ç›¸é—œã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„é€²è¡Œäº†ç´°èƒå¢æ®–ã€é·ç§»å’Œå‡‹äº¡çš„å¯¦é©—ï¼Œä»¥è©•ä¼°PSMB8-AS1çš„åŠŸèƒ½ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œé™ä½PSMB8-AS1çš„è¡¨é”èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒPSMB8-AS1å¯ä»¥ä½œç‚ºmiR-888-5pçš„åˆ†å­æµ·ç¶¿ï¼Œè€ŒmiR-888-5på‰‡èª¿æ§SLC4A7çš„è¡¨é”ã€‚é€²ä¸€æ­¥çš„å¯¦é©—è­‰å¯¦ï¼Œéè¡¨é”miR-888-5pæˆ–é™ä½SLC4A7çš„è¡¨é”éƒ½èƒ½æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ã€‚æ­¤å¤–ï¼Œè£¸é¼ å¯¦é©—é¡¯ç¤ºï¼Œç§»æ¤PSMB8-AS1æ•²é™¤çš„èƒƒç™Œç´°èƒå¾Œï¼Œè…«ç˜¤é«”ç©é¡¯è‘—æ¸›å°‘ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éYY1/PSMB8-AS1/miR-888-5p/SLC4A7è»¸ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œé¡¯ç¤ºå…¶åœ¨èƒƒç™Œé é˜²å’Œæ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBiochemical and biophysical research communicationsã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœä¸åƒ…ç¾å‘³ï¼Œé‚„å¯èƒ½å°æˆ‘å€‘çš„å¥åº·å¤§æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹æˆåˆ†å¯èƒ½å°é é˜²èƒƒç™Œæœ‰åŠ©ç›Šã€‚é€™é …ç ”ç©¶ä¸»è¦åœ¨æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•é€éèª¿ç¯€æŸäº›åˆ†å­ä¾†æŠ‘åˆ¶èƒƒç™Œçš„å½¢æˆã€‚\n\nç ”ç©¶è€…å€‘å°æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒé€²è¡Œäº†é«˜é€šé‡æ¸¬åºï¼Œä¸¦ç™¼ç¾ä¸€ç¨®åå«PSMB8-AS1çš„åˆ†å­åœ¨èƒƒç™Œç´°èƒä¸­è¡¨é”ä¸Šå‡ï¼Œé€™èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡æœ‰é—œã€‚ä»–å€‘é‚„é€²è¡Œäº†å„ç¨®å¯¦é©—ä¾†äº†è§£é€™ç¨®åˆ†å­çš„åŠŸèƒ½ï¼Œçµæœé¡¯ç¤ºï¼Œé™ä½PSMB8-AS1çš„è¡¨é”èƒ½æœ‰æ•ˆæ¸›å°‘ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒçš„æ­»äº¡ã€‚\n\né€™é …ç ”ç©¶çš„ç™¼ç¾è®“æˆ‘å€‘å°é£²é£Ÿèˆ‡å¥åº·çš„é—œä¿‚æœ‰äº†æ–°çš„èªè­˜ï¼\n\nğŸ”é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼é™ä½èƒƒç™Œé¢¨éšªã€‚\n2. PSMB8-AS1åœ¨èƒƒç™Œç´°èƒä¸­è¡¨é”ä¸Šå‡ï¼Œèˆ‡ç”Ÿå­˜ç‡è² ç›¸é—œã€‚\n3. é™ä½PSMB8-AS1çš„è¡¨é”å¯æ¸›å°‘ç™Œç´°èƒå¢æ®–å’Œé·ç§»ï¼Œä¿ƒé€²å‡‹äº¡ã€‚\n\né›–ç„¶é€™äº›çµæœä»¤äººæŒ¯å¥®ï¼Œä½†ä»éœ€æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ‡‰ç”¨å“¦ï¼",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of a study on sulforaphane. Include symbols representing broccoli and sulforaphane, simplified illustrations of experimental subjects like cells or mice, arrows or flow lines indicating the experimental steps, and a section highlighting the main results such as protective effects or changes observed in cancer cell behavior.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41056875/"
  },
  {
    "id": "41235157",
    "title_en": "Novel magnolol-sulforaphane hybrids as potent antitumor agents: synthesis and biological characterization.",
    "pub_date": "2025 Oct",
    "journal": "RSC medicinal chemistry",
    "abstract_en": "The natural product-based hybrid strategy is a promising approach for innovative drug discovery. Leveraging the privileged architecture of sulforaphane-a prominent anticancer natural product-we engineered a novel library of magnolol-sulforaphane molecular hybrids for antitumor evaluation through a concise synthetic strategy for the pharmacophore of sulforaphane (SFN), culminating in the identification of CTNPC8 as a promising anticancer compound. Notably, CTNPC8 not only displays exceptional broad-spectrum anticancer activity with potency surpassing both parent compounds and cisplatin, but also exhibits potent <i>in vitro</i> efficacy against the challenging nasopharyngeal carcinoma (NPC) cell model. Mechanistic studies in nasopharyngeal carcinoma models reveal that CTNPC8 triggers mitochondrial-mediated apoptosis through regulating ROS generation and induces G<sub>2</sub>/M phase arrest. Transcriptomic profiling coupled with validation experiments reveals that CTNPC8 exerts its anti-NPC activity primarily by modulating the Akt/mTOR pathway. The present study provided a valuable strategy for discovering new antitumor agents through hybrid molecular design, nominating CTNPC8 as a promising hit compound for anti-NPC research.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€å€‹æœ‰è¶£çš„æ–¹å‘ï¼Œå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å•Ÿç¤ºã€‚ç‰¹åˆ¥æ˜¯é‡å°ç™Œç—‡çš„æ²»ç™‚ï¼Œç ”ç©¶è€…å€‘é€éçµåˆå¤©ç„¶ç”¢ç‰©çš„ç‰¹æ€§ï¼Œé–‹ç™¼å‡ºæ–°çš„åŒ–åˆç‰©ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„é¸æ“‡ã€‚éš¨è‘—å°ç™Œç—‡æ²»ç™‚éœ€æ±‚çš„å¢åŠ ï¼Œé€™æ¨£çš„å‰µæ–°ç­–ç•¥å¯èƒ½æœƒå¹«åŠ©æˆ‘å€‘æ‰¾åˆ°æ›´æœ‰æ•ˆçš„è—¥ç‰©ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œç”Ÿå­˜ç‡ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°ç™Œç—‡çš„è—¥ç‰©é–‹ç™¼ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œï¼ˆnasopharyngeal carcinoma, NPCï¼‰çš„æ²»ç™‚ã€‚ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼åˆ©ç”¨è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶ç”¢ç‰©çš„ç‰¹æ€§ï¼Œè¨­è¨ˆå‡ºä¸€ç³»åˆ—æ–°çš„åˆ†å­æ··åˆç‰©ï¼Œä»¥è©•ä¼°å…¶æŠ—è…«ç˜¤çš„æ½›åŠ›ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…é—œå¿ƒè—¥ç‰©çš„æ•ˆæœï¼Œé‚„æ¢ç´¢å…¶ä½œç”¨æ©Ÿåˆ¶ï¼ŒæœŸæœ›èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘å‰µé€ äº†ä¸€å€‹æ–°çš„åˆ†å­åº«ï¼Œé€™äº›åˆ†å­æ˜¯ç”±è˜¿è””ç¡«ç´ å’Œå¦ä¸€ç¨®åŒ–åˆç‰©ï¼ˆmagnololï¼‰çµåˆè€Œæˆã€‚ç ”ç©¶çš„å°è±¡ä¸»è¦æ˜¯é¼»å’½ç™Œç´°èƒæ¨¡å‹ï¼Œé€éä¸€ç³»åˆ—çš„åˆæˆç­–ç•¥ä¾†è©•ä¼°é€™äº›æ··åˆç‰©çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…å€‘é‚„é€²è¡Œäº†æ©Ÿåˆ¶ç ”ç©¶ï¼Œä»¥äº†è§£é€™äº›æ–°åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç´°èƒçš„ç”Ÿé•·å’Œæ­»äº¡éç¨‹ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒCTNPC8é€™å€‹æ–°åŒ–åˆç‰©å±•ç¾å‡ºå„ªç•°çš„æŠ—ç™Œæ´»æ€§ï¼Œç”šè‡³è¶…éäº†å…¶åŸå§‹æˆåˆ†å’Œé †é‰‘ï¼ˆcisplatinï¼‰ã€‚åœ¨é¼»å’½ç™Œç´°èƒæ¨¡å‹ä¸­ï¼ŒCTNPC8èƒ½æœ‰æ•ˆèª˜å°ç´°èƒæ­»äº¡ï¼Œä¸¦ä¸”å½±éŸ¿ç´°èƒé€±æœŸçš„é€²ç¨‹ã€‚é€²ä¸€æ­¥çš„ç ”ç©¶é¡¯ç¤ºï¼ŒCTNPC8çš„æŠ—é¼»å’½ç™Œæ´»æ€§ä¸»è¦æ˜¯é€éèª¿ç¯€Akt/mTORé€šè·¯ä¾†å¯¦ç¾çš„ã€‚é€™äº›çµæœé¡¯ç¤ºï¼ŒCTNPC8å¯èƒ½æˆç‚ºæœªä¾†æŠ—é¼»å’½ç™Œç ”ç©¶ä¸­çš„ä¸€å€‹æœ‰å‰æ™¯çš„å€™é¸è—¥ç‰©ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€å€‹æœ‰è¶£çš„æ–¹å‘ï¼Œå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å•Ÿç¤ºã€‚ç‰¹åˆ¥æ˜¯é‡å°ç™Œç—‡çš„æ²»ç™‚ï¼Œç ”ç©¶è€…å€‘é€éçµåˆå¤©ç„¶ç”¢ç‰©çš„ç‰¹æ€§ï¼Œé–‹ç™¼å‡ºæ–°çš„åŒ–åˆç‰©ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„é¸æ“‡ã€‚éš¨è‘—å°ç™Œç—‡æ²»ç™‚éœ€æ±‚çš„å¢åŠ ï¼Œé€™æ¨£çš„å‰µæ–°ç­–ç•¥å¯èƒ½æœƒå¹«åŠ©æˆ‘å€‘æ‰¾åˆ°æ›´æœ‰æ•ˆçš„è—¥ç‰©ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œç”Ÿå­˜ç‡ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°ç™Œç—‡çš„è—¥ç‰©é–‹ç™¼ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œï¼ˆnasopharyngeal carcinoma, NPCï¼‰çš„æ²»ç™‚ã€‚ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼åˆ©ç”¨è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶ç”¢ç‰©çš„ç‰¹æ€§ï¼Œè¨­è¨ˆå‡ºä¸€ç³»åˆ—æ–°çš„åˆ†å­æ··åˆç‰©ï¼Œä»¥è©•ä¼°å…¶æŠ—è…«ç˜¤çš„æ½›åŠ›ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…é—œå¿ƒè—¥ç‰©çš„æ•ˆæœï¼Œé‚„æ¢ç´¢å…¶ä½œç”¨æ©Ÿåˆ¶ï¼ŒæœŸæœ›èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘å‰µé€ äº†ä¸€å€‹æ–°çš„åˆ†å­åº«ï¼Œé€™äº›åˆ†å­æ˜¯ç”±è˜¿è””ç¡«ç´ å’Œå¦ä¸€ç¨®åŒ–åˆç‰©ï¼ˆmagnololï¼‰çµåˆè€Œæˆã€‚ç ”ç©¶çš„å°è±¡ä¸»è¦æ˜¯é¼»å’½ç™Œç´°èƒæ¨¡å‹ï¼Œé€éä¸€ç³»åˆ—çš„åˆæˆç­–ç•¥ä¾†è©•ä¼°é€™äº›æ··åˆç‰©çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…å€‘é‚„é€²è¡Œäº†æ©Ÿåˆ¶ç ”ç©¶ï¼Œä»¥äº†è§£é€™äº›æ–°åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç´°èƒçš„ç”Ÿé•·å’Œæ­»äº¡éç¨‹ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒCTNPC8é€™å€‹æ–°åŒ–åˆç‰©å±•ç¾å‡ºå„ªç•°çš„æŠ—ç™Œæ´»æ€§ï¼Œç”šè‡³è¶…éäº†å…¶åŸå§‹æˆåˆ†å’Œé †é‰‘ï¼ˆcisplatinï¼‰ã€‚åœ¨é¼»å’½ç™Œç´°èƒæ¨¡å‹ä¸­ï¼ŒCTNPC8èƒ½æœ‰æ•ˆèª˜å°ç´°èƒæ­»äº¡ï¼Œä¸¦ä¸”å½±éŸ¿ç´°èƒé€±æœŸçš„é€²ç¨‹ã€‚é€²ä¸€æ­¥çš„ç ”ç©¶é¡¯ç¤ºï¼ŒCTNPC8çš„æŠ—é¼»å’½ç™Œæ´»æ€§ä¸»è¦æ˜¯é€éèª¿ç¯€Akt/mTORé€šè·¯ä¾†å¯¦ç¾çš„ã€‚é€™äº›çµæœé¡¯ç¤ºï¼ŒCTNPC8å¯èƒ½æˆç‚ºæœªä¾†æŠ—é¼»å’½ç™Œç ”ç©¶ä¸­çš„ä¸€å€‹æœ‰å‰æ™¯çš„å€™é¸è—¥ç‰©ã€‚",
    "fb_post": "æ ¹æ“šã€ŠRSC medicinal chemistryã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶è®“æˆ‘å°å¥åº·å’Œç™Œç—‡æ²»ç™‚å……æ»¿äº†å¸Œæœ›ï¼ç ”ç©¶äººå“¡å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶æˆåˆ†ï¼Œé€™å€‹æˆåˆ†ä¾†è‡ªæ–¼æˆ‘å€‘å¸¸è¦‹çš„é’èŠ±æ¤°èœã€‚ä»–å€‘æƒ³çœ‹çœ‹é€™ç¨®æˆåˆ†èƒ½å¦å¹«åŠ©å°æŠ—é¼»å’½ç™Œï¼Œé€™æ˜¯ä¸€ç¨®å½±éŸ¿å–‰åš¨çš„ç™Œç—‡ã€‚\n\nç ”ç©¶è€…å€‘è¨­è¨ˆäº†ä¸€ç³»åˆ—æ–°çš„åŒ–åˆç‰©ï¼Œä¸¦åœ¨å¯¦é©—å®¤ä¸­æ¸¬è©¦å®ƒå€‘å°ç™Œç´°èƒçš„å½±éŸ¿ã€‚ä»–å€‘ç™¼ç¾å…¶ä¸­ä¸€å€‹æ–°åŒ–åˆç‰©ï¼Œåç‚ºCTNPC8ï¼Œç«Ÿç„¶å±•ç¾å‡ºæ¯”å‚³çµ±è—¥ç‰©ï¼ˆåƒæ˜¯é †é‰‘ï¼‰æ›´å¼·çš„æŠ—ç™Œèƒ½åŠ›ï¼é€™å€‹åŒ–åˆç‰©èƒ½æœ‰æ•ˆèª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä¸¦å½±éŸ¿å®ƒå€‘çš„ç”Ÿé•·éç¨‹ã€‚\n\né€™é …ç ”ç©¶ä¸åƒ…è®“æˆ‘å€‘çœ‹åˆ°äº†å¤©ç„¶æˆåˆ†çš„æ½›åŠ›ï¼Œä¹Ÿç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚å¸¶ä¾†äº†æ–°çš„å¸Œæœ›ã€‚ä»¥ä¸‹æ˜¯å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæŠ—é¼»å’½ç™Œçš„æ–°é¸æ“‡ã€‚\n2. CTNPC8é¡¯ç¤ºå‡ºå¼·å¤§çš„æŠ—ç™Œæ´»æ€§ã€‚\n3. é€™é …ç ”ç©¶æœ‰åŠ©æ–¼æœªä¾†é–‹ç™¼æ›´æœ‰æ•ˆçš„ç™Œç—‡è—¥ç‰©ã€‚",
    "image_prompt": "Create an infographic that explains the experimental process and main results of a study on a natural compound called sulforaphane, derived from broccoli. The image should have a simple and clear layout with a light background. Include symbols representing sulforaphane and simplified illustrations of cancer cells. Use arrows or flow lines to show the experimental steps. Add a section labeled 'Main Results' that highlights the protective effects of the new compound CTNPC8 against nasopharyngeal cancer.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "é¼»å’½ç™Œ Nasopharyngeal Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41235157/"
  },
  {
    "id": "41181585",
    "title_en": "Sulforaphane alleviates hepatocyte pyroptosis via activating Nrf2-HO-1 signaling during septic acute liver injury.",
    "pub_date": "2025",
    "journal": "Frontiers in pharmacology",
    "abstract_en": "Acute liver injury (ALI) caused by sepsis is a fatal disease with a high mortality rate and poor prognosis. Sulforaphane (SFN) is a natural isothiocyanate that has robust antioxidant and anti-inflammatory properties. The aim of this study was to identify the pharmacological effects and therapeutic mechanisms of SFN in lipopolysaccharide (LPS)-induced ALI. The role of SFN in ALI was investigated using a mouse model of LPS-induced ALI. Briefly, eighteen mice were divided into three groups: control, LPS, and LPS + SFN, which were intraperitoneally injected for 2Â days before LPS treatment. 24Â h after the LPS injection, blood and liver tissues were collected for further analysis. The hematoxylin and eosin (HE) staining showed a lot of visible necrosis areas, inflammatory cell infiltration, and congestion in liver. Meanwhile, Ly6G and F4/80 staining showed increased infiltration of neutrophils and macrophages in liver, these results indicated that LPS induced sever ALI. As inflammatory response plays a vital role in the pathogenesis of LPS-induced ALI, we detected the occurrence of pyroptosis in liver by ribonucleic acid (RNA) sequencing. The results showed that pyroptosis was significantly promoted by LPS, as indicated by gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses, revealing the activation of pyroptosis, interleukin (IL)-1 production, IL-18 production, and inflammatory signaling pathways. Then, we explored the effect of SFN on LPS-induced ALI. The results showed that SFN obviously reduced LPS-induced plasma alanine aminotransferase and aspartate aminotransferase level, pathological injuries and TdT-mediated dUTP nick-end labeling (TUNEL) positive cells, indicating protective effect of SFN on ALI. Furthermore, SFN also showed robust effect on LPS-induced inflammatory response in liver, as reflected by suppressing the infiltration of neutrophils and macrophages, and downregulating mRNA levels of C-X-C motif chemokine ligand 9, IL-6, monocyte chemoattractant protein-1, and tumor necrosis factor-Î± in liver of LPS treated mice. Furthermore, SFN blocked hepatocyte pyroptosis, and suppressed plasma IL-1Î² and IL-18 levels of LPS treated mice. Mechanistically, SFN selectively activated nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling to mediate pyroptotic cell death. SFN also reversed the inhibited superoxide dismutase activity and induced malondialdehyde content in liver of LPS exposed mice. SFN ameliorated liver injury and inflammation during LPS-induced ALI by suppressing hepatocyte pyroptosis via the activation of Nrf2/HO-1 signaling. This study provides new evidence for the potential treatment of ALI with SFN.",
    "para1": "æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰æ˜¯ä¸€ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‡´å‘½ç–¾ç—…ï¼Œæ­»äº¡ç‡é«˜ä¸”é å¾Œä¸è‰¯ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨é€™ç¨®æƒ…æ³ä¸‹çš„æ½›åœ¨ç™‚æ•ˆï¼Œå¯èƒ½ç‚ºæ”¹å–„è‚æå‚·çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚ç”±æ–¼è˜¿è””ç¡«ç´ å…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚ç‰¹æ€§ï¼Œé€™ä½¿å¾—å®ƒåœ¨é é˜²å’Œæ²»ç™‚è‚æå‚·æ–¹é¢é¡¯å¾—å°¤ç‚ºé‡è¦ã€‚äº†è§£é€™äº›æ©Ÿåˆ¶å¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥ï¼Œæ¸›å°‘æ•—è¡€ç—‡å¼•èµ·çš„è‚æå‚·çš„é¢¨éšªï¼Œä¸¦æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„æ€¥æ€§è‚æå‚·çš„è—¥ç†ä½œç”¨åŠå…¶æ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è‚æå‚·çš„ç™¼å±•ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ•—è¡€ç—‡å¼•èµ·çš„æ€¥æ€§è‚æå‚·ä¸­ï¼Œæ˜¯å¦èƒ½å¤ æ¸›è¼•ç‚ç—‡åæ‡‰å’Œç´°èƒæ­»äº¡çš„æƒ…æ³ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°‡æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ åœ¨è‚è‡Ÿå¥åº·ä¸­çš„æ½›åœ¨è§’è‰²ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†å°é¼ æ¨¡å‹ä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°LPSèª˜å°çš„æ€¥æ€§è‚æå‚·çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å°‡18éš»å°é¼ åˆ†ç‚ºä¸‰çµ„ï¼šå°ç…§çµ„ã€LPSçµ„å’ŒLPS + è˜¿è””ç¡«ç´ çµ„ã€‚åœ¨LPSè™•ç†å‰ï¼Œé€™äº›å°é¼ æ¥å—äº†ç‚ºæœŸå…©å¤©çš„è…¹è…”æ³¨å°„ã€‚LPSæ³¨å°„å¾Œ24å°æ™‚ï¼Œç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„è¡€æ¶²å’Œè‚è‡Ÿçµ„ç¹”é€²è¡Œé€²ä¸€æ­¥åˆ†æï¼Œä¸¦ä½¿ç”¨çµ„ç¹”æŸ“è‰²ç­‰æ–¹æ³•ä¾†è©•ä¼°è‚è‡Ÿçš„æå‚·æƒ…æ³ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›å°‘LPSèª˜å°çš„è‚è‡Ÿæå‚·å’Œç‚ç—‡åæ‡‰ã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ é™ä½äº†è¡€æ¼¿ä¸­çš„è‚é…¶æ°´å¹³ï¼Œä¸¦æ¸›å°‘äº†è‚è‡Ÿä¸­çš„ç‚ç—‡ç´°èƒæµ¸æ½¤ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æŠ‘åˆ¶è‚ç´°èƒçš„ç„¦äº¡ï¼Œä¸¦èª¿ç¯€å¤šç¨®èˆ‡ç‚ç—‡ç›¸é—œçš„åŸºå› è¡¨é”ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéæ¿€æ´»ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†ä¿è­·è‚è‡Ÿï¼Œé›–ç„¶é€™äº›ç™¼ç¾éœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶è‡¨åºŠæ‡‰ç”¨çš„æ½›åŠ›ã€‚",
    "explanation_zh": "æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰æ˜¯ä¸€ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‡´å‘½ç–¾ç—…ï¼Œæ­»äº¡ç‡é«˜ä¸”é å¾Œä¸è‰¯ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨é€™ç¨®æƒ…æ³ä¸‹çš„æ½›åœ¨ç™‚æ•ˆï¼Œå¯èƒ½ç‚ºæ”¹å–„è‚æå‚·çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚ç”±æ–¼è˜¿è””ç¡«ç´ å…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚ç‰¹æ€§ï¼Œé€™ä½¿å¾—å®ƒåœ¨é é˜²å’Œæ²»ç™‚è‚æå‚·æ–¹é¢é¡¯å¾—å°¤ç‚ºé‡è¦ã€‚äº†è§£é€™äº›æ©Ÿåˆ¶å¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥ï¼Œæ¸›å°‘æ•—è¡€ç—‡å¼•èµ·çš„è‚æå‚·çš„é¢¨éšªï¼Œä¸¦æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„æ€¥æ€§è‚æå‚·çš„è—¥ç†ä½œç”¨åŠå…¶æ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è‚æå‚·çš„ç™¼å±•ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ•—è¡€ç—‡å¼•èµ·çš„æ€¥æ€§è‚æå‚·ä¸­ï¼Œæ˜¯å¦èƒ½å¤ æ¸›è¼•ç‚ç—‡åæ‡‰å’Œç´°èƒæ­»äº¡çš„æƒ…æ³ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°‡æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ åœ¨è‚è‡Ÿå¥åº·ä¸­çš„æ½›åœ¨è§’è‰²ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†å°é¼ æ¨¡å‹ä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°LPSèª˜å°çš„æ€¥æ€§è‚æå‚·çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å°‡18éš»å°é¼ åˆ†ç‚ºä¸‰çµ„ï¼šå°ç…§çµ„ã€LPSçµ„å’ŒLPS + è˜¿è””ç¡«ç´ çµ„ã€‚åœ¨LPSè™•ç†å‰ï¼Œé€™äº›å°é¼ æ¥å—äº†ç‚ºæœŸå…©å¤©çš„è…¹è…”æ³¨å°„ã€‚LPSæ³¨å°„å¾Œ24å°æ™‚ï¼Œç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„è¡€æ¶²å’Œè‚è‡Ÿçµ„ç¹”é€²è¡Œé€²ä¸€æ­¥åˆ†æï¼Œä¸¦ä½¿ç”¨çµ„ç¹”æŸ“è‰²ç­‰æ–¹æ³•ä¾†è©•ä¼°è‚è‡Ÿçš„æå‚·æƒ…æ³ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›å°‘LPSèª˜å°çš„è‚è‡Ÿæå‚·å’Œç‚ç—‡åæ‡‰ã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ é™ä½äº†è¡€æ¼¿ä¸­çš„è‚é…¶æ°´å¹³ï¼Œä¸¦æ¸›å°‘äº†è‚è‡Ÿä¸­çš„ç‚ç—‡ç´°èƒæµ¸æ½¤ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æŠ‘åˆ¶è‚ç´°èƒçš„ç„¦äº¡ï¼Œä¸¦èª¿ç¯€å¤šç¨®èˆ‡ç‚ç—‡ç›¸é—œçš„åŸºå› è¡¨é”ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéæ¿€æ´»ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†ä¿è­·è‚è‡Ÿï¼Œé›–ç„¶é€™äº›ç™¼ç¾éœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶è‡¨åºŠæ‡‰ç”¨çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in pharmacologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢æœ‰ä¸€ç¨®å«è˜¿è””ç¡«ç´ çš„æˆåˆ†ï¼Œå¯èƒ½å°æˆ‘å€‘çš„è‚è‡Ÿå¥åº·æœ‰å¾ˆå¤§å¹«åŠ©ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰ï¼Œé€™æ˜¯ä¸€ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„åš´é‡ç–¾ç—…ï¼Œå°ç”Ÿå‘½æ§‹æˆå¨è„…ã€‚ç ”ç©¶è€…æƒ³äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™ç¨®è‚æå‚·ï¼Œç‰¹åˆ¥æ˜¯å®ƒèƒ½å¦æ¸›å°‘ç‚ç—‡å’Œç´°èƒæ­»äº¡ã€‚  \n  \nåœ¨å¯¦é©—ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨å°é¼ ä¾†è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚ä»–å€‘å°‡å°é¼ åˆ†æˆä¸‰çµ„ï¼šä¸€çµ„ä¸è™•ç†ï¼Œå¦ä¸€çµ„æ³¨å°„äº†å¼•èµ·è‚æå‚·çš„ç‰©è³ªï¼Œæœ€å¾Œä¸€çµ„å‰‡åœ¨æ³¨å°„å¾Œçµ¦äºˆè˜¿è””ç¡«ç´ ã€‚ç¶“é24å°æ™‚çš„è§€å¯Ÿï¼Œç ”ç©¶è€…åˆ†æäº†å°é¼ çš„è¡€æ¶²å’Œè‚è‡Ÿçµ„ç¹”ã€‚  \n  \nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæ¸›å°‘è‚è‡Ÿçš„æå‚·å’Œç‚ç—‡ï¼Œä¸¦é™ä½è‚é…¶æ°´å¹³ï¼Œé€™æ˜¯è‚è‡Ÿå¥åº·çš„é‡è¦æŒ‡æ¨™ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°è˜¿è””ç¡«ç´ åœ¨ä¿è­·è‚è‡Ÿæ–¹é¢çš„æ½›åŠ›å……æ»¿æœŸå¾…ï¼  \n  \nğŸ” ç¸½çµä¸€ä¸‹ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„æ€¥æ€§è‚æå‚·ã€‚  \n2. å®ƒèƒ½æ¸›å°‘è‚è‡Ÿçš„ç‚ç—‡åæ‡‰ã€‚  \n3. é€™äº›çµæœç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main findings of a study on the effects of sulforaphane from radishes on acute liver injury. The image should include simplified icons of radishes or broccoli to represent sulforaphane, and simplified representations of mice as experimental subjects. Use arrows or flow lines to show the experimental steps: control group, LPS injection, and sulforaphane treatment. Include a section labeled 'Main Findings' that highlights protective effects and changes observed in liver health.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§è‚æå‚· Acute Liver Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41181585/"
  },
  {
    "id": "41099966",
    "title_en": "Sulforaphane improves exercise-induced NRF2 signaling in older adults: an in vivo-ex vivo approach.",
    "pub_date": "2025 Oct",
    "journal": "GeroScience",
    "abstract_en": "Redox signaling is a key mechanism of exercise-induced adaptation. However, studies have demonstrated impaired responses to acute exercise in older organisms. Adjunctive therapies to augment exercise effects may overcome these deficits. Sulforaphane (SFN), a phytochemical from cruciferous vegetables, stimulates NRF2. This study tested the hypothesis that combining acute exercise (in vivo stimulus) with ex vivo SFN treatment would induce greater NRF2 activation and signaling in older adults compared to either treatment alone. Twenty-five older adults (12 men, 13 women; mean age: 67â€‰Â±â€‰5Â years) performed 30-min cycling exercise (AET). Blood was drawn before and immediately after the AET to isolate PBMCs and incubate with and without SFN (5Â ÂµM) treatment (four conditions: DMSO (CON), SFN, exercise (EX), and EXâ€‰+â€‰SFN). PBMCs were harvested after 2-h or 5-h incubation for measures of NRF2 or gene expression for NQO1, HO-1, GR, and GCLC targets, respectively. All treatments (SFN, EX, EXâ€‰+â€‰SFN) increased NRF2 activation compared to CON (pâ€‰<â€‰0.05). The response to EXâ€‰+â€‰SFN was significantly greater than either SFN or EX alone (2.1-fold versus 1.5-fold, pâ€‰=â€‰0.01). SFN stimulation resulted in a significant upregulation of all four genes compared to control (pâ€‰<â€‰0.001). EXâ€‰+â€‰SFN treatment stimulated a greater increase in gene expression compared to EX (pâ€‰<â€‰0.05); however, SFN did not differ statistically from EXâ€‰+â€‰SFN, suggesting a possible ceiling effect of the SFN concentration in terms of gene expression. There were no significant sex differences in any of the responses. These data suggest that combining exercise with SFN may amplify the strength of NRF2/ARE redox signaling in older adults. ClinicalTrials.gov ID: NCT04848792.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æœ‰è¶£çš„å•Ÿç¤ºã€‚éš¨è‘—å¹´é½¡å¢é•·ï¼Œäººé«”å°é‹å‹•çš„åæ‡‰å¯èƒ½æœƒæ¸›å¼±ï¼Œé€™ä½¿å¾—è€å¹´äººæ›´é›£å¾é‹å‹•ä¸­ç²å¾—å¥åº·ç›Šè™•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éçµåˆé‹å‹•èˆ‡ç‰¹å®šçš„è¼”åŠ©ç™‚æ³•ï¼Œåƒæ˜¯è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„é€™ç¨®æƒ…æ³ï¼Œå¾è€Œå¢å¼·è€å¹´äººçš„å¥åº·ç‹€æ…‹ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†çš„å¥åº·ä¿ƒé€²ç­–ç•¥å¯ä»¥è€ƒæ…®å°‡é‹å‹•èˆ‡ç‡Ÿé¤Šæˆåˆ†çµåˆï¼Œä»¥é”åˆ°æ›´å¥½çš„æ•ˆæœã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨é‹å‹•èˆ‡è˜¿è””ç¡«ç´ çµåˆå°è€å¹´äººå¥åº·çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œå¦‚ä½•é€éé€™ç¨®çµåˆä¾†å¢å¼·è€å¹´äººåœ¨é‹å‹•å¾Œçš„ç”Ÿç†åæ‡‰ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼ä¸€ç¨®åç‚º NRF2 çš„ä¿¡è™Ÿå‚³å°æ©Ÿåˆ¶çš„æ¿€æ´»ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯æ¸¬è©¦é‹å‹•èˆ‡è˜¿è””ç¡«ç´ çš„è¯åˆä½¿ç”¨æ˜¯å¦èƒ½æ¯”å–®ç¨ä½¿ç”¨å…¶ä¸­ä¸€ç¨®æ–¹æ³•æ›´æœ‰æ•ˆåœ°ä¿ƒé€² NRF2 çš„æ´»åŒ–ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œå…±æœ‰25ä½è€å¹´åƒèˆ‡è€…ï¼ˆ12ä½ç”·æ€§å’Œ13ä½å¥³æ€§ï¼Œå¹³å‡å¹´é½¡67æ­²ï¼‰åƒåŠ äº†30åˆ†é˜çš„é¨è‡ªè¡Œè»Šé‹å‹•ã€‚ç ”ç©¶è€…åœ¨é‹å‹•å‰å’Œé‹å‹•å¾Œç«‹å³æŠ½å–è¡€æ¶²ï¼Œä»¥åˆ†é›¢å¤–å‘¨è¡€å–®æ ¸ç´°èƒï¼ˆPBMCsï¼‰ï¼Œä¸¦å°‡é€™äº›ç´°èƒèˆ‡æˆ–ä¸èˆ‡è˜¿è””ç¡«ç´ é€²è¡Œè™•ç†ã€‚å¯¦é©—è¨­è¨ˆåŒ…å«å››ç¨®æ¢ä»¶ï¼šå°ç…§çµ„ï¼ˆDMSOï¼‰ã€è˜¿è””ç¡«ç´ ã€é‹å‹•å’Œé‹å‹•åŠ è˜¿è””ç¡«ç´ ã€‚é€™äº›ç´°èƒåœ¨ä¸åŒçš„æ™‚é–“é»é€²è¡Œæ”¶é›†ï¼Œä»¥æ¸¬é‡ NRF2 çš„æ´»åŒ–å’Œç›¸é—œåŸºå› çš„è¡¨é”ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œæ‰€æœ‰çš„è™•ç†çµ„ï¼ˆè˜¿è””ç¡«ç´ ã€é‹å‹•ã€é‹å‹•åŠ è˜¿è””ç¡«ç´ ï¼‰éƒ½æ¯”å°ç…§çµ„æœ‰æ›´é«˜çš„ NRF2 æ´»åŒ–ã€‚ç‰¹åˆ¥æ˜¯é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„çµ„åˆï¼Œå…¶åæ‡‰é¡¯è‘—é«˜æ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ æˆ–é‹å‹•ï¼Œé¡¯ç¤ºå‡ºé€™ç¨®çµ„åˆçš„æ½›åŠ›ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ çš„åˆºæ¿€ä¹Ÿé¡¯è‘—ä¸Šèª¿äº†å››å€‹åŸºå› çš„è¡¨é”ã€‚é›–ç„¶é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„çµ„åˆåœ¨åŸºå› è¡¨é”ä¸Šæœ‰æ›´å¤§çš„å¢å¼·ï¼Œä½†è˜¿è””ç¡«ç´ çš„æ•ˆæœä¼¼ä¹åœ¨æŸå€‹æ¿ƒåº¦ä¸‹é”åˆ°äº†ä¸Šé™ï¼Œæœªä¾†çš„ç ”ç©¶å¯ä»¥é€²ä¸€æ­¥æ¢è¨é€™ä¸€é»ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æœ‰è¶£çš„å•Ÿç¤ºã€‚éš¨è‘—å¹´é½¡å¢é•·ï¼Œäººé«”å°é‹å‹•çš„åæ‡‰å¯èƒ½æœƒæ¸›å¼±ï¼Œé€™ä½¿å¾—è€å¹´äººæ›´é›£å¾é‹å‹•ä¸­ç²å¾—å¥åº·ç›Šè™•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éçµåˆé‹å‹•èˆ‡ç‰¹å®šçš„è¼”åŠ©ç™‚æ³•ï¼Œåƒæ˜¯è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„é€™ç¨®æƒ…æ³ï¼Œå¾è€Œå¢å¼·è€å¹´äººçš„å¥åº·ç‹€æ…‹ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†çš„å¥åº·ä¿ƒé€²ç­–ç•¥å¯ä»¥è€ƒæ…®å°‡é‹å‹•èˆ‡ç‡Ÿé¤Šæˆåˆ†çµåˆï¼Œä»¥é”åˆ°æ›´å¥½çš„æ•ˆæœã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨é‹å‹•èˆ‡è˜¿è””ç¡«ç´ çµåˆå°è€å¹´äººå¥åº·çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œå¦‚ä½•é€éé€™ç¨®çµåˆä¾†å¢å¼·è€å¹´äººåœ¨é‹å‹•å¾Œçš„ç”Ÿç†åæ‡‰ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼ä¸€ç¨®åç‚º NRF2 çš„ä¿¡è™Ÿå‚³å°æ©Ÿåˆ¶çš„æ¿€æ´»ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯æ¸¬è©¦é‹å‹•èˆ‡è˜¿è””ç¡«ç´ çš„è¯åˆä½¿ç”¨æ˜¯å¦èƒ½æ¯”å–®ç¨ä½¿ç”¨å…¶ä¸­ä¸€ç¨®æ–¹æ³•æ›´æœ‰æ•ˆåœ°ä¿ƒé€² NRF2 çš„æ´»åŒ–ã€‚\n\nå¯¦é©—ä¸­ï¼Œå…±æœ‰25ä½è€å¹´åƒèˆ‡è€…ï¼ˆ12ä½ç”·æ€§å’Œ13ä½å¥³æ€§ï¼Œå¹³å‡å¹´é½¡67æ­²ï¼‰åƒåŠ äº†30åˆ†é˜çš„é¨è‡ªè¡Œè»Šé‹å‹•ã€‚ç ”ç©¶è€…åœ¨é‹å‹•å‰å’Œé‹å‹•å¾Œç«‹å³æŠ½å–è¡€æ¶²ï¼Œä»¥åˆ†é›¢å¤–å‘¨è¡€å–®æ ¸ç´°èƒï¼ˆPBMCsï¼‰ï¼Œä¸¦å°‡é€™äº›ç´°èƒèˆ‡æˆ–ä¸èˆ‡è˜¿è””ç¡«ç´ é€²è¡Œè™•ç†ã€‚å¯¦é©—è¨­è¨ˆåŒ…å«å››ç¨®æ¢ä»¶ï¼šå°ç…§çµ„ï¼ˆDMSOï¼‰ã€è˜¿è””ç¡«ç´ ã€é‹å‹•å’Œé‹å‹•åŠ è˜¿è””ç¡«ç´ ã€‚é€™äº›ç´°èƒåœ¨ä¸åŒçš„æ™‚é–“é»é€²è¡Œæ”¶é›†ï¼Œä»¥æ¸¬é‡ NRF2 çš„æ´»åŒ–å’Œç›¸é—œåŸºå› çš„è¡¨é”ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œæ‰€æœ‰çš„è™•ç†çµ„ï¼ˆè˜¿è””ç¡«ç´ ã€é‹å‹•ã€é‹å‹•åŠ è˜¿è””ç¡«ç´ ï¼‰éƒ½æ¯”å°ç…§çµ„æœ‰æ›´é«˜çš„ NRF2 æ´»åŒ–ã€‚ç‰¹åˆ¥æ˜¯é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„çµ„åˆï¼Œå…¶åæ‡‰é¡¯è‘—é«˜æ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ æˆ–é‹å‹•ï¼Œé¡¯ç¤ºå‡ºé€™ç¨®çµ„åˆçš„æ½›åŠ›ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ çš„åˆºæ¿€ä¹Ÿé¡¯è‘—ä¸Šèª¿äº†å››å€‹åŸºå› çš„è¡¨é”ã€‚é›–ç„¶é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„çµ„åˆåœ¨åŸºå› è¡¨é”ä¸Šæœ‰æ›´å¤§çš„å¢å¼·ï¼Œä½†è˜¿è””ç¡«ç´ çš„æ•ˆæœä¼¼ä¹åœ¨æŸå€‹æ¿ƒåº¦ä¸‹é”åˆ°äº†ä¸Šé™ï¼Œæœªä¾†çš„ç ”ç©¶å¯ä»¥é€²ä¸€æ­¥æ¢è¨é€™ä¸€é»ã€‚",
    "fb_post": "æ ¹æ“šã€ŠGeroScienceã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿé‹å‹•æ­é…ä¸€äº›ç‰¹åˆ¥çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œå¯èƒ½æœƒè®“è€å¹´äººçš„å¥åº·ç‹€æ…‹æ›´å¥½ï¼é€™é …ç ”ç©¶å°±æ¢è¨äº†é‹å‹•å’Œä¸€ç¨®å«è˜¿è””ç¡«ç´ çš„æˆåˆ†å¦‚ä½•ä¸€èµ·å½±éŸ¿è€å¹´äººçš„å¥åº·ã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œéš¨è‘—å¹´é½¡å¢é•·ï¼Œäººé«”å°é‹å‹•çš„åæ‡‰æœƒæ¸›å¼±ï¼Œé€™ä½¿å¾—è€å¹´äººæ›´é›£å¾é‹å‹•ä¸­ç²å¾—å¥½è™•ã€‚ç‚ºäº†æ”¹å–„é€™ç¨®æƒ…æ³ï¼Œä»–å€‘è¨­è¨ˆäº†ä¸€å€‹å¯¦é©—ï¼Œè®“25ä½å¹³å‡67æ­²çš„è€å¹´äººé€²è¡Œ30åˆ†é˜çš„é¨è‡ªè¡Œè»Šé‹å‹•ï¼Œä¸¦åœ¨é‹å‹•å‰å¾ŒæŠ½å–è¡€æ¶²ä¾†è§€å¯Ÿèº«é«”åæ‡‰ã€‚å¯¦é©—ä¸­ï¼Œæœ‰äº›äººåªé‹å‹•ï¼Œæœ‰äº›äººå‰‡åœ¨é‹å‹•æ™‚æ­é…è˜¿è””ç¡«ç´ ã€‚çµæœé¡¯ç¤ºï¼Œé‹å‹•åŠ è˜¿è””ç¡«ç´ çš„çµ„åˆæ•ˆæœæœ€ä½³ï¼Œèƒ½æ›´æœ‰æ•ˆåœ°æ¿€æ´»èº«é«”ä¸­çš„ä¸€ç¨®ä¿è­·æ©Ÿåˆ¶ï¼Œé¡¯ç¤ºå‡ºé€™ç¨®æ­é…çš„æ½›åŠ›ã€‚ä»¥ä¸‹æ˜¯å¹¾å€‹é‡é»ï¼š\n1. é‹å‹•å’Œè˜¿è””ç¡«ç´ çš„çµåˆæœ‰åŠ©æ–¼æå‡è€å¹´äººçš„å¥åº·ã€‚\n2. é€™ç¨®çµ„åˆèƒ½æ›´æœ‰æ•ˆæ¿€æ´»èº«é«”çš„ä¿è­·æ©Ÿåˆ¶ã€‚\n3. æœªä¾†çš„ç ”ç©¶å¯ä»¥é€²ä¸€æ­¥æ¢ç´¢è˜¿è””ç¡«ç´ çš„æœ€ä½³ä½¿ç”¨æ¿ƒåº¦ã€‚",
    "image_prompt": "Create a simple and informative illustration that explains the experimental method and main results of a study on the effects of exercise combined with a compound called sulforaphane on elderly health. The design should feature a flat style with a light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of human participants or cells, arrows or flow lines showing the experimental steps, and a section labeled 'Main Results' highlighting protective effects or observed changes.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41099966/"
  },
  {
    "id": "40763479",
    "title_en": "Sulforaphane modulates macrophage polarization via JAK1/STAT1 inhibition to promote tendon repair in tendinopathy.",
    "pub_date": "2025 Oct",
    "journal": "International immunopharmacology",
    "abstract_en": "Imbalanced M1/M2 macrophage polarization is central to tendinopathy pathogenesis. Sulforaphane (SFN), a natural compound with anti-inflammatory properties, may modulate macrophage polarization. This study utilized a collagenase-induced mouse model of tendinopathy to evaluate the therapeutic effects of local SFN administration on tendinopathy in vivo. Furthermore, the effects of SFN on macrophage polarization were investigated in vitro, and RNA sequencing was used to explore the mechanisms by which SFN regulates macrophage polarization in vivo. Finally, an ex vivo human pathological tendon culture system was employed to explore the therapeutic effects of SFN on tendinopathic lesions. In this study, we found that SFN modulated the polarization of M1 macrophages towards M2 macrophages, thereby effectively modulating the inflammatory response. RNA sequencing and Western blot analyses indicated that the effect of SFN was mediated through the JAK1/STAT1 signaling pathway. In a collagenase-induced mouse model of tendinopathy, local injection of SFN led to a significant improvement in tendon tissue structure, with the collagen matrix restoring its natural dense parallel arrangement. Furthermore, there was an increase in local M2 macrophages and a decrease in M1 macrophages, which promoted the resolution of inflammation. Finally, the immunomodulatory effect of SFN on macrophages was also validated in tendon tissue from patients with tendinopathy. SFN can effectively alleviate tendinopathy by promoting the polarization of M1 macrophages towards M2 macrophages, an effect achieved through the inhibition of the JAK1/STAT1 signaling pathway, thereby providing a promising therapeutic approach for the treatment of tendinopathy.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚Œè…±ç—…çš„æ²»ç™‚æ–¹é¢ã€‚è‚Œè…±ç—…æ˜¯ä¸€ç¨®å¸¸è¦‹çš„é‹å‹•å‚·å®³ï¼Œé€šå¸¸ä¼´éš¨è‘—ç–¼ç—›å’ŒåŠŸèƒ½å—é™ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éèª¿ç¯€å…ç–«ç´°èƒçš„åŠŸèƒ½ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•è‚Œè…±ç—…çš„ç—‡ç‹€ï¼Œé€™å°æ–¼é‹å‹•å“¡å’Œä¸€èˆ¬äººä¾†èªªéƒ½æ˜¯ä¸€å€‹é‡è¦çš„å¥åº·è­°é¡Œã€‚è‹¥èƒ½æœ‰æ•ˆæ”¹å–„è‚Œè…±çš„å¥åº·ï¼Œå°‡æœ‰åŠ©æ–¼æå‡é‹å‹•è¡¨ç¾å’Œç”Ÿæ´»å“è³ªï¼Œä¸¦æ¸›å°‘å› ç‚ºè‚Œè…±ç—…è€Œé€ æˆçš„é†«ç™‚è² æ“”ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•åˆ©ç”¨é€™ç¨®å¤©ç„¶åŒ–åˆç‰©ä¾†èª¿ç¯€å…ç–«ç³»çµ±ä¸­çš„å·¨å™¬ç´°èƒï¼Œé€²è€Œæ”¹å–„è‚Œè…±çš„å¥åº·ç‹€æ…‹ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶è‘—é‡æ–¼å·¨å™¬ç´°èƒçš„M1å’ŒM2å‹æ¥µåŒ–ï¼Œé€™å…©ç¨®å‹æ…‹åœ¨ç‚ç—‡åæ‡‰ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½æ‰¾åˆ°æ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œå¹«åŠ©é‚£äº›å—åˆ°è‚Œè…±ç—…å›°æ“¾çš„äººã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®ç”±è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¾†æ¨¡æ“¬è‚Œè…±ç—…ï¼Œä¸¦è©•ä¼°å±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…ä¹Ÿåœ¨é«”å¤–å¯¦é©—ä¸­è§€å¯Ÿè˜¿è””ç¡«ç´ å°å·¨å™¬ç´°èƒæ¥µåŒ–çš„å½±éŸ¿ï¼Œä¸¦åˆ©ç”¨RNAæ¸¬åºæŠ€è¡“æ¢ç´¢å…¶èª¿ç¯€æ©Ÿåˆ¶ã€‚æœ€å¾Œï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨äº†äººé¡ç—…ç†è‚Œè…±çš„åŸ¹é¤Šç³»çµ±ä¾†é€²ä¸€æ­¥é©—è­‰è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…è®Šçš„ç™‚æ•ˆï¼Œé€™æ¨£çš„è¨­è¨ˆè®“ç ”ç©¶çµæœæ›´å…·èªªæœåŠ›ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æœ‰æ•ˆèª¿ç¯€M1å‹å·¨å™¬ç´°èƒå‘M2å‹çš„æ¥µåŒ–ï¼Œé€™æœ‰åŠ©æ–¼æ¸›å°‘ç‚ç—‡åæ‡‰ã€‚RNAæ¸¬åºå’Œè›‹ç™½è³ªå°è·¡åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨æ˜¯é€éJAK1/STAT1ä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚åœ¨è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¸­ï¼Œå±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ é¡¯è‘—æ”¹å–„äº†è‚Œè…±çµ„ç¹”çš„çµæ§‹ï¼Œä¸¦ä¿ƒé€²äº†M2å‹å·¨å™¬ç´°èƒçš„å¢åŠ å’ŒM1å‹å·¨å™¬ç´°èƒçš„æ¸›å°‘ï¼Œé€™äº›è®ŠåŒ–æœ‰åŠ©æ–¼ç‚ç—‡çš„ç·©è§£ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¹Ÿåœ¨è‚Œè…±ç—…æ‚£è€…çš„çµ„ç¹”ä¸­é©—è­‰äº†è˜¿è””ç¡«ç´ çš„å…ç–«èª¿ç¯€æ•ˆæœï¼Œé¡¯ç¤ºå‡ºå…¶æ½›åœ¨çš„æ²»ç™‚åƒ¹å€¼ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚Œè…±ç—…çš„æ²»ç™‚æ–¹é¢ã€‚è‚Œè…±ç—…æ˜¯ä¸€ç¨®å¸¸è¦‹çš„é‹å‹•å‚·å®³ï¼Œé€šå¸¸ä¼´éš¨è‘—ç–¼ç—›å’ŒåŠŸèƒ½å—é™ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éèª¿ç¯€å…ç–«ç´°èƒçš„åŠŸèƒ½ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•è‚Œè…±ç—…çš„ç—‡ç‹€ï¼Œé€™å°æ–¼é‹å‹•å“¡å’Œä¸€èˆ¬äººä¾†èªªéƒ½æ˜¯ä¸€å€‹é‡è¦çš„å¥åº·è­°é¡Œã€‚è‹¥èƒ½æœ‰æ•ˆæ”¹å–„è‚Œè…±çš„å¥åº·ï¼Œå°‡æœ‰åŠ©æ–¼æå‡é‹å‹•è¡¨ç¾å’Œç”Ÿæ´»å“è³ªï¼Œä¸¦æ¸›å°‘å› ç‚ºè‚Œè…±ç—…è€Œé€ æˆçš„é†«ç™‚è² æ“”ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•åˆ©ç”¨é€™ç¨®å¤©ç„¶åŒ–åˆç‰©ä¾†èª¿ç¯€å…ç–«ç³»çµ±ä¸­çš„å·¨å™¬ç´°èƒï¼Œé€²è€Œæ”¹å–„è‚Œè…±çš„å¥åº·ç‹€æ…‹ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶è‘—é‡æ–¼å·¨å™¬ç´°èƒçš„M1å’ŒM2å‹æ¥µåŒ–ï¼Œé€™å…©ç¨®å‹æ…‹åœ¨ç‚ç—‡åæ‡‰ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½æ‰¾åˆ°æ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œå¹«åŠ©é‚£äº›å—åˆ°è‚Œè…±ç—…å›°æ“¾çš„äººã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®ç”±è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¾†æ¨¡æ“¬è‚Œè…±ç—…ï¼Œä¸¦è©•ä¼°å±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…ä¹Ÿåœ¨é«”å¤–å¯¦é©—ä¸­è§€å¯Ÿè˜¿è””ç¡«ç´ å°å·¨å™¬ç´°èƒæ¥µåŒ–çš„å½±éŸ¿ï¼Œä¸¦åˆ©ç”¨RNAæ¸¬åºæŠ€è¡“æ¢ç´¢å…¶èª¿ç¯€æ©Ÿåˆ¶ã€‚æœ€å¾Œï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨äº†äººé¡ç—…ç†è‚Œè…±çš„åŸ¹é¤Šç³»çµ±ä¾†é€²ä¸€æ­¥é©—è­‰è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…è®Šçš„ç™‚æ•ˆï¼Œé€™æ¨£çš„è¨­è¨ˆè®“ç ”ç©¶çµæœæ›´å…·èªªæœåŠ›ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æœ‰æ•ˆèª¿ç¯€M1å‹å·¨å™¬ç´°èƒå‘M2å‹çš„æ¥µåŒ–ï¼Œé€™æœ‰åŠ©æ–¼æ¸›å°‘ç‚ç—‡åæ‡‰ã€‚RNAæ¸¬åºå’Œè›‹ç™½è³ªå°è·¡åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨æ˜¯é€éJAK1/STAT1ä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚åœ¨è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¸­ï¼Œå±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ é¡¯è‘—æ”¹å–„äº†è‚Œè…±çµ„ç¹”çš„çµæ§‹ï¼Œä¸¦ä¿ƒé€²äº†M2å‹å·¨å™¬ç´°èƒçš„å¢åŠ å’ŒM1å‹å·¨å™¬ç´°èƒçš„æ¸›å°‘ï¼Œé€™äº›è®ŠåŒ–æœ‰åŠ©æ–¼ç‚ç—‡çš„ç·©è§£ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¹Ÿåœ¨è‚Œè…±ç—…æ‚£è€…çš„çµ„ç¹”ä¸­é©—è­‰äº†è˜¿è””ç¡«ç´ çš„å…ç–«èª¿ç¯€æ•ˆæœï¼Œé¡¯ç¤ºå‡ºå…¶æ½›åœ¨çš„æ²»ç™‚åƒ¹å€¼ã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational immunopharmacologyã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢æœ‰ä¸€ç¨®ç¥å¥‡çš„æˆåˆ†å«è˜¿è””ç¡«ç´ ï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾å®ƒå°è‚Œè…±ç—…æœ‰å¹«åŠ©ï¼è‚Œè…±ç—…æ˜¯é‹å‹•å“¡å¸¸è¦‹çš„å›°æ“¾ï¼Œæœƒé€ æˆç–¼ç—›å’Œæ´»å‹•ä¸ä¾¿ã€‚é€™é …ç ”ç©¶çš„ç§‘å­¸å®¶å€‘å¥½å¥‡ï¼Œæ€éº¼åˆ©ç”¨é€™ç¨®å¤©ç„¶æˆåˆ†ä¾†æ”¹å–„è‚Œè…±çš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯é€éèª¿æ•´æˆ‘å€‘èº«é«”çš„å…ç–«ç´°èƒã€‚ \n\nä»–å€‘ç”¨è€é¼ æ¨¡æ“¬è‚Œè…±ç—…ï¼Œç„¶å¾Œæ³¨å°„è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå®ƒå°å…ç–«ç´°èƒçš„å½±éŸ¿ã€‚çµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆå¹«åŠ©èª¿ç¯€å…ç–«ç´°èƒçš„ç‹€æ…‹ï¼Œæ¸›å°‘ç‚ç—‡ï¼Œä¸¦æ”¹å–„è‚Œè…±çš„çµæ§‹ï¼é€™å°æ–¼é‹å‹•å“¡å’Œä¸€èˆ¬äººä¾†èªªï¼Œéƒ½æ˜¯å€‹å¥½æ¶ˆæ¯ï¼\n\næ‰€ä»¥ï¼Œé€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‚Œè…±å¥åº·ã€‚\n2. å®ƒèƒ½æ¸›å°‘ç‚ç—‡ï¼Œè®“æˆ‘å€‘çš„è‚Œè…±æ›´å¼·å£¯ã€‚\n3. é€™é …ç™¼ç¾ç‚ºæœªä¾†çš„è‚Œè…±ç—…æ²»ç™‚æä¾›äº†æ–°æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic with a light background that explains the experiment and main results of the study on radish sulforaphane. Include simple icons representing radish or broccoli, simplified figures of experimental subjects like humans, animals, or cells, and arrows or flow lines showing the experimental steps. Highlight a section labeled 'Main Results' that indicates protective effects or changes observed in the study.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚Œè…±ç—… Tendinopathy",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40763479/"
  },
  {
    "id": "41060333",
    "title_en": "Sulforaphane from broccoli, an epigenetic modulator in cancer cells.",
    "pub_date": "2025 Oct",
    "journal": "Discover oncology",
    "abstract_en": "The consumption of cruciferous vegetables offers several health benefits due to some of their compounds. Sulforaphane (SFN), a compound found in cabbage and broccoli, has received special attention in recent years due to its anticancer activities. The main objective of this systematic review is to examine the epigenetic and genetic effects of SFN on cancers (in vitro and in vivo) which contribute to its anticancer activities. We only analyzed studies that combined its epigenetic effects and anticancer activities due to the multitude of studies on SFN over the past few years. We found that SFN is able to regulate epigenetic mechanisms and promote the prevention and treatment of several cancers. Definitely, it prevents tumor growth and acts as a histone deacetylase (HDAC) inhibitor, a DNA methyltransferase (DNMT) inhibitor, and a microRNA regulator in several cancers. These epigenetic regulations lead indirectly to a hyperregulation or deregulation of the expression of genes involved in carcinogenesis. SFN hasn't any major epigenetic effect on normal cells. This review revealed that the anticancer activities attributable to SFN are largely related to its ability to modulate cancer cell epigenome. These capabilities to modulate the epigenome make SFN a promising anticancer agent with significant therapeutic potential.",
    "para1": "é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–å°å¥åº·æœ‰è¨±å¤šå¥½è™•ï¼Œé€™ä¸»è¦æ˜¯å› ç‚ºå®ƒå€‘å«æœ‰ä¸€äº›ç‰¹æ®Šçš„åŒ–åˆç‰©ã€‚å…¶ä¸­ï¼Œè˜¿è””ç¡«ç´ å› å…¶æŠ—ç™Œç‰¹æ€§è€Œå—åˆ°ç‰¹åˆ¥é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›æ–°çš„è¦‹è§£ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚æ–¹é¢ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿åŸºå› å’Œè¡¨è§€éºå‚³å­¸ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†å°æŠ—ç™Œç—‡ï¼Œé€²è€Œæ”¹å–„äººé¡çš„å¥åº·ç‹€æ³ã€‚",
    "para2": "é€™é …ç³»çµ±æ€§å›é¡§çš„ä¸»è¦ç›®çš„æ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç™Œç—‡çš„è¡¨è§€éºå‚³å’Œéºå‚³å½±éŸ¿ã€‚ç ”ç©¶è€…å°ˆæ³¨æ–¼åˆ†æè˜¿è””ç¡«ç´ çš„è¡¨è§€éºå‚³æ•ˆæ‡‰èˆ‡æŠ—ç™Œæ´»å‹•ä¹‹é–“çš„é—œè¯ï¼Œå› ç‚ºè¿‘å¹´ä¾†æœ‰è¨±å¤šé—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ã€‚é€™é …ç ”ç©¶å¸Œæœ›èƒ½å¤ æ•´åˆé€™äº›è³‡è¨Šï¼Œæ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•åœ¨åˆ†å­å±¤é¢ä¸Šå½±éŸ¿ç™Œç´°èƒï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å…¶æ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†å¤šé …é—œæ–¼è˜¿è””ç¡«ç´ çš„å¯¦é©—ï¼ŒåŒ…æ‹¬é«”å¤–å’Œé«”å…§çš„ç ”ç©¶ã€‚é€™äº›ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•èª¿ç¯€ç™Œç´°èƒçš„è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦è©•ä¼°å…¶å°ä¸åŒé¡å‹ç™Œç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…ç‰¹åˆ¥é—œæ³¨è˜¿è””ç¡«ç´ ä½œç‚ºçµ„è›‹ç™½å»ä¹™é†¯åŒ–é…¶ï¼ˆHDACï¼‰æŠ‘åˆ¶åŠ‘ã€DNA ç”²åŸºè½‰ç§»é…¶ï¼ˆDNMTï¼‰æŠ‘åˆ¶åŠ‘å’Œå¾®å°RNAèª¿ç¯€åŠ‘çš„ä½œç”¨ï¼Œé€™äº›éƒ½æ˜¯å½±éŸ¿ç™Œç—‡ç™¼å±•çš„é‡è¦å› ç´ ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿ç¯€ç™Œç´°èƒçš„è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦ä¿ƒé€²å¤šç¨®ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä¸”å°æ­£å¸¸ç´°èƒæ²’æœ‰é¡¯è‘—çš„è¡¨è§€éºå‚³å½±éŸ¿ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ´»æ€§èˆ‡å…¶èª¿ç¯€ç™Œç´°èƒè¡¨è§€åŸºå› çµ„çš„èƒ½åŠ›å¯†åˆ‡ç›¸é—œï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºæŠ—ç™ŒåŠ‘çš„æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "explanation_zh": "é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–å°å¥åº·æœ‰è¨±å¤šå¥½è™•ï¼Œé€™ä¸»è¦æ˜¯å› ç‚ºå®ƒå€‘å«æœ‰ä¸€äº›ç‰¹æ®Šçš„åŒ–åˆç‰©ã€‚å…¶ä¸­ï¼Œè˜¿è””ç¡«ç´ å› å…¶æŠ—ç™Œç‰¹æ€§è€Œå—åˆ°ç‰¹åˆ¥é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›æ–°çš„è¦‹è§£ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚æ–¹é¢ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿åŸºå› å’Œè¡¨è§€éºå‚³å­¸ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†å°æŠ—ç™Œç—‡ï¼Œé€²è€Œæ”¹å–„äººé¡çš„å¥åº·ç‹€æ³ã€‚\n\né€™é …ç³»çµ±æ€§å›é¡§çš„ä¸»è¦ç›®çš„æ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç™Œç—‡çš„è¡¨è§€éºå‚³å’Œéºå‚³å½±éŸ¿ã€‚ç ”ç©¶è€…å°ˆæ³¨æ–¼åˆ†æè˜¿è””ç¡«ç´ çš„è¡¨è§€éºå‚³æ•ˆæ‡‰èˆ‡æŠ—ç™Œæ´»å‹•ä¹‹é–“çš„é—œè¯ï¼Œå› ç‚ºè¿‘å¹´ä¾†æœ‰è¨±å¤šé—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ã€‚é€™é …ç ”ç©¶å¸Œæœ›èƒ½å¤ æ•´åˆé€™äº›è³‡è¨Šï¼Œæ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•åœ¨åˆ†å­å±¤é¢ä¸Šå½±éŸ¿ç™Œç´°èƒï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å…¶æ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†å¤šé …é—œæ–¼è˜¿è””ç¡«ç´ çš„å¯¦é©—ï¼ŒåŒ…æ‹¬é«”å¤–å’Œé«”å…§çš„ç ”ç©¶ã€‚é€™äº›ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•èª¿ç¯€ç™Œç´°èƒçš„è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦è©•ä¼°å…¶å°ä¸åŒé¡å‹ç™Œç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…ç‰¹åˆ¥é—œæ³¨è˜¿è””ç¡«ç´ ä½œç‚ºçµ„è›‹ç™½å»ä¹™é†¯åŒ–é…¶ï¼ˆHDACï¼‰æŠ‘åˆ¶åŠ‘ã€DNA ç”²åŸºè½‰ç§»é…¶ï¼ˆDNMTï¼‰æŠ‘åˆ¶åŠ‘å’Œå¾®å°RNAèª¿ç¯€åŠ‘çš„ä½œç”¨ï¼Œé€™äº›éƒ½æ˜¯å½±éŸ¿ç™Œç—‡ç™¼å±•çš„é‡è¦å› ç´ ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿ç¯€ç™Œç´°èƒçš„è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦ä¿ƒé€²å¤šç¨®ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä¸”å°æ­£å¸¸ç´°èƒæ²’æœ‰é¡¯è‘—çš„è¡¨è§€éºå‚³å½±éŸ¿ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ´»æ€§èˆ‡å…¶èª¿ç¯€ç™Œç´°èƒè¡¨è§€åŸºå› çµ„çš„èƒ½åŠ›å¯†åˆ‡ç›¸é—œï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºæŠ—ç™ŒåŠ‘çš„æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠDiscover oncologyã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡æœ‰å€‹å«è˜¿è””ç¡«ç´ çš„æˆåˆ†ï¼Œå¯èƒ½æ˜¯å°æŠ—ç™Œç—‡çš„å°å¹«æ‰‹ï¼é€™ç¯‡ç ”ç©¶å°ˆæ³¨æ–¼äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒï¼Œä¸¦æ¢ç´¢å®ƒçš„æŠ—ç™Œæ½›åŠ›ã€‚ç ”ç©¶è€…å€‘åˆ†æäº†å¤šå€‹å¯¦é©—ï¼Œå¾ç´°èƒåˆ°å‹•ç‰©ï¼Œçœ‹çœ‹è˜¿è””ç¡«ç´ æ˜¯æ€éº¼èª¿ç¯€ç™Œç´°èƒçš„åŸºå› æ´»å‹•ï¼Œé€²è€Œå½±éŸ¿ç™Œç—‡çš„ç™¼å±•ã€‚\n\nç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤çš„ç”Ÿé•·ï¼Œå°æ­£å¸¸ç´°èƒçš„å½±éŸ¿ä¹Ÿå¾ˆå°ï¼Œé€™è®“å®ƒåœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸Šå±•ç¾å‡ºæ½›åŠ›ã€‚ä¸éï¼Œé€™äº›çµæœé‚„éœ€è¦æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªå“¦ï¼\n\nğŸ”é‡é»æ•´ç†ï¼š  \n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼èª¿ç¯€ç™Œç´°èƒçš„åŸºå› æ´»å‹•ã€‚  \n2. å®ƒèƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œå°æ­£å¸¸ç´°èƒå½±éŸ¿ä¸å¤§ã€‚  \n3. ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "image_prompt": "Create a flat illustration explaining the experimental methods and main results of a study on sulforaphane. The image should have a light background with soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans, animals, or cells. Use arrows or flow lines to show the experimental steps. Include a section labeled 'Main Results' highlighting protective effects or changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41060333/"
  },
  {
    "id": "40553560",
    "title_en": "Antibacterial effects of sulforaphane - AÂ phytonutrient derived from broccoli asÂ promising candidate in the combat ofÂ bacterial infections.",
    "pub_date": "2025 Oct",
    "journal": "European journal of microbiology & immunology",
    "abstract_en": "Bacterial pathogens, particularly antibiotic-resistant strains may constitute major challenges for the successful treatment of infected patients. Therefore, novel antibiotics or alternative, antibiotics-independent compounds with antimicrobial properties such as phytonutrients are needed. Our systematic literature review summarizes current knowledge on antibacterial effects of sulforaphane (SFN) in vitro and in vivo, including human studies. The isothiocyanate SFN is abundant in plants from the BrassicaceaeÂ family including broccoli. The 28 reports reviewed herein revealed that SFN i.) exerted antimicrobial effects against a variety of Gram-positive and Gram-negative bacteria; ii.) counteracted distinct virulence factors such as biofilm formation and toxin production (e.g. Shiga toxin); iii.)Â enhanced antibacterial immune cell responses mounting in anti-oxidant and anti-inflammatory actions thereby supporting bacterial killing and dampening inflammatory cell and tissue damage; iv.) prevented from aspirin-induced small intestinal cell injury; and v.) alleviated Helicobacter pylori-induced gastritis. In conclusion, given its antibacterial, immune-modulatory, and disease-alleviating effects, SFN constitutesÂ a promising alternative antibiotic-independent candidate for the treatment of bacterial infections, warranting further consideration in clinical trials.",
    "para1": "åœ¨ç•¶å‰æŠ—ç”Ÿç´ æŠ—è—¥æ€§æ—¥ç›Šåš´é‡çš„æƒ…æ³ä¸‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•è®Šå¾—å°¤ç‚ºé‡è¦ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œè˜¿è””ç¡«ç´ çš„è¦‹è§£ï¼Œé€™æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰æ¤ç‰©çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œå¯èƒ½å°æŠ—ç´°èŒæ„ŸæŸ“æœ‰å¹«åŠ©ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†æˆ‘å€‘æˆ–è¨±èƒ½å¤ ä¾è³´é€™é¡å¤©ç„¶æˆåˆ†ä¾†å°æŠ—ä¸€äº›é›£ä»¥æ²»ç™‚çš„ç´°èŒï¼Œå¾è€Œæ¸›å°‘å°å‚³çµ±æŠ—ç”Ÿç´ çš„ä¾è³´ï¼Œä¸¦å¯èƒ½é™ä½æŠ—è—¥æ€§å•é¡Œçš„é¢¨éšªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å®ƒå°æ–¼æŠ—ç”Ÿç´ æŠ—è—¥æ€§ç´°èŒçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©åœ¨å¯¦é©—å®¤å’Œäººé«”ä¸­çš„ä½œç”¨ï¼Œä¸¦è©•ä¼°å®ƒæ˜¯å¦èƒ½æˆç‚ºæŠ—ç”Ÿç´ çš„æ›¿ä»£å“ã€‚é€™ä¸åƒ…æ¶‰åŠåˆ°ç´°èŒçš„ç”Ÿé•·æŠ‘åˆ¶ï¼Œé‚„åŒ…æ‹¬å°å…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œé€™äº›éƒ½æ˜¯ç•¶å‰é†«å­¸ç•Œé—œæ³¨çš„é‡è¦å•é¡Œã€‚",
    "para3": "ç ”ç©¶åœ˜éšŠé€²è¡Œäº†ç³»çµ±æ€§çš„æ–‡ç»å›é¡§ï¼Œåˆ†æäº†28ç¯‡æœ‰é—œè˜¿è””ç¡«ç´ çš„å ±å‘Šï¼Œé€™äº›å ±å‘Šæ¶µè“‹äº†å¯¦é©—å®¤ç ”ç©¶å’Œäººé«”ç ”ç©¶ã€‚ä»–å€‘é—œæ³¨çš„é‡é»åŒ…æ‹¬è˜¿è””ç¡«ç´ å°ä¸åŒé¡å‹ç´°èŒçš„æŠ—èŒæ•ˆæœï¼Œä»¥åŠå®ƒå¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„åæ‡‰ã€‚é€™äº›ç ”ç©¶ä¸åƒ…æ¢è¨äº†è˜¿è””ç¡«ç´ çš„ç›´æ¥æŠ—èŒä½œç”¨ï¼Œé‚„è€ƒå¯Ÿäº†å®ƒåœ¨æ¸›å°‘ç™¼ç‚å’Œç´°èƒæå‚·æ–¹é¢çš„æ½›åŠ›ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šç¨®é©è˜­æ°é™½æ€§å’Œé™°æ€§ç´°èŒå…·æœ‰æŠ—èŒæ•ˆæœï¼Œä¸¦èƒ½æŠ‘åˆ¶ä¸€äº›ç´°èŒçš„æ¯’æ€§å› å­ï¼Œå¦‚ç”Ÿç‰©è†œå½¢æˆå’Œæ¯’ç´ ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½å¢å¼·å…ç–«ç´°èƒçš„åæ‡‰ï¼Œä¸¦å°æŠ—ç”±é˜¿æ–¯åŒ¹éˆå¼•èµ·çš„å°è…¸ç´°èƒæå‚·ï¼Œç”šè‡³æ¸›è¼•ç”±å¹½é–€èºæ—‹æ¡¿èŒå¼•èµ·çš„èƒƒç‚ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å‰æ™¯çš„æŠ—èŒæ›¿ä»£å“ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„è‡¨åºŠè©¦é©—ä¾†é©—è­‰å…¶æ•ˆæœã€‚",
    "explanation_zh": "åœ¨ç•¶å‰æŠ—ç”Ÿç´ æŠ—è—¥æ€§æ—¥ç›Šåš´é‡çš„æƒ…æ³ä¸‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•è®Šå¾—å°¤ç‚ºé‡è¦ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œè˜¿è””ç¡«ç´ çš„è¦‹è§£ï¼Œé€™æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰æ¤ç‰©çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œå¯èƒ½å°æŠ—ç´°èŒæ„ŸæŸ“æœ‰å¹«åŠ©ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†æˆ‘å€‘æˆ–è¨±èƒ½å¤ ä¾è³´é€™é¡å¤©ç„¶æˆåˆ†ä¾†å°æŠ—ä¸€äº›é›£ä»¥æ²»ç™‚çš„ç´°èŒï¼Œå¾è€Œæ¸›å°‘å°å‚³çµ±æŠ—ç”Ÿç´ çš„ä¾è³´ï¼Œä¸¦å¯èƒ½é™ä½æŠ—è—¥æ€§å•é¡Œçš„é¢¨éšªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å®ƒå°æ–¼æŠ—ç”Ÿç´ æŠ—è—¥æ€§ç´°èŒçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©åœ¨å¯¦é©—å®¤å’Œäººé«”ä¸­çš„ä½œç”¨ï¼Œä¸¦è©•ä¼°å®ƒæ˜¯å¦èƒ½æˆç‚ºæŠ—ç”Ÿç´ çš„æ›¿ä»£å“ã€‚é€™ä¸åƒ…æ¶‰åŠåˆ°ç´°èŒçš„ç”Ÿé•·æŠ‘åˆ¶ï¼Œé‚„åŒ…æ‹¬å°å…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œé€™äº›éƒ½æ˜¯ç•¶å‰é†«å­¸ç•Œé—œæ³¨çš„é‡è¦å•é¡Œã€‚\n\nç ”ç©¶åœ˜éšŠé€²è¡Œäº†ç³»çµ±æ€§çš„æ–‡ç»å›é¡§ï¼Œåˆ†æäº†28ç¯‡æœ‰é—œè˜¿è””ç¡«ç´ çš„å ±å‘Šï¼Œé€™äº›å ±å‘Šæ¶µè“‹äº†å¯¦é©—å®¤ç ”ç©¶å’Œäººé«”ç ”ç©¶ã€‚ä»–å€‘é—œæ³¨çš„é‡é»åŒ…æ‹¬è˜¿è””ç¡«ç´ å°ä¸åŒé¡å‹ç´°èŒçš„æŠ—èŒæ•ˆæœï¼Œä»¥åŠå®ƒå¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„åæ‡‰ã€‚é€™äº›ç ”ç©¶ä¸åƒ…æ¢è¨äº†è˜¿è””ç¡«ç´ çš„ç›´æ¥æŠ—èŒä½œç”¨ï¼Œé‚„è€ƒå¯Ÿäº†å®ƒåœ¨æ¸›å°‘ç™¼ç‚å’Œç´°èƒæå‚·æ–¹é¢çš„æ½›åŠ›ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šç¨®é©è˜­æ°é™½æ€§å’Œé™°æ€§ç´°èŒå…·æœ‰æŠ—èŒæ•ˆæœï¼Œä¸¦èƒ½æŠ‘åˆ¶ä¸€äº›ç´°èŒçš„æ¯’æ€§å› å­ï¼Œå¦‚ç”Ÿç‰©è†œå½¢æˆå’Œæ¯’ç´ ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½å¢å¼·å…ç–«ç´°èƒçš„åæ‡‰ï¼Œä¸¦å°æŠ—ç”±é˜¿æ–¯åŒ¹éˆå¼•èµ·çš„å°è…¸ç´°èƒæå‚·ï¼Œç”šè‡³æ¸›è¼•ç”±å¹½é–€èºæ—‹æ¡¿èŒå¼•èµ·çš„èƒƒç‚ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å‰æ™¯çš„æŠ—èŒæ›¿ä»£å“ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„è‡¨åºŠè©¦é©—ä¾†é©—è­‰å…¶æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠEuropean journal of microbiology & immunologyã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„æ—¥å¸¸é£²é£Ÿä¸­ç«Ÿç„¶å¯èƒ½è—è‘—å°æŠ—ç´°èŒçš„ç§˜å¯†æ­¦å™¨ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶èšç„¦æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œå®ƒä¸»è¦ä¾†è‡ªé’èŠ±æ¤°èœã€‚éš¨è‘—æŠ—ç”Ÿç´ æŠ—è—¥æ€§å•é¡Œæ—¥ç›Šåš´é‡ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½æ‰¾åˆ°æ–°çš„æ²»ç™‚æ–¹æ³•ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯äº†è§£è˜¿è””ç¡«ç´ å°æŠ—ç´°èŒçš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯é‚£äº›å°æŠ—ç”Ÿç´ å·²ç¶“ç”¢ç”ŸæŠ—è—¥æ€§çš„ç´°èŒã€‚\n\nç ”ç©¶åœ˜éšŠåˆ†æäº†28ç¯‡ç›¸é—œå ±å‘Šï¼Œæ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èŒç”Ÿé•·å’Œå…ç–«ç³»çµ±ã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½é˜»æ­¢å¤šç¨®ç´°èŒçš„ç”Ÿé•·ï¼Œé‚„èƒ½å¢å¼·æˆ‘å€‘çš„å…ç–«åæ‡‰ï¼Œç”šè‡³å°æŸäº›èƒƒéƒ¨å•é¡Œæœ‰å¹«åŠ©ã€‚\n\né€™è£¡æœ‰å¹¾å€‹é‡é»è®“ä½ äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼š\n1. è˜¿è””ç¡«ç´ å°å¤šç¨®ç´°èŒæœ‰æŠ—èŒæ•ˆæœã€‚\n2. å®ƒèƒ½æ¸›å°‘ç´°èŒçš„æ¯’æ€§å› å­ï¼Œåƒæ˜¯æ¯’ç´ ç”¢ç”Ÿã€‚\n3. æœ‰åŠ©æ–¼å¢å¼·å…ç–«ç³»çµ±ï¼Œå¯èƒ½å°æŠ—æŸäº›èƒƒç‚ã€‚\n\né›–ç„¶é€™äº›çµæœä»¤äººæŒ¯å¥®ï¼Œä½†ä»éœ€æ›´å¤šè‡¨åºŠè©¦é©—ä¾†ç¢ºèªå®ƒçš„æ•ˆæœï¼Œè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æœªä¾†çš„ç ”ç©¶å§ï¼",
    "image_prompt": "Create a flat design infographic explaining the research on sulforaphane. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans or cells, and arrows or flow lines indicating the experimental process. Add a section highlighting the main results, such as protective effects and changes observed in immune response and bacterial toxicity.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¹½é–€èºæ—‹æ¡¿èŒæ„ŸæŸ“ Helicobacter pylori Infection",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40553560/"
  },
  {
    "id": "40597512",
    "title_en": "In vitro gastrointestinal digestion of broccolis sprout extract: Impact on the bioaccesibility of sulforaphane and total phenolic.",
    "pub_date": "2025 Oct",
    "journal": "Food research international (Ottawa, Ont.)",
    "abstract_en": "Broccoli sprout extract is rich in phenolic compounds and sulforaphane (SFN) and the gastrointestinal digestion process can affect the bioaccessibility of these substances. This study aimed to evaluate the antioxidant capacity and the content of total phenolic compounds (TPC) and SFN in broccoli sprout extract before and during in vitro gastrointestinal digestion (GID). The antioxidant capacity was determined using different assays (FRAP, ABTS and DPPH), and the TPC and sulforaphane content was measured using the Folin-Ciocalteu method and high performance liquid chromatography (HPLC), respectively. The in vitro digestion analyses followed the INFOGEST 2.0 protocol. Additionally, microbiological characterization and chemical composition analysis of broccoli sprouts were conducted. The microbiological analyses indicated that the sprouts were safe for consumption, with high amounts of TPC, antioxidant capacity, and SFN content. The TPC content decreased significantly (pÂ <Â 0.001) after GID, from 1740.0Â Î¼gÂ eq. GAE/g before digestion to 536.5Â Î¼gÂ eq. GAE/g in the gastric phase and 211.0Â Î¼gÂ eq. GAE/g in the enteric phase. The antioxidant capacity also decreased significantly after simulated digestion compared to initial values. A lower (pÂ <Â 0.001) SFN content was identified in the gastric phase (18.6Â mg/g) compared to the intestinal phase (27.8Â mg/g), although both showed lower SFN levels than the undigested sample, which contained 72.2Â mg/g of SFN. In conclusion, simulated digestion significantly reduced the amount of TPC and SFN, likely due to degradation or biotransformation of the compounds under digestion conditions.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æœ‰è¶£çš„å•Ÿç¤ºã€‚é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­å¯Œå«çš„è˜¿è””ç¡«ç´ å’Œå…¶ä»–é…šé¡åŒ–åˆç‰©ï¼Œå¯èƒ½å°æŠ—æ°§åŒ–å’Œä¿è­·ç´°èƒæœ‰å¹«åŠ©ã€‚ç„¶è€Œï¼Œé€™äº›æœ‰ç›Šæˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­æœƒå—åˆ°å½±éŸ¿ï¼Œé€™æ„å‘³è‘—æˆ‘å€‘åœ¨æ”å–é€™äº›é£Ÿç‰©æ™‚ï¼Œå¯èƒ½éœ€è¦è€ƒæ…®å¦‚ä½•æœ€å¤§åŒ–å…¶å¥åº·æ•ˆç›Šã€‚äº†è§£é€™äº›æˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­çš„è®ŠåŒ–ï¼Œèƒ½å¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°åˆ©ç”¨é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šåƒ¹å€¼ï¼Œé€²è€Œä¿ƒé€²å¥åº·æˆ–é é˜²æŸäº›ç–¾ç—…ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­çš„æŠ—æ°§åŒ–èƒ½åŠ›ä»¥åŠå…¶ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ¨¡æ“¬çš„è…¸èƒƒæ¶ˆåŒ–éç¨‹ä¸­é€™äº›æˆåˆ†çš„è®ŠåŒ–ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›é‡è¦æˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­å¦‚ä½•å—åˆ°å½±éŸ¿ï¼Œä¸¦è©•ä¼°å…¶åœ¨æ¶ˆåŒ–å¾Œçš„ç”Ÿç‰©å¯åŠæ€§ï¼Œé€™å°æ–¼æ—¥å¸¸é£²é£Ÿçš„å¥åº·å½±éŸ¿æœ‰è‘—é‡è¦çš„æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸åŒçš„æ¸¬è©¦æ–¹æ³•ä¾†è©•ä¼°é’èŠ±æ¤°èœèŠ½æå–ç‰©çš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒ…æ‹¬FRAPã€ABTSå’ŒDPPHç­‰æ¸¬è©¦ã€‚æ­¤å¤–ï¼Œç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡å‰‡é€éFolin-Ciocalteuæ–¹æ³•å’Œé«˜æ•ˆæ¶²ç›¸è‰²è­œï¼ˆHPLCï¼‰é€²è¡Œæ¸¬é‡ã€‚ç ”ç©¶é‚„éµå¾ªäº†INFOGEST 2.0å”è­°é€²è¡Œæ¨¡æ“¬æ¶ˆåŒ–åˆ†æï¼Œä¸¦å°é’èŠ±æ¤°èœèŠ½çš„å¾®ç”Ÿç‰©ç‰¹å¾µå’ŒåŒ–å­¸æˆåˆ†é€²è¡Œäº†åˆ†æï¼Œä»¥ç¢ºä¿å…¶å®‰å…¨æ€§å’Œç‡Ÿé¤Šåƒ¹å€¼ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œæ¨¡æ“¬æ¶ˆåŒ–éç¨‹é¡¯è‘—é™ä½äº†é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­çš„ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œç¶“éæ¶ˆåŒ–å¾Œï¼Œç¸½é…šé¡åŒ–åˆç‰©çš„å«é‡å¾æ¶ˆåŒ–å‰çš„1740.0 Î¼g eq. GAE/gé™è‡³èƒƒç›¸çš„536.5 Î¼g eq. GAE/gå’Œè…¸ç›¸çš„211.0 Î¼g eq. GAE/gï¼ŒæŠ—æ°§åŒ–èƒ½åŠ›ä¹Ÿé¡¯è‘—ä¸‹é™ã€‚æ­¤å¤–ï¼Œèƒƒç›¸ä¸­çš„è˜¿è””ç¡«ç´ å«é‡ç‚º18.6 mg/gï¼Œè€Œè…¸ç›¸å‰‡ç‚º27.8 mg/gï¼Œå…©è€…å‡ä½æ–¼æœªæ¶ˆåŒ–æ¨£æœ¬çš„72.2 mg/gã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œæ¶ˆåŒ–éç¨‹å¯èƒ½å°è‡´é€™äº›æœ‰ç›Šæˆåˆ†çš„é™è§£æˆ–è½‰åŒ–ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æœ‰è¶£çš„å•Ÿç¤ºã€‚é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­å¯Œå«çš„è˜¿è””ç¡«ç´ å’Œå…¶ä»–é…šé¡åŒ–åˆç‰©ï¼Œå¯èƒ½å°æŠ—æ°§åŒ–å’Œä¿è­·ç´°èƒæœ‰å¹«åŠ©ã€‚ç„¶è€Œï¼Œé€™äº›æœ‰ç›Šæˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­æœƒå—åˆ°å½±éŸ¿ï¼Œé€™æ„å‘³è‘—æˆ‘å€‘åœ¨æ”å–é€™äº›é£Ÿç‰©æ™‚ï¼Œå¯èƒ½éœ€è¦è€ƒæ…®å¦‚ä½•æœ€å¤§åŒ–å…¶å¥åº·æ•ˆç›Šã€‚äº†è§£é€™äº›æˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­çš„è®ŠåŒ–ï¼Œèƒ½å¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°åˆ©ç”¨é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šåƒ¹å€¼ï¼Œé€²è€Œä¿ƒé€²å¥åº·æˆ–é é˜²æŸäº›ç–¾ç—…ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­çš„æŠ—æ°§åŒ–èƒ½åŠ›ä»¥åŠå…¶ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ¨¡æ“¬çš„è…¸èƒƒæ¶ˆåŒ–éç¨‹ä¸­é€™äº›æˆåˆ†çš„è®ŠåŒ–ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›é‡è¦æˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­å¦‚ä½•å—åˆ°å½±éŸ¿ï¼Œä¸¦è©•ä¼°å…¶åœ¨æ¶ˆåŒ–å¾Œçš„ç”Ÿç‰©å¯åŠæ€§ï¼Œé€™å°æ–¼æ—¥å¸¸é£²é£Ÿçš„å¥åº·å½±éŸ¿æœ‰è‘—é‡è¦çš„æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸åŒçš„æ¸¬è©¦æ–¹æ³•ä¾†è©•ä¼°é’èŠ±æ¤°èœèŠ½æå–ç‰©çš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒ…æ‹¬FRAPã€ABTSå’ŒDPPHç­‰æ¸¬è©¦ã€‚æ­¤å¤–ï¼Œç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡å‰‡é€éFolin-Ciocalteuæ–¹æ³•å’Œé«˜æ•ˆæ¶²ç›¸è‰²è­œï¼ˆHPLCï¼‰é€²è¡Œæ¸¬é‡ã€‚ç ”ç©¶é‚„éµå¾ªäº†INFOGEST 2.0å”è­°é€²è¡Œæ¨¡æ“¬æ¶ˆåŒ–åˆ†æï¼Œä¸¦å°é’èŠ±æ¤°èœèŠ½çš„å¾®ç”Ÿç‰©ç‰¹å¾µå’ŒåŒ–å­¸æˆåˆ†é€²è¡Œäº†åˆ†æï¼Œä»¥ç¢ºä¿å…¶å®‰å…¨æ€§å’Œç‡Ÿé¤Šåƒ¹å€¼ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œæ¨¡æ“¬æ¶ˆåŒ–éç¨‹é¡¯è‘—é™ä½äº†é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­çš„ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œç¶“éæ¶ˆåŒ–å¾Œï¼Œç¸½é…šé¡åŒ–åˆç‰©çš„å«é‡å¾æ¶ˆåŒ–å‰çš„1740.0 Î¼g eq. GAE/gé™è‡³èƒƒç›¸çš„536.5 Î¼g eq. GAE/gå’Œè…¸ç›¸çš„211.0 Î¼g eq. GAE/gï¼ŒæŠ—æ°§åŒ–èƒ½åŠ›ä¹Ÿé¡¯è‘—ä¸‹é™ã€‚æ­¤å¤–ï¼Œèƒƒç›¸ä¸­çš„è˜¿è””ç¡«ç´ å«é‡ç‚º18.6 mg/gï¼Œè€Œè…¸ç›¸å‰‡ç‚º27.8 mg/gï¼Œå…©è€…å‡ä½æ–¼æœªæ¶ˆåŒ–æ¨£æœ¬çš„72.2 mg/gã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œæ¶ˆåŒ–éç¨‹å¯èƒ½å°è‡´é€™äº›æœ‰ç›Šæˆåˆ†çš„é™è§£æˆ–è½‰åŒ–ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood research international (Ottawa, Ont.)ã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ¥¦ ä½ çŸ¥é“é’èŠ±æ¤°èœèŠ½è£¡æœ‰ä»€éº¼ç§˜å¯†å—ï¼Ÿé€™äº›å°èŠ½èŠ½ä¸åƒ…å¯æ„›ï¼Œé‚„å¯èƒ½å°æˆ‘å€‘çš„å¥åº·å¤§æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ¢è¨äº†é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­çš„è˜¿è””ç¡«ç´ å’Œå…¶ä»–æŠ—æ°§åŒ–æˆåˆ†ï¼Œé€™äº›æˆåˆ†åœ¨æˆ‘å€‘æ¶ˆåŒ–éç¨‹ä¸­æœƒç™¼ç”Ÿè®ŠåŒ–ï¼Œå½±éŸ¿å®ƒå€‘çš„å¥åº·åŠŸæ•ˆã€‚ \n\nç ”ç©¶è€…å€‘æ¨¡æ“¬äº†æˆ‘å€‘çš„è…¸èƒƒæ¶ˆåŒ–éç¨‹ï¼Œçœ‹çœ‹é€™äº›ç¥å¥‡çš„æˆåˆ†åœ¨æ¶ˆåŒ–å¾Œçš„è®ŠåŒ–ã€‚çµæœç™¼ç¾ï¼Œæ¶ˆåŒ–éç¨‹æœƒé¡¯è‘—é™ä½é’èŠ±æ¤°èœèŠ½ä¸­çš„ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ å«é‡ï¼Œé€™å¯èƒ½æœƒå½±éŸ¿å®ƒå€‘çš„æŠ—æ°§åŒ–èƒ½åŠ›ã€‚ \n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š  \n1. æ¶ˆåŒ–å¾Œï¼Œç¸½é…šé¡åŒ–åˆç‰©çš„å«é‡å¤§å¹…ä¸‹é™ï¼Œå¾1740.0é™åˆ°536.5å’Œ211.0 Î¼g eq. GAE/gã€‚  \n2. è˜¿è””ç¡«ç´ åœ¨èƒƒå’Œè…¸ä¸­çš„å«é‡ä¹Ÿä½æ–¼æœªæ¶ˆåŒ–æ¨£æœ¬ã€‚  \n3. é€™é¡¯ç¤ºæ¶ˆåŒ–éç¨‹å¯èƒ½æœƒè®“é€™äº›æœ‰ç›Šæˆåˆ†æ¸›å°‘æˆ–è½‰åŒ–ã€‚  \n\næ‰€ä»¥ï¼Œåƒé’èŠ±æ¤°èœèŠ½çš„æ™‚å€™ï¼Œæˆ‘å€‘å¯ä»¥æƒ³æƒ³æ€éº¼æ¨£æ‰èƒ½æ›´å¥½åœ°å¸æ”¶å®ƒå€‘çš„ç‡Ÿé¤Šï¼",
    "image_prompt": "Create an infographic illustrating the experiment on broccoli sprouts and the main findings. Use flat design style with a light background and soft colors. Include symbols representing broccoli and sulforaphane. Simplified illustrations of human or animal subjects can be added. Use arrows or flow lines to show the experimental steps. Include a section labeled 'Main Findings' highlighting the decrease in total phenolic compounds and sulforaphane after digestion.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40597512/"
  },
  {
    "id": "41026407",
    "title_en": "The Adaptive Laboratory Evolution Technology Enhances Sulforaphane Production of Lactobacillus plantarum CR12.",
    "pub_date": "2025 Sep",
    "journal": "Probiotics and antimicrobial proteins",
    "abstract_en": "T he sulforaphane production of wild-type Lactobacillus plantarum CR12 (L. plantarum CR12) is limited. Researchers found that adaptive laboratory evolution (ALE) technology can enhance the production of microorganism by altering the growth environment of microorganisms. However, the effectiveness of enhancing the transformation function of L. plantarum CR12 and the safety of the adaptive strain are unknown. To clarify the above problem, ALE technology was used to enhance the sulforaphane conversion rate of L. plantarum CR12. The results showed that the glucoraphanin conversion rate, sulforaphane production rate, and sulforaphane conversion efficiency of adaptive strain were significantly higher than those of the wild-type strain. The adaptive strain could produce sulforaphane in vivo and regulate the gut microbiota structure. The genomes showed that the adaptive strain consists of a 4,165,885Â bp chromosome with a GC content of 36.8%, encoding 4172 protein-coding genes. Compared with the wild-type strain, the adaptive strain expresses more glycoside hydrolases and glycosyl transferases, indicating that the adaptive strain possesses higher carbohydrate metabolic capability. Genes related to glucoraphanin metabolism (cliT, bglF, and bglA) were detected in both the genomes of the wild-type strain and adaptive strain, indicating that both the wild-type strain and adaptive strain possess sulforaphane production capabilities. Therefore, the adaptive strain can be safely used to increase the in vivo production of sulforaphane, ultimately improving human health. This research is aimed at providing genetic evidence for further formulating rational genetic engineering strategies to transform the wild-type strain into an overproducer.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éæ”¹è‰¯å¾®ç”Ÿç‰©çš„ç”Ÿé•·ç’°å¢ƒï¼Œå¯ä»¥æå‡è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœä¸­çš„åŒ–åˆç‰©ï¼Œå°æ–¼ä¿ƒé€²å¥åº·å’Œé é˜²æŸäº›ç–¾ç—…å¯èƒ½æœ‰æ­£é¢å½±éŸ¿ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†å¯èƒ½é€éåŸºå› å·¥ç¨‹æŠ€è¡“ï¼Œè®“æŸäº›å¾®ç”Ÿç‰©èƒ½æ›´æœ‰æ•ˆåœ°ç”¢ç”Ÿé€™ç¨®æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œé€²è€Œæ”¹å–„æˆ‘å€‘çš„å¥åº·ç‹€æ³ï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•åˆ©ç”¨é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ï¼ˆALEï¼‰ä¾†æå‡ä¹³é…¸èŒLactobacillus plantarum CR12ï¼ˆL. plantarum CR12ï¼‰å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–èƒ½åŠ›ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®æ”¹è‰¯èŒæ ªçš„è½‰åŒ–åŠŸèƒ½æ˜¯å¦èƒ½æœ‰æ•ˆæå‡ï¼Œä»¥åŠå…¶å®‰å…¨æ€§å¦‚ä½•ã€‚é€™æ˜¯ä¸€å€‹é—œæ–¼å¾®ç”Ÿç‰©æ”¹è‰¯çš„ç ”ç©¶ï¼Œç›®çš„æ˜¯ç‚ºäº†æé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ï¼Œé€²è€Œå¯èƒ½å°äººé¡å¥åº·ç”¢ç”Ÿæ­£é¢å½±éŸ¿ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨ALEæŠ€è¡“ä¾†æ”¹è‰¯L. plantarum CR12çš„ç”Ÿé•·ç’°å¢ƒï¼Œä»¥æé«˜å…¶è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€‚ç ”ç©¶åœ˜éšŠæ¯”è¼ƒäº†æ”¹è‰¯å¾Œçš„èŒæ ªèˆ‡é‡ç”Ÿå‹èŒæ ªåœ¨è˜¿è””ç¡«ç´ ç”¢é‡å’Œè½‰åŒ–æ•ˆç‡ä¸Šçš„å·®ç•°ã€‚é€™äº›å¯¦é©—ä¸åƒ…è©•ä¼°äº†èŒæ ªçš„ç”¢é‡ï¼Œé‚„åˆ†æäº†å…¶åŸºå› çµ„ï¼Œä»¥äº†è§£æ”¹è‰¯èŒæ ªåœ¨ç¢³æ°´åŒ–åˆç‰©ä»£è¬èƒ½åŠ›ä¸Šçš„æå‡ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ”¹è‰¯èŒæ ªåœ¨è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€ç”¢é‡å’Œè½‰åŒ–æ•ˆç‡ä¸Šå‡é¡¯è‘—é«˜æ–¼é‡ç”Ÿå‹èŒæ ªã€‚æ­¤å¤–ï¼Œæ”¹è‰¯èŒæ ªèƒ½åœ¨é«”å…§ç”¢ç”Ÿè˜¿è””ç¡«ç´ ä¸¦èª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„çµæ§‹ã€‚åŸºå› çµ„åˆ†æé¡¯ç¤ºï¼Œæ”¹è‰¯èŒæ ªæ“æœ‰æ›´é«˜çš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬èƒ½åŠ›ï¼Œä¸¦ä¸”å…©ç¨®èŒæ ªå‡å…·å‚™è˜¿è””ç¡«ç´ çš„ç”Ÿç”¢èƒ½åŠ›ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œæ”¹è‰¯èŒæ ªå¯ä»¥å®‰å…¨åœ°ç”¨æ–¼æå‡é«”å…§è˜¿è””ç¡«ç´ çš„ç”¢é‡ï¼Œæœ€çµ‚å¯èƒ½æ”¹å–„äººé¡å¥åº·ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éæ”¹è‰¯å¾®ç”Ÿç‰©çš„ç”Ÿé•·ç’°å¢ƒï¼Œå¯ä»¥æå‡è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœä¸­çš„åŒ–åˆç‰©ï¼Œå°æ–¼ä¿ƒé€²å¥åº·å’Œé é˜²æŸäº›ç–¾ç—…å¯èƒ½æœ‰æ­£é¢å½±éŸ¿ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†å¯èƒ½é€éåŸºå› å·¥ç¨‹æŠ€è¡“ï¼Œè®“æŸäº›å¾®ç”Ÿç‰©èƒ½æ›´æœ‰æ•ˆåœ°ç”¢ç”Ÿé€™ç¨®æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œé€²è€Œæ”¹å–„æˆ‘å€‘çš„å¥åº·ç‹€æ³ï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•åˆ©ç”¨é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ï¼ˆALEï¼‰ä¾†æå‡ä¹³é…¸èŒLactobacillus plantarum CR12ï¼ˆL. plantarum CR12ï¼‰å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–èƒ½åŠ›ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®æ”¹è‰¯èŒæ ªçš„è½‰åŒ–åŠŸèƒ½æ˜¯å¦èƒ½æœ‰æ•ˆæå‡ï¼Œä»¥åŠå…¶å®‰å…¨æ€§å¦‚ä½•ã€‚é€™æ˜¯ä¸€å€‹é—œæ–¼å¾®ç”Ÿç‰©æ”¹è‰¯çš„ç ”ç©¶ï¼Œç›®çš„æ˜¯ç‚ºäº†æé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ï¼Œé€²è€Œå¯èƒ½å°äººé¡å¥åº·ç”¢ç”Ÿæ­£é¢å½±éŸ¿ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨ALEæŠ€è¡“ä¾†æ”¹è‰¯L. plantarum CR12çš„ç”Ÿé•·ç’°å¢ƒï¼Œä»¥æé«˜å…¶è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€‚ç ”ç©¶åœ˜éšŠæ¯”è¼ƒäº†æ”¹è‰¯å¾Œçš„èŒæ ªèˆ‡é‡ç”Ÿå‹èŒæ ªåœ¨è˜¿è””ç¡«ç´ ç”¢é‡å’Œè½‰åŒ–æ•ˆç‡ä¸Šçš„å·®ç•°ã€‚é€™äº›å¯¦é©—ä¸åƒ…è©•ä¼°äº†èŒæ ªçš„ç”¢é‡ï¼Œé‚„åˆ†æäº†å…¶åŸºå› çµ„ï¼Œä»¥äº†è§£æ”¹è‰¯èŒæ ªåœ¨ç¢³æ°´åŒ–åˆç‰©ä»£è¬èƒ½åŠ›ä¸Šçš„æå‡ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ”¹è‰¯èŒæ ªåœ¨è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€ç”¢é‡å’Œè½‰åŒ–æ•ˆç‡ä¸Šå‡é¡¯è‘—é«˜æ–¼é‡ç”Ÿå‹èŒæ ªã€‚æ­¤å¤–ï¼Œæ”¹è‰¯èŒæ ªèƒ½åœ¨é«”å…§ç”¢ç”Ÿè˜¿è””ç¡«ç´ ä¸¦èª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„çµæ§‹ã€‚åŸºå› çµ„åˆ†æé¡¯ç¤ºï¼Œæ”¹è‰¯èŒæ ªæ“æœ‰æ›´é«˜çš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬èƒ½åŠ›ï¼Œä¸¦ä¸”å…©ç¨®èŒæ ªå‡å…·å‚™è˜¿è””ç¡«ç´ çš„ç”Ÿç”¢èƒ½åŠ›ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œæ”¹è‰¯èŒæ ªå¯ä»¥å®‰å…¨åœ°ç”¨æ–¼æå‡é«”å…§è˜¿è””ç¡«ç´ çš„ç”¢é‡ï¼Œæœ€çµ‚å¯èƒ½æ”¹å–„äººé¡å¥åº·ã€‚",
    "fb_post": "æ ¹æ“šã€ŠProbiotics and antimicrobial proteinsã€‹æ–¼ 2025 å¹´ 9 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡æœ‰ç¨®ç¥å¥‡çš„æˆåˆ†å«è˜¿è””ç¡«ç´ å—ï¼Ÿå®ƒå°æˆ‘å€‘çš„å¥åº·å¯èƒ½æœ‰å¾ˆå¤§çš„å¹«åŠ©å“¦ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ¢è¨äº†å¦‚ä½•æé«˜é€™ç¨®æˆåˆ†çš„ç”¢é‡ï¼Œè®“æˆ‘å€‘ä¸€èµ·ä¾†çœ‹çœ‹ï¼\n\nç ”ç©¶è€…å€‘ä½¿ç”¨äº†ä¸€ç¨®å«åšé©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ï¼ˆALEï¼‰çš„æ–¹å¼ï¼Œä¾†æ”¹è‰¯ä¸€ç¨®ä¹³é…¸èŒï¼ˆLactobacillus plantarum CR12ï¼‰ï¼Œå¸Œæœ›é€™ç¨®æ”¹è‰¯å¾Œçš„èŒæ ªèƒ½æ›´æœ‰æ•ˆåœ°è½‰åŒ–å‡ºè˜¿è””ç¡«ç´ ã€‚ä»–å€‘ä¸åƒ…é—œæ³¨é€™ç¨®èŒæ ªçš„å®‰å…¨æ€§ï¼Œé‚„æƒ³çŸ¥é“å®ƒèƒ½ç”¢ç”Ÿå¤šå°‘è˜¿è””ç¡«ç´ ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶åœ˜éšŠç™¼ç¾ï¼Œç¶“éæ”¹è‰¯çš„èŒæ ªåœ¨è˜¿è””ç¡«ç´ çš„ç”¢é‡å’Œè½‰åŒ–æ•ˆç‡ä¸Šï¼Œè¡¨ç¾å¾—æ¯”æœªæ”¹è‰¯çš„èŒæ ªå¥½å¾—å¤šï¼æ›´æœ‰è¶£çš„æ˜¯ï¼Œé€™ç¨®æ”¹è‰¯èŒæ ªé‚„èƒ½åœ¨é«”å…§èª¿ç¯€è…¸é“å¾®ç”Ÿç‰©çš„çµæ§‹ï¼Œé€™å°æˆ‘å€‘çš„è…¸é“å¥åº·ä¾†èªªæ˜¯å€‹å¥½æ¶ˆæ¯ï¼\n\nğŸ” é€™é …ç ”ç©¶çš„å¹¾å€‹é‡é»ï¼š\n1. æ”¹è‰¯çš„ä¹³é…¸èŒèƒ½æ›´æœ‰æ•ˆåœ°ç”¢ç”Ÿè˜¿è””ç¡«ç´ ã€‚\n2. æ”¹è‰¯èŒæ ªåœ¨è…¸é“ä¸­èƒ½å¤ èª¿ç¯€å¾®ç”Ÿç‰©ç¾¤ã€‚\n3. é€™äº›ç™¼ç¾å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„æˆ‘å€‘çš„å¥åº·ç‹€æ³ï¼",
    "image_prompt": "Create a flat design infographic on a light background explaining the experimental method and main results of a study on increasing the production of a beneficial compound called sulforaphane from broccoli. Include simple icons representing broccoli and sulforaphane, a simplified representation of the experimental subjects (like humans or cells), arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting key findings such as improved production rates and health benefits.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41026407/"
  }
]